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ABSTRACT 
 
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation 
channels that most notably influence dopamine (DA) release.  In this thesis, I 
examine the role of nAChRs in mediating DA-related behaviors such as 
movement and drug dependence.  To accomplish this, I utilized a “gain-of-
function” knock-in mouse (the Leu9’Ala line) containing agonist-hypersensitive 
α4* nAChRs (* indicates other nAChR subunits in addition to α4 are within the 
receptor complex) that renders receptors 50-fold more sensitive to nicotine and 
acetylcholine than wild-type (WT) receptors.  I found that DHβE, a selective 
antagonist for α4β2* nAChRs, induced reversible and robust motor dysfunction 
characterized by hypolocomotion, akinesia, catalepsy, tremor, and clasping in 
Leu9’Ala but not WT mice.  Reversal of the phenotype was achieved by targeting 
dopamine signaling.  Blockade of mutant α4* nAChRs elicited activation of brain 
regions in the basal ganglia including dorsal striatum and substantia nigra pars 
reticulata indicated by c-Fos immunoreactivity. These data indicate that blocking 
α4* nAChRs in Leu9’Ala mice activates the indirect motor pathway resulting in a 
motor deficit.  We also determined that α4* nAChRs involved in motor behaviors 
did not contain the α6 subunit, a nAChR subunit highly expressed in DAergic 
neurons suggesting that different nAChR subtypes modulating striatal DA release 
have separate functions in motor output.   Conditioned place aversion and 
hypolocomotion, behaviors elicited during nicotine withdrawal, were also induced 
by DHβE in nicotine-naïve Leu9’Ala but not WT mice.  Together these data 
suggest that DHβE globally reduces DA release in the CNS.  In a separate 
project, I determined that α4* and α6* nAChRs modulate drug-induced hypnosis.  
Activation of nAChRs increased sensitivity to ketamine-induced hypnosis; 
whereas antagonizing nAChRs had the opposite effect.  Additionally, α4 
knockout (KO) mice were less sensitive to the hypnotic effects of ketamine, but 
α6 KO were more sensitive.  High doses of ethanol induce an anesthesia-like 
state characterized by immobility, analgesia, and hypnosis.   Testing the effects 
of ethanol hypnosis in α4 KO revealed that α4* nAChR do not play a large role in 
the acute effects of ethanol-induced hypnosis, but are involved in tolerance to 
this ethanol-induced behavior.  The mechanisms of anesthetic-induced hypnosis 
are still largely unclear, despite the wide use of anesthesia.  Future work on 
these receptors and their involvement in the anesthetic response will help to 
define a mechanism for hypnosis and improve the use of anesthetic drugs.   
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CHAPTER I. 
INTRODUCTION 
 
 
2I.A. OVERVIEW 
This thesis will examine nicotinic acetylcholine receptors and their role in motor 
function, withdrawal-like behavior, and the hypnotic effects of ketamine and 
alcohol.  The beginning of the first chapter briefly outlines of the molecular 
structure and function of nicotinic acetylcholine receptors (nAChRs) in order to 
provide a basic understanding of these complex receptors.  The second part of 
Chapter I focuses on dopamine in the motor pathway and the functions of 
nAChRs, specifically in the dorsal striatum.  This is a preface for Chapter II, 
which investigates a motor deficit phenotype induced by blocking α4* nAChRs, 
using the nAChR antagonist DHβE, in a hypersensitive nAChR-expressing 
mouse.  The third section is dedicated to nicotine withdrawal and provides a brief 
overview of the reward pathway, reviewing current literature on nAChR 
involvement in the nicotine withdrawal syndrome.  This provides background on 
nicotine withdrawal in order link research in Chapter III investigating withdrawal-
like behaviors induced by blocking α4* nAChRs in hypersensitive expressing 
nAChR expressing mice.  The final section of Chapter I reviews anesthesia, 
specifically on ketamine, and the function of nAChRs in the anesthetic response, 
to supplement research presented in Chapter IV on nAChR involvement in the 
hypnotic effects of ketamine.  Chapter V discusses the research presented in 
Chapters II-IV, and the implications and future directions of these studies.   
 
 
3I.B. Nicotinic Acetylcholine Receptors 
 
STRUCTURE 
 
Nicotine and the endogenous neurotransmitter acetylcholine (ACh) are potent 
agonists of excitatory ligand-gated cation channels known as nicotinic 
acetylcholine receptors (nAChRs) (Albuquerque et al., 2009).  They are a part of 
the super-family of cys-loop ligand-gated ion channels (LGICs) that include γ -
amino butyric acid (GABA), glycine and 5-hydroxytryptamine (5-HT) receptors 
(Gotti and Clementi, 2004, Millar and Gotti, 2009).  All LGICs share a conserved 
sequence separated by linked cysteines on the amino (N) terminus (Zouridakis et 
al., 2009).   
 
To date there are 17 known nAChR subunits (α1-α10, β1-4, γ , δ , and ε ) 
(Albuquerque et al., 2009).  Muscle nAChRs, which mediate the fast transmission 
at the skeletal neuromuscular junction, are pentameric and formed by the co-
assembly of α1, β1, γ , δ, and ε  subunits (Gotti et al., 2009, Zouridakis et al., 
2009).  In embryonic stages, muscle nAChRs express α12, β1, γ , and δ, but in 
adults the γ  subunit is replaced by the ε subunit.  In these receptors, the ligand 
binding domain rests at the interface between α and γ , δ, and ε  subunits 
(Zouridakis et al., 2009).   
 
4Neuronal nAChR are expressed throughout the nervous system.  Twelve 
neuronal nicotinic acetylcholine receptor (nAChR) subunits have been identified 
as α subunits (α2-α10) and β subunits (β2-β4).  Neuronal nAChRs co-assemble 
as homomeric or heteromeric pentamers.  Homomeric receptors are composed 
of 5 identical α subunits, only formed by α7, α9, and α10.  Agonists to these 
receptors bind at the interface between neighboring α subunits.  Heteromeric 
receptors are composed of a combination of at least 2 α and 2 β subunits.  
Agonists to heteromeric nAChRs bind at the interface of the α (α2, α3, α4, or α6) 
and β (β2 or β4) subunits.   Subunits α5 and β3 are considered accessory 
subunits because they do not contribute to ligand binding (Zouridakis et al., 
2009).   
 
Each subunit has 4 transmembrane (TM) domains (designated TM1-4) 
separating an extracellular N and C terminus (Figure I-1A) (Gotti and Clementi, 
2004).  Subunits share high conservation, except in the intracellular loop 
between the TM3 and TM4 domains which can vary in size and amino acid 
sequence (Albuquerque et al., 2009).  α subunits are characterized by a 
conserved cysteine pair located on the N terminus, necessary for ligand binding, 
in LGICs.  The β subunit has a complementary site that also contributes to 
binding (Gotti and Clementi, 2004, Millar and Gotti, 2009).  
 
5High-resolution structural imaging from the Torpedo muscle nAChR has helped 
to determine the structure of nAChRs (Zouridakis et al., 2009).  In a formed 
receptor, the subunits are arranged in order: α, γ, α, β, δ (Millar and Harkness, 
2008).  The TM2 domain of each subunit creates the hydrophilic pore of the 
receptor, domains TM1 and TM3 protect TM2 from the lipid bilayer, and the TM4 
domain remains the most exposed to the lipid membrane (Albuquerque et al., 
2009, Gotti et al., 2009).  The pore of the channel is wide at the top of the 
receptor and funnels down to a constricted TM2 ring that provides ion selectivity 
(Albuquerque et al., 2009).  The cysteine loop of the N-terminus wraps around 
the outside of the neighboring subunit and creates a binding pocket at the 
interface of these two subunits (Albuquerque et al., 2009).  
 
NAChRs can exist in 3 different transitional states: resting/closed, open, and 
desensitized (Gotti and Clementi, 2004).  Ligand binding will switch 
resting/closed receptors into an open conformation by a twisting action of the 
TM2 region to favor a more hydrophilic conformation and allow Na+, Ca2+, and K+ 
to flow down their electrochemical gradients leading to depolarization of the 
neurons (Albuquerque et al., 2009, Gotti et al., 2009).  In response to prolonged 
exposure to agonist receptors transition into a desensitized state, in which the 
ligand is bound, but receptors are closed and passage of ions through the pore is 
blocked.   
6Figure I-1.  Structure of nicotinic acetylcholine receptors 
A) Schematic representation of an individual subunit.   Each subunit contains an 
extracellular N and C terminus and 4 transmembrane domains (labeled M1-4).  
The variable loop is located intracellularly between M3 and M4 and is unique to 
each subunit.  B) A pentameric nAChR embedded in a lipid membrane.  C) and 
D) Examples of homomeric and heteromeric receptors.  Red triangles indicate 
ACh-binding sites.   Figure was taken with permission from (Hendrickson et al., 
2013).  
FUNCTION 
 
Subunit composition determines the pharmacological and biophysical properties 
of nAChRs.  Distinct nAChR subtypes also exhibit distinct expression patterns in 
the central nervous system (CNS).  Homomeric α7 nAChRs are widely 
expressed throughout the brain.  They are characterized by low affinity (in the µM 
range) to ACh, high Ca2+ permeability, a large conductance, rapid 
7desensitization, and high sensitivity (nM concentrations) to the nAChR antagonist 
α-bungarotoxin (Gotti and Clementi, 2004, Albuquerque et al., 2009).  Rapid 
desensitization is thought to prevent excitotoxicity by abundance of Ca2+ influx 
(Gotti and Clementi, 2004).  The densest population of α7 nAChRs is found in 
the hippocampus where they modulate glutamate and GABA release from pre-
synaptic terminals, depolarize the membrane, and initiate intracellular processes 
in post-synaptic cells (Gotti and Clementi, 2004).  α7 is normally found in a 
homomeric conformation, however heteromeric α7* nAChRs have been 
described in hippocampal interneurons and the intracardiac and superior cervical 
ganglia (Gotti and Clementi, 2004). 
 
Heteromeric α4β2* nAChR subtypes account for up to 90% of high affinity 
nAChR receptors expressed in a wide variety of neuronal subtypes throughout 
the CNS (Gotti et al., 2009).  These receptors are characterized by their high 
affinity for nicotine (in the nM-low mM range) and acetylcholine.  They are also 
activated by the partial agonist cytisine, blocked by dihydro-β-erythrodine 
(DHβE), and insensitive to methyllcaconitine (MLA) and choline (Albuquerque et 
al., 2009).  The stoichiometry of α and β subunits, in an α4β2 nAChR may also 
influence nAChR biophysical and pharmacological properties.  For example, 
receptors in the (α4)3(β2)2 conformation have a lower affinity for nicotine than 
(α4)2(β2)3.  The stoichiometry also confers differences in antagonist sensitivities 
and Ca2+ permeability (Gotti et al., 2009, Millar and Gotti, 2009).   
8 
High affinity α4β2* nAChRs also may co-assemble with other subunits such as 
α5, α6 and β3.  Incorporation of the α5 subunit increases ion conductance, Ca2+ 
permeability, desensitization rate, and agonist affinity (Ramirez-Latorre et al., 
1996, Gotti et al., 2009, Millar and Gotti, 2009).   The α4α5β2 population makes 
up about 20% of the high affinity receptors in the brain (Brown et al., 2007).    
The α4α6β2β3 nAChRs are mainly found in dopaminergic (DAergic) terminals 
and exhibit increased sensitivity to agonist compared to α4(non-α6)β2* nAChRs  
(Salminen et al., 2007).  These receptors have a more dominant role in ACh-
mediated dopamine (DA) release in the nucleus accumbens (NAc) rather than 
the dorsal striatum which is dominated by α4α5β2* nAChRs (Exley et al., 2012). 
 
Chronic nicotine exposure will lead to a general upregulation of nAChRs in the 
brain, but not equally amongst all nAChRs subtypes and brain regions (Gotti et 
al., 2009).  Overall, there is a greater extent of upregulation of high affinity 
nAChRs, mainly α4β2* nAChRs (Gotti et al., 2009).  Radioligand binding of 
[125I]epabatidine in chronic nicotine treated mice reveals a 20-30% increase in 
high affinity nAChR binding in cortical areas, dorsal striatum (ST), NAc, ventral 
tegmental area (VTA) and superior colliculus (Even et al., 2008).  However, an 
upregulation of α7 nAChR expression, using the a7 nAChR antagonist α-
[125I]bungarotoxin, was measured in the cortex and hippocampus  after chronic 
nicotine in mice (Marks et al., 1985).  However, not all nAChRs are upregulated.  
9For example, incorporation of α5 in α4β2* nAChR renders α4α5β2* nAChRs 
resistant to upregulation (Mao et al., 2008).  There is even greater complexity 
among the α6* nAChR population.  This is exemplified by an upregulation of 
α6(non-α4)β2* nAChRs and a downregulation of α4α6β2β3 nAChRs (Perez et 
al., 2008).  Furthermore, incorporation of the β3 subunit in α6* nAChRs confers 
resistance to nicotine-induced downregulation (Perry et al., 2007).   
 
GENETICALLY MODIFIED MICE 
 
The diversity of biophysical and pharmacological properties of nAChRs suggest 
that the variety of nAChRs subtypes is not just a mechanism for redundancy but 
rather a reflection of specific functional roles of each receptor subtype.  Currently 
knock-out (KO) models have been created for subunits α2-7, α9 and β2-4 (Drago 
et al., 2003, Gotti and Clementi, 2004, Lotfipour et al., 2013). Various knock-in 
models, introducing mutations in subunits resulting in hypersensitive receptors, 
are available for subunits α3, α4, α6, α7, and β2 (Tammimaki et al., 2011).   To 
determine subunit contribution to behaviors evaluated in this thesis, I used a 
combination of targeting nAChRs by using nAChRs agonists and antagonists and 
mice with genetic modifications in the α4 and α6 subunits.   
 
In this thesis I utilize Leu9′Ala mice, which provide the ability to test for 
sufficiency of α4* nAChRs.  The gain of function mutation was first discovered in 
10
chick α7 subunit by Revah et al. and since then mutations have been reproduced 
in the α3-α7, α9, and β2-β4 subunits (Revah et al., 1991, Drenan and Lester, 
2012).  The point mutation from a leucine to an alanine resided at the 9’ position 
in the α-helical TM2 pore-forming region of the subunit.  This point mutation 
affects the gating properties of this channel so that receptors are 50-fold more 
sensitive to nicotine and ACh than WT receptors (Miyazawa et al., 2003, Tapper 
et al., 2004).  
 
The Leu9′Ala mouse line was created by the knock-in approach where 
homologous recombination in embryonic stem cells replaced a WT α4 subunit 
gene allele with the mutant allele (Tapper et al., 2004).  The advantage of this 
mutation is that it provides the ability to selective activate α4* nAChRs with low 
doses of nicotine or ACh that will not result in a response from WT receptors.  
For example, a low dose of nicotine induced a hypothermic response and 
conditioned a place preference in Leu9′Ala but not WT mice (Tapper et al., 
2004). 
 
To test for the necessity of α4* nAChRs, α4 KO mice are utilized.  These mice 
lack the gene encoding for the α4 subunit, Chrna4.  More specifically, a 750 bp 
fragment was deleted from exon 5 of Chrna4 (Ross et al., 2000). This fragment 
encodes the first hydrophobic transmembrane domain, TM1, through the second 
cytoplasmic loop, thus rendering α4 receptors non-functional.  α4 KO mice are 
11
viable, fertile, and are born in Mendelian proportions with no gross abnormalities 
(Ross et al., 2000).  Quantitative autoradiography indicates that the α4 KO mice 
lack almost all high affinity binding sites, except in the superior colliculus, 
retroflexus, medial habenula (Hb) and interpenduncular nucleus (IPN), thus 
verifying a reduction in nAChRs containing the α4 subunit.  Additionally, mRNA 
levels of other nAChR subunits do not differ between WT and α4 KO mice, 
suggesting that compensation has not occurred upon deletion of the α4 subunit 
in mutant mice.  In a battery of behavioral tests in α4 KO mice, nicotine did not 
induce hypolocomotion, rearing or sniffing behaviors apparent in WT mice, thus 
supporting the lack of α4* nAChRs (Ross et al., 2000).   
 
KO mice with a genetic deletion of the α6 subunit were used to test for the 
necessity of α6* nAChRs.  Homologous recombination was used to create a 4kb 
deletion replaced with a neomyocin cassette in Chrna6 (Champtiaux et al., 
2002).  The deletion removed exons 1 and 2, which encoded the ATG initiator 
codon, the signal peptide, and the N terminus of the subunit therefore preventing 
transcription of subunit.  In situ hybridization confirmed the α6 subunit was not 
expressed and no compensatory changes in the mRNA levels of other subunits 
were detected.  α6 KO mice were viable and born in Mendelian ratios, had 
normal growth rates, and did not exhibit major physical or neurological defects.
12
I.C. Motor Behavior 
 
THE BASAL GANGLIA AND THE REGULATION OF MOVEMENT 
  
One of the major functions of the basal ganglia system is to regulate voluntary 
movement.   
Figure I-2. The primary motor circuit in the CNS   
This is a wire diagram illustrating the connectivity of the striatal circuit.  There are 
two pathways, the direct and indirect pathways, which originate in the striatum.  
Activation of the direct pathway facilitates movement by activating the cortex and 
the indirect pathway inhibits the cortex to suppress movement.  
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Figure I-2 illustrates the simplified fundamental circuitry of the basal ganglia 
(Quik and Wonnacott, 2011).  The substantia nigra pars compacta (SNpc) 
provides a DAergic input into the dorsal striatum, which is the driving force of the 
motor circuit.  DA activates two populations of GABAergic neurons that regulate 
either the direct or indirect pathway, which ultimately inhibits or disinhibits the 
cortex.  Movement is facilitated by activation of the direct pathway.  The direct 
pathway begins in the striatum which sends GABAergic projections to inhibit the 
globus pallidus internal segment (GPi)/substantia nigra pars reticulata (SNpr).  
This results in a disinhibition of the thalamus, thus allowing activation of the the 
cortex and eventually facilitates movement.  Suppression of movement is 
regulated by the indirect pathway, in which the GPi/SNpr is activated by 
subthalamic nucleus (STN) through the globus pallidus internal segment (GPe).  
Activation of the GPi/SNpr leads to an inhibition of the thalamus so cortex 
activation is blocked.  
 
This separate and opposing regulation of the direct and indirect pathway has 
been the long-standing accepted model for movement output (Cerovic et al., 
2013).  Optogenetics have been used to demonstrate that direct pathway 
activation leads to increased movement (Kravitz et al., 2010).  New evidence 
shows that this circuit may be more complex and both pathways work in concert 
with each other to facilitate movement, rather than the current model which 
14
suggests there is a stronger activation of the direct pathways during movement 
and a stronger activation of the indirect pathway to stop movement.  Cui et al. 
used an in vivo approach, combining fiber optics and time-correlated photon 
counting in the dorsal striatum, to show that the direct and indirect pathway were 
both activated during initiated movement (Cui et al., 2013).   This implies that 
direct pathway is activated to facilitate wanted movement and simultaneous 
activation of the indirect pathway suppresses unwanted actions during 
movement.   
 
THE STRIATUM 
 
The direct and indirect pathways originate in the striatum, making this region 
central to the basal ganglia system (Figure I-3).  Medium spiny neurons (MSNs) 
make up 90% of the neuronal population in the striatum and provide the 
GABAergic output of this brain region (Surmeier et al., 2010).  These neurons 
regulate the indirect and direct pathways, which are modified by DA via excitatory 
or inhibitory G protein-coupled DA receptor expression.  MSNs expressing 
excitatory D1Rs (DA 1 receptors) activate the direct pathway, whereas D2Rs (DA 
2 receptors) are inhibitory and modulate striatal GABAergic output of the indirect 
pathway.  
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The indirect pathway is normally more active.  Increases in DA will turn off the 
indirect pathway to inhibit suppression of movement and concurrently turn on the 
direct pathway to facilitate movement. D1R KO mice had decreases in rearing 
during the open field test (Drago et al., 1994).  D2R KO mice exhibited akinesia, 
bradykinesia, abnormal posture, and abnormal gait (Baik et al., 1995, Kelly et al., 
1998).  Specific ablation of D2Rs in the dorsal striatum, but not the ventral 
striatum, leads to hyperactivity in mice, indicating that there is an imbalance of 
the direct and indirect pathways (Kelly et al., 1998, Durieux et al., 2009).  
Naturally occurring dysfunction of these two pathways underlies movement 
disorders.  For example, DAergic neurodegeneration in Parkinson’s disease 
leads to indirect pathway overactivity resulting in difficulties in movement 
initiation, rigidity, freezing, and tremors. 
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Figure I-3. The striatum   
This is a schematic representation of the projections into and out of the striatum.  
The striatum receives a glutamatergic (Glu) input from the cortex and a DAergic 
input from the SNpc.  GABAergic striatal output is mediated by these inputs as 
well as by cholinergic and GABAergic interneurons. GABAergic medium spiny 
neurons of the direct pathway contain excitatory dopamine receptors (D1Rs) to 
activate the direct pathway and inhibitory dopamine receptors (D2Rs) modulate 
the indirect pathway. Neuronal nAChRs are expressed throughout the striatum, 
except on MSNs, to modulate striatal output (Grady et al., 2007, McClure-Begley 
et al., 2009, Quik et al., 2009). 
 
GABAergic and cholinergic interneurons make up about 5-10% of the striatal 
neuronal population and modulate striatal output.  GABAergic interneurons are 
classified into fast-spiking interneurons (FSI) and persistent low–threshold 
spiking interneurons (PLTI) (Gittis and Kreitzer, 2012).  FSIs receive strong 
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cortical innervations and regulate the majority of feedforward inhibition of both 
D1R and D2R MSNs, however FSIs preferentially project to D1R MSNs (Gittis et 
al., 2010, Gittis and Kreitzer, 2012). PLTIs may not have large consequences on 
striatal output because they make weak and sparse connections with MSNs, but 
they release neuropeptides to modulate the striatal circuitry (Gittis et al., 2010).  
Conversely, about 20% of PLTIs express neuropeptide Y, make strong 
connections with MSNs, and have a strong response to ACh, which suggests 
that these PLTIs play a larger role in striatal output (Gittis and Kreitzer, 2012, Luo 
et al., 2013).   
Only making up about 1-2% of the striatal neuron population, tonically active 
cholinegeric interneurons bathe the striatum in the highest concentrations of ACh 
found in the brain (Kreitzer, 2009, Quik and Wonnacott, 2011).  Anatomically, 
these large aspiny interneurons have extensive axons that project throughout the 
striatum and are innervated by cortical and thalamic projections (Calabresi et al., 
2000).  These neurons tonically fire action potentials and pause during synaptic 
DA input from the SNpc (Kreitzer, 2009, Quik and Wonnacott, 2011).  Expression 
of D2Rs on cholinergic interneurons also act as a feedback mechanism (Kreitzer, 
2009). 
 
Under resting conditions, a rhythmic pacemacker activity of SNpc DAergic 
neurons keeps continuous 10-20 nM concentration of DA in the striatum (Quik 
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and Wonnacott, 2011, Rice et al., 2011).  Activation of SNpc DAergic neurons 
results in a bursting firing pattern, which increases striatal DA to concentrations 
in the high µM-low mM range.  It also causes a pause in the tonic firing of 
cholinergic neurons to reduce ACh levels (Wonnacott, 2008, Kreitzer, 2009, Quik 
and Wonnacott, 2011).  This activity shows that there is a fine balance of DA and 
ACh concentrations in the striatum.  
 
Depleting ACh in striatal slices drops DA levels to as low as 10% of baseline DA 
concentrations (Zhou et al., 2001), suggesting that neuronal nAChRs are 
important mediators of DA release.  Moreover, synchronous cholinergic 
stimulation can evoke terminal DA release, suggesting that terminally located 
nAChRs are sufficient to modulate DA release (Threlfell et al., 2012).  There are 
a variety of nAChR subtypes involved in this response (see Fig. I-3) (Grady et al., 
2007, McClure-Begley et al., 2009, Quik et al., 2009).   Because of the 
heterogeneity of nAChR subtypes in DAergic nerve terminals, there are two 
major questions researchers are trying to answer: why is there redundancy of 
nAChRs in the striatum and are there separate functional roles for individual 
nAChR subtypes expressed in the striatum?  Application of DHβE to striatal 
slices results in the same 90% reduction in DA concentrations as achieved by 
depleting striatal ACh, providing evidence that β2* nAChRs modulate ACh-
evoked DA release (Zhou et al., 2001). Nicotine-stimulated DA release was also 
abolished in β2 KO mice, confirming that β2* nAChRs are necessary for nAChR 
19
agonist evoked DA release (Grady et al., 2002).  DA release studies in striatal 
synaptosomes revealed that the β2* nAChRs can be separated into α−Conotoxin 
MII (α−CtxMII) sensitive (α6*) and insensitive (α4*) nAChRs.  The α−CtxMII 
sensitive nAChRs are composed of α4α6β2β3, α6β2β3, and α6β2 nAChRs and 
mediates about 30% of nicotine evoked DA release (Grady et al., 2002, 
Champtiaux et al., 2003, Cui et al., 2003, Salminen et al., 2007).  The α−CtxMII 
insensitive nAChR population is composed of α4β2 and α4α5β2 nAChRs 
(Champtiaux et al., 2003, Salminen et al., 2004, Brown et al., 2007, Salminen et 
al., 2007, Grady et al., 2010).   Of the α4* nAChR population, α4α5β2 and 
α4α6β2β3 nAChRs are only found on DAergic terminals, whereas α4β2 nAChRs 
are expressed on both DAergic terminals and GABAergic interneurons (Gotti and 
Clementi, 2004).   Although α4α6β2β3* nAChRs are present in striatal DAergic 
terminals, α4α5* nAChR are more functionally dominant in the dorsal striatum 
(Champtiaux et al., 2003, McClure-Begley et al., 2009, Exley et al., 2012).  
 
Evidence from fast-scan cyclic voltammetry (FSCV) reveal that control of DA 
release by α4β2* and α6β2* nAChRs is different.  For example, increased DA 
release in α4 KO mice after burst firing (7-pulse) rather than a decrease 
observed in WT mice, suggest that α4* nAChR play a role in burst firing (Meyer 
et al., 2008).  Alternately, α6β2* nAChR modulate ~65-80% of single-pulse 
nAChR mediated DA release (Perez et al., 2009, Perez et al., 2010).  Together 
these data suggest that α6β2* nAChRs play a more prominent role tonic firing 
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(single pulse) important in DA maintenance, whereas α4β2* nAChR play a larger 
role in burst firing (repeated pulse), which is thought to control initiation and/or 
execution of movement (Exley et al., 2008, Meyer et al., 2008, Perez et al., 2008, 
Perez et al., 2009, Perez et al., 2010).  However, the contribution of α4* and α6* 
nAChRs to movement still largely remains to be identified.   
 
NAChRs AND MOVEMENT 
  
To date very little is known about the role of nAChRs in motor output.  One of the 
main challenges to identify their functional role in locomotor behavior is that 
pharmacological blockade of nAChRs has no effect on spontaneous locomotor 
activity in WT mice (Dwoskin et al., 2008, Jackson et al., 2009b).   Increases in 
locomotor activity in the β2 and β3 KO mouse models are apparent in the open 
field test (Cui et al., 2003, Granon et al., 2003, Avale et al., 2008).  Re-
expressing the β2 subunit in the SNpc of β2 KO mice reverses this effect, 
suggesting the hyperactivity is a consequence of an imbalance of DA 
transmission (Avale et al., 2008).  α4 and α6 nAChR subunit KO models do not 
reveal any major motor dysfunctions, most likely due to compensatory 
mechanisms (masking their true effects) (Ross et al., 2000, Champtiaux et al., 
2002, Marubio et al., 2003).  Since α4 and α6 KO mice have no gross locomotor 
deficits, they provide limited ability to identify functional roles of these nAChR 
subtypes in motor behavior.    
21
 
Gain-of-function mouse models may provide more promising results.  Basal 
hyperactivity measured in a gain-of-function α6* nAChR mice was reversed back 
to WT levels by knocking-out the α4 subunit (Drenan et al., 2010).  This study 
demonstrates that that α4α6* nAChRs influence motor output.   This suggests 
that nAChR subtypes expressed in the striatum have specific functions in motor 
behavior, which may be identified by combining pharmacology, KO and gain-of-
function mouse models.  
NAChRs AND PARKINSON’S DISEASE 
 
Being second only to Alzheimer’s disease, Parkinson’s disease (PD) is the 
second most common neurodegenerative disease (Bosco et al., 2011).  
According to the National Parkinson’s Foundation, it is estimated about 1% of the 
US population over 60 has PD and about 60,000 new cases are diagnosed a 
year.  The resulting direct and indirect governmental costs are about 25 billion 
dollars per year (Bosco et al., 2011, Gazewood et al., 2013).  PD is also the 14th 
leading cause of the death in the US causing about 20,000 deaths a year 
(Murphy et al., 2012). 
 
PD is a disease of aging, with typical disease onset around the age of 60 
(Gazewood et al., 2013).  Primary clinical features of PD include bradykinesia, 
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rigidity, resting tremor, and postural instability (Schapira, 2009). PD patients also 
experience non-motor symptoms, such as autonomic deficits, psychiatric 
symptoms, behavioral changes, dementia, and sleep disorders, but treatment of 
PD is predominantly focused on alleviation of motor symptoms (Schapira, 2009, 
Quik et al., 2012, Gazewood et al., 2013).   
 
Symptoms of PD are caused by neurodegeneration of DAergic neurons in the 
SNpc.  Accompanying DAergic neuron loss, there is formation of cytosolic 
aggregates of proteins, mainly consisting of α synuclen and ubiquitin proteins, 
also known as Lewy bodies widespread throughout the brain (Bosco et al., 2011, 
Schapira and Jenner, 2011).  The largest problem in PD diagnosis is that motor 
symptoms only become apparent after about 80% of DA neurons are lost.  
Furthermore, a true diagnosis can only be made post-mortem to identify the 
presence of Lewy bodies and loss of DAergic neurons in the SNpc.  
 
In the first era of Parkinson’s care, anti-cholinergic drugs were used to treat PD 
symptoms by correcting the imbalance of low DA and high acetylcholine levels in 
the brain (Brocks, 1999).  The side effects of these drugs outweighed their 
effectiveness and so they were phased out after the discovery of dopamine 
replacement therapies such as dihydroxyphenylalanine (L-dopa) (Brocks, 1999, 
Gazewood et al., 2013).  Despite their effectiveness, tolerance to L-dopa 
treatment occurs after long-term use.  Furthermore, overuse of these drugs leads 
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to dyskinesias (involuntary movements) which can be as debilitating as PD 
symptoms (Quik et al., 2011a). Dopamine replacement drugs only manage motor 
symptoms, but do not treat non-motor symptoms nor delay or stop progression of 
disease.  Current therapies are ineffective for long-term treatment, do not 
address non-motor symptoms, or target neurodegeneration, therefore there is a 
great need to identify novel targets for the development of therapeutic drugs that 
will address these issues.  
 
Smokers have a lower incidence of PD (Sugita et al., 2001).   Studies have 
revealed correlations between lowered PD risk and duration of smoking (Thacker 
et al., 2007, Chen et al., 2010).  Current smokers had a 79% decreased risk of 
PD compared with non-smokers, but former smokers’ risk was only decreased by 
22% (Thacker et al., 2007).   There is also an effect of recency of smoking, such 
that smoking cessation within 0-9 years provided reduced risk that persisted up 
to 24 years, but no neuroprotective effects were measured for smokers who had 
quit more than 25 years previously (Thacker et al., 2007).  It has even been 
reported that second-hand smoke may provide protection against 
neurodegeneration in PD (Searles Nielsen et al., 2012).  
 
Nicotine is most likely the agent in cigarettes that provides the neuroprotective 
effects.  Protective effects of chronic nicotine treatment against drug-induced 
lesioning have been identified in neuronal cell lines, primary cell culture, and in 
24
vitro studies of rodents and non-human primates (Quik et al., 2009, Takeuchi et 
al., 2009, Quik et al., 2012).  Huang et al. showed that nicotine only provided 
protection from lesion-induced degeneration when administered before lesioning 
in rats and monkeys, but not after (Huang et al., 2009).  Furthermore, nAChR 
subunits are differentially affected by lesioning and nicotine neuroprotection 
(Ryan et al., 2001). Parkinson’s patients and lesioned monkeys and rodents 
exhibit preferential declines in expression of α4α6β2β3 nAChRs followed by 
declines in α6β2* nAChRs in more severe lesions, while α4(non-α6)β2* nAChR 
are less affected (Bordia et al., 2007, Khwaja et al., 2007, Quik et al., 2011b).   It 
is possible that the lack of α4β2* nAChR loss may be a reflection of their 
expression on non-DAergic neurons that do not undergo degeneration.  
However, nicotine is not neuroprotective in α4 KO mice, suggesting that α4* 
nAChRs are necessary for nicotine neuroprotection against lesioning (Ryan et 
al., 2001).  Further studies also show that in non-nicotine treated mice the α4α6* 
nAChRs are preferentially lost during nigrostriatal damage, however, nicotine can 
protect α4α6* nAChRs from this decline following nigrostriatal damage (Huang et 
al., 2009).  Together this suggests that both α4* and α6* nAChRs may be good 
therapeutic targets for Parkinson’s disease.  
 
Drug trials using nicotine to treat PD symptoms have been inconclusive (Quik et 
al., 2011a, Quik et al., 2012).  Out of 10 trials conducted, only 5 trials provided 
promising results for nicotine as a therapy and one study even showed negative 
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effects of nicotine on motor symptoms (Ebersbach et al., 1999, Quik et al., 
2011a, Quik et al., 2012).  It is possible that differences in nicotine administration 
and in dosing may account for these disparities.   
 
There is still potential for nicotine as a neuroprotective agent, but this still 
remains untested in human trials. Studies in rodents and non-human primates, 
suggest that nicotine alleviates L-dopa-induced dyskinesias (Quik et al., 2007, 
Bordia et al., 2008).  This implies that nicotine may also still provide alleviation 
from dyskinesias in humans (Quik et al., 2007).  Lesion studies in rodents also 
suggest that the use of selective drugs targeting α4* and α6* nAChRs may 
provide better outcomes of neuroprotection and treatment of motor symptoms 
(Bordia et al., 2007, Khwaja et al., 2007, Huang et al., 2009, Quik et al., 2011a, 
Quik and Wonnacott, 2011).  
 
I.D. Nicotine Withdrawal 
 
According to the Centers for Disease Control (CDC), tobacco-related diseases 
cause about 440,000 deaths and results in medical costs of about 96 billion 
dollars each year in the United States alone (2008).   Therefore, there is great 
personal and global incentive to quit smoking.  However, the nicotine withdrawal 
syndrome is an uncomfortable state, resulting from nicotine abstinence, and is 
thought to be the driving force of relapse (Shiffman, 1979, Kenny and Markou, 
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2001).  Commonly experienced symptoms include gastrointestinal disturbances, 
nausea, tobacco cravings, tremors, cognitive deficits, irritability, drowsiness, 
depression, and anxiety (De Biasi and Salas, 2008).  Intensity of the withdrawal 
syndrome and likeliness to remain abstinent are negatively correlated with 
duration of smoking (Hughes et al., 2008).  Smoking cessation therapies are 
available, but only increase cessation success to 20% from 3-5% when nicotine 
cessation therapies are not used (Nides, 2008).  Therefore, better therapeutic 
approaches need to be developed to aid in smoking cessation to increase 
success rates.  
 
NICOTINE IN THE REWARD PATHWAY 
 
Nicotine activates the reward circuitry, also known as the mesocorticolimbic 
pathway.  In this pathway, DAergic neurons originating in the ventral tegmental 
area (VTA) project to the nucleus accumbens (NAc) and the prefrontal cortex 
(PFC) (Markou, 2008, Hendrickson et al., 2013).  Output of the VTA is 
determined by glutamatergic inputs from the NAc and PFC, cholinergic tone 
provided by the tegmental pendunculopontine (TPP) nucleus, and inhibition of 
VTA DAergic neurons by VTA GABAergic interneurons (Fig. 1-4).  Nicotinic 
acetylcholine receptors expressed throughout the reward pathway contribute to 
the output of the NAc. 
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Figure I-4 nAChR expression in the mesocorticolimbic pathway  
A simplified schematic of the reward circuitry displays nAChR expression 
(Hendrickson et al., 2013). The prefrontal cortex (green) and the tegmental 
pedunculopontine nucleus (TPP) send excitatory projections onto the VTA. 
Within the VTA, GABAergic (γ-Aminobutyric-acid, GABA) interneurons send 
inhibitory projections onto the DAergic neurons, which project to the NAc.   After 
acute nicotine stimulation of the reward pathway, these complex interactions 
ultimately result in DA release into the NAc.  
 
Nicotine, like all drugs of abuse, stimulates DA release in the NAc (Pietila and 
Ahtee, 2000, Laviolette and van der Kooy, 2004, Markou, 2008).  Conversely, 
nicotine withdrawal is associated with decreased neuronal activity in the VTA 
leading to decreased extracellular DA levels within the NAc (Hildebrand et al., 
1998, Liu and Jin, 2004). Decreased NAc DA levels also occur after systemic 
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administration of nAChR antagonists to precipitate withdrawal in nicotine 
dependent rats (Fung et al., 1996, Hildebrand et al., 1998, Gaddnas et al., 2002).  
Furthermore, local injection of nAChR antagonists into the VTA, but not the NAc, 
also precipitates a withdrawal phenotype in rats, implicating the VTA as a region 
of interest in nicotine dependence research (Hildebrand et al., 1999, Bruijnzeel 
and Markou, 2004).  
 
Nicotinic acetylcholine receptors mediate the response to nicotine and ACh in the 
reward pathway.  Their expression is highly diverse, indicated in Fig. I-4, and 
indicates selective nAChR subtype functions.  Glutamatergic input is modulated 
by α7* nAChRs while DAergic output is modulated by α4* and α6* nAchRs.   
VTA GABAergic neurons also express α4* nAChRs therefore these receptors 
have a more complex modulation of VTA output.   
 
CHRONIC NICOTINE UPREGULATES nAChRS  
 
A withdrawal state cannot be induced without chronic drug treatment.  One of the 
major neuroadaptations that occurs in response to chronic nicotine treatment is 
the upregulation of nAChRs in the reward circuit, which is thought to play a 
significant role in dependence and upon cessation of nicotine treatment 
(withdrawal).  Increases in nAChR binding with radiolabelled nicotine have been 
measured in post-mortem human brains and in rodents exposed to chronic 
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nicotine (Govind et al., 2009).  Chronic nicotine-induced upregulation measured 
in the midbrain of mice was reversed after 7 days of nicotine cessation (Marks et 
al., 1985, Pauly et al., 1996). Nicotine binding in the VTA also shows that greater 
receptor upregulation is associated with longer nicotine treatment (Pietila et al., 
1998).  
 
There is a greater upregulation of high affinity nAChRs compared with other 
nAChRs subtypes such as α7* nAChRs following chronic nicotine treatment 
(Marks et al., 1985, Nuutinen et al., 2005, Even et al., 2008).   High affinity 
receptor upregulation is dependent upon β2 subunit expression.  This was 
demonstrated by elimination of epabatidine binding in β2 KO mice after chronic 
nicotine exposure (McCallum et al., 2006).   Specific up regulation α4β2 nAChRs 
was visualized, by attaching α4 and β2 subunits to yellow and cyan fluorescent 
protein respectively, in HEK293T cells and cultured midbrain neurons after 
chronic nicotine (Nashmi et al., 2003).  Upregulation of the high affinity α4β2* 
nAChRs suggests these receptors are important for nicotine dependence.   
 
Although increased nAChR binding occurs after chronic nicotine exposure, 
mRNA levels for α2, α3, α4, α5 and β2 subunits remained unchanged (Marks et 
al., 1992, Pauly et al., 1996).  Peng et al. provided evidence, in both cultured 
cells and Xenopus oocytes, that upregulation of α4β2* nAChRs in response to 
chronic nicotine exposure is accompanied by a reduction in α4β2* nAChR 
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turnover rate and degradation, hence proposing this mechanism as a method for 
nAChR upregulation (Peng et al., 1994). Reviewed in Govind et al., other studies 
have also identified changes in cell surface turnover rates, receptor trafficking, 
subunit maturation and assembly, changes in receptor stoichiometry, inhibition of 
degradation, and nAChRs conformation changes as mechanisms to mediate 
posttranslational nAChR upregulation (Govind et al., 2009).  
 
THE WITHDRAWAL SYNDROME 
 
A nicotine withdrawal syndrome can be elicited in rodents after chronic nicotine 
administration (Malin et al., 1992, Isola et al., 1999, Kenny and Markou, 2001).  
Symptoms are categorized into somatic and affective symptoms.  Somatic 
symptoms, also known as physical symptoms, include abnormal behaviors (e.g., 
jumping, teeth chattering, ptosis, tremors, shakes) and normal behaviors that 
occur more frequently during withdrawal (e.g., grooming, scratching, and 
rearing).  Affective symptoms are mood disturbances such as anxiety, reduced 
locomotor activity, hyperalgesia, anhedonia (reward deficit), and aversion (De 
Biasi and Salas, 2008).   
 
In rodents, the most common symptoms tested for an affective withdrawal 
syndrome are hyperalgesia (sensitivity to pain), anhedonia (decreased reward), 
anxiety, and aversion.  The hot plate (HP) and tail flick (TF) tests are most 
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commonly used to assess hyperalgesia.  To test if a drug is rewarding, 
intracranial self-stimulation (ICSS) is performed.  Anxiety tests include elevated-
plus maze, light-dark box test, and marble burying tests.  Aversion is tested using 
classical Pavlovian conditioning to train mice to associate the aversive effects of 
a drug with a specific environment.  Also, another measures for affective 
withdrawal that utilizes Pavlonian conditioning is contexual fear-conditioning 
(CFC).    
 
Withdrawal research is currently focused on identifying the specific nAChR 
subtypes that modulate somatic or affective withdrawal symptoms. Phenotypes in 
rodents chronically treated with nicotine can be elicited by either discontinuation 
of nicotine administration (spontaneous withdrawal) or precipitated by 
administration of selective nAChRs antagonists.   Therefore, a combination of 
pharmacology and nAChR subunit KO mouse models can be used to identify 
which subunits modulate the different aspects of nicotine withdrawal.   
 
Initial studies of the nicotine withdrawal syndrome revealed that systemic 
administration of non-selective nAChR antagonists mecamylamine elicit both 
somatic and affective withdrawal symptoms (Malin et al., 1994, Suzuki et al., 
1996, Watkins et al., 2000).  Intraventricular infusion of hexamethonium (a non-
selective antagonists that does not cross the blood brain barrier), as well as 
infusion of mecamylmaine into the VTA, IPN, and Hb could also induce somatic 
32
withdrawal symptoms, showing a strong involvement of the CNS in nicotine 
withdrawal (Malin et al., 1997, Hildebrand et al., 1999, Salas et al., 2009).  
Identification of nAChRs subtypes involved in somatic and affective withdrawal 
symptoms are reviewed in Tables I-1 and I-2.  
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Table I-1. Neural nAChRs subunits modulating classical nicotine withdrawal in rodents identified by 
pharmacological nAChR targeting  
Affective Drug Subunit Somatic 
HP TF EPM CPA CFC ICSS 
Reference 
HEX (s.c. or i.p.) ns - 
- 
+ 
 
- 
 
- 
- 
 
- 
- 
 
 
 
+ 
  (Malin et al., 1997) 
(Damaj et al., 2003) 
(Grabus et al., 2004) 
(Jackson et al., 2009a) 
HEX (i.c.v.) ns +       (Malin et al., 1997) 
Chlorisondamine (s.c.) ns + 
+ 
      
- 
(Hildebrand et al., 1997) 
(Watkins et al., 2000) 
Chlorisondamine (i.c.v.) ns +      + (Watkins et al., 2000) 
MEC (i.p. or s.c.) ns + 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
+ 
 
+ 
 
 
 
 
+ 
- 
 
 
 
 
- 
- 
+ 
 
+ 
 
+ 
 
 
+ 
  
 
 
+ 
 
 
 
+ 
+ 
+ 
(Malin et al., 1994) 
(Suzuki et al., 1996) 
(Hildebrand et al., 1997) 
(Watkins et al., 2000) 
(Damaj et al., 2003) 
(Grabus et al., 2004) 
(Jackson et al., 2008) 
(Johnson et al., 2008) 
(Stoker et al., 2008) 
(Jackson et al., 2009a) 
DHβE (i.p.) α4β2*  
- 
+ 
- 
 
 
- 
 
 
 
- 
- 
 
 
+ 
- 
 
+ 
 
 
 
 
 
+ 
 
 
 
 
 
 
+ 
+ 
 
 
 
+ 
+ 
(Epping-Jordan et al., 1998) 
(Watkins et al., 2000) 
(Damaj et al., 2003) 
(Grabus et al., 2004) 
(Kenny and Markou, 2005) 
(Stoker et al., 2008) 
(Portugal et al., 2008) 
(Jackson et al., 2009a) 
α-CtxMII (i.c.v.) α6* - - - - +   (Jackson et al., 2009b) 
MLA (i.p.) α7* + 
- 
+ - 
- 
- 
- 
 
 
- 
  (Damaj et al., 2003) 
(Grabus et al., 2004) 
(Jackson et al., 2009a) 
CPA: conditioned place aversion, CFC: contextual fear conditioning, EPM: elevated plus maze, HP: hot plate test, i.c.v: 
intracerebroventricular infusion, i.p.: intraperitoneal injection, ICSS: intracranial self-stimulation, ns: non specific, s.c.: 
subcutaneous, and TF: tail flick test, +: positive for signs, -: negative for signs, blank: not tested 
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Table I-2. Neural nAChRs subunits modulating classical nicotine withdrawal in rodents identified by 
spontaneous or precipitated withdrawal in KO mice 
Affective KO mouse Somatic 
HP TF EPM CPA CFC ICSS 
Reference 
α2 KO -       (Salas et al., 2009) M 
α3 KO         
α4 KO         
α5 KO - 
- 
+  + +   (Jackson et al., 2008) M 
(Salas et al., 2009) M 
α6 KO         
α7 KO - 
- 
- 
 
+ 
- 
 
- 
-  
 
+ 
 
 
+ 
 
 
 
+ 
 
 
 
 
- 
(Grabus et al., 2005b) S 
(Salas et al., 2007) M 
(Jackson et al., 2008) S/M 
(Portugal et al., 2008) S 
(Stoker et al., 2012) S/M 
β2 KO + 
+ 
+ 
 
 
- 
  
 
- 
 
 
- 
 
 
 
+ 
 
 
 
 
(Salas et al., 2004) M 
(Besson et al., 2006) M 
(Jackson et al., 2008) S/M 
(Portugal et al., 2008) S 
β3 KO         
β4 KO - 
- 
- +     
+ 
(Salas et al., 2004) M 
(Stoker et al., 2012) S/M 
 
Withdrawal was precipitated with mecamylamine (i.p.) or spontantous (S) in KO mouse studies.  +: means signs were present 
(suggesting that the deleted subunit is not involved), -: negative for signs (suggesting the subunit is involved), blank: not 
tested, CPA: conditioned place aversion, CFC: contextual fear conditioning, EPM: elevated plus maze, HP: hot plate test, 
ICSS: intracranial self-stimulation, and TF: tail flick test
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Observing and counting specific somatic behavioral events measures the 
somatic withdrawal syndrome. KO models have indicated α2*, α5*, and β4* 
nAChRs as modulating somatic signs.   Precipitation of somatic, but not affective 
symptoms specifically CPA and anxiety, by α-Conotoxin AU1B implicates α3β4* 
nAChR in modulation of somatic symptoms only (Jackson et al., 2013).  α7* 
nAChRs only partially modulate somatic withdrawal, indicated by only a slight 
reduction but not elimination of somatic signs in a KO model and precipitation of 
some somatic signs by MLA (Damaj et al., 2003, Grabus et al., 2005a, Salas et 
al., 2007).  Although β2* nAChRs have been implicated by both DHβE and in a 
KO model for somatic withdrawal, apparent somatic behaviors were very limited, 
therefore it is understood that these receptors have a minor impact on somatic 
signs (Malin et al., 1998, Besson et al., 2006).  
 
A variety of subunits modulate the affective withdrawal syndrome, however not 
all subtypes are involved in all affective symptoms (Tables I-1 and I-2).  The β4 
and α7 subunits modulate the reward deficits measured by increases in 
intracranial self-stimulation (ICSS) (Stoker et al., 2012).  Additionally, α7* 
nAChRs are involved in hyperalgesic effects of withdrawal, but not in withdrawal 
induced CPA or anxiety (Damaj et al., 2003, Grabus et al., 2004, Grabus et al., 
2005b, Salas et al., 2007, Jackson et al., 2008, Portugal et al., 2008, Jackson et 
al., 2009a, Stoker et al., 2012).  Precipitation of anxiety and a CPA response by 
α-CtxMII in nicotine dependent mice has implicated α6* nAChRs in affective 
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withdrawal.  Targeting α4β2* nAChRs with DHβE precipitates anxiety, cognitive 
dysfunction (CFC), CPA, and reduced reward.  These affective withdrawal 
behaviors modulated by β2* nAChRs have been confirmed using β2 KO mouse 
(Jackson et al., 2008, Portugal et al., 2008).  Furthermore, varenicline, a partial 
agonist of α4β2* and α6β2* nAChRs (and a current smoking cessation drug), 
alleviates CFC during nicotine withdrawal, thus further confirming their role and 
indicating β2* nAChRs as good therapeutic targets for nicotine cessation 
(Raybuck et al., 2008, Bordia et al., 2012).   The only other receptor thus far 
implicated in an affective withdrawal syndrome are α6* nAChRs (Jackson et al., 
2009b).  Testing in α6 KO mice is required to confirm the function of α6* nAChRs 
in affective withdrawal symptoms.  
 
BRAIN REGIONS ASSOCIATED WITH NICOTINE WITHDRAWAL 
 
Providing the DAergic input to the NAc, it is no surprise that the VTA plays a 
central role in modulating nicotine withdrawal.  Studies have identified this region 
as sufficient to induce a nicotine withdrawal syndrome.  Hildebrand et al. showed 
that direct infusion of mecamylamine, a non-specific nAChR antagonist, into the 
VTA of nicotine-dependent mice decreased locomotor activity and elicited 
somatic withdrawal signs (Hildebrand et al., 1999).  MLA infused into the VTA will 
also induce locomotor depression and lowered NAc DA levels, implicating α7* 
nAChRs (Nomikos et al., 1999).  Interestingly, α4* nAChR upregulation by 
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chronic nicotine is selective to GABAergic and not DAergic neurons in the VTA 
(Nashmi et al., 2007).  In a recent study, Tan et al. used optogenetic activation of 
GABAergic VTA neurons to induce a CPA in nicotine naïve mice (Tan et al., 
2012).  Together this suggests that aversion in nicotine withdrawal may be 
through a GABAergic mechanism mediated by α4β2* nAChRs.   
 
Functionally and anatomically connected to the mesocorticolimbic pathway, the 
habenula and interpenducular nucleus (IPN) make up an “anti-reward” circuit 
implicated by its response to aversive stimuli (De Biasi and Salas, 2008, Bianco 
and Wilson, 2009).  Recently it has become of interest because it is sufficient to 
induce a somatic nicotine withdrawal syndrome.  Optogenetic stimulation of 
GABAergic neurons in the IPN induces somatic withdrawal signs but not affective 
symptoms (as measured by anxiety) (Zhao-Shea et al., 2013).  Somatic 
withdrawal signs can be precipitated by directly infusing mecamylamine into the 
habenula or IPN (Hughes et al., 2008, Salas et al., 2009).  Together with KO data 
and high receptor expression, α2*, α5*, and β4* nAChRs are thought to modulate 
this somatic response (Salas et al., 2004, Hughes et al., 2008, Salas et al., 
2009).  Infusion of an antagonist selective for β4* nAChRs, SR16584, into the 
IPN also induced somatic withdrawal symptoms in nicotine dependent mice, 
implicating β4* nAChRs in the IPN are important for somatic withdrawal (Zhao-
Shea et al., 2013).  In the medial habenula and IPN, α3β4* nAChRs can co-
assemble with the α5 subunit, however α-conotoxin AU1B precipitation of 
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somatic withdrawal signs in α5 KO mice suggest that modulation by α3β4* 
nAChRs is independent of α5 (Jackson et al., 2013).   
 
In addition to somatic withdrawal, the medial habenula may also modulate 
affective withdrawal signs.  Unpublished data from our lab shows that 
mecamylamine infusion into the medial habenula of mice precipitates anxiety in 
drug naïve mice (work done by Xueyan ‘Alice’ Pang).  This may be mediated 
through α4* nAChRs based on functional α4* nAChR expression in the medial 
habenula and their known modulation of affective withdrawal (Epping-Jordan et 
al., 1998, Watkins et al., 2000, Damaj et al., 2003, Kenny and Markou, 2005, 
Portugal et al., 2008, Stoker et al., 2008, Fonck et al., 2009, Jackson et al., 
2009a).   
 
I.E. General Anesthesia 
 
The first applications for inhalation drugs, such as chloroform and nitrous oxide, 
as a means to eliminate pain during surgery, were discovered in the 1840’s 
(Rudolph and Antkowiak, 2004).  Barbiturates were discovered about 60 years 
later and became the principle class of anesthetics for the next 50 years 
(Ferguson, 2010).  These drugs were phased out in favor of “safer” drugs, like 
bromides and benzodiazepines, as a result of the addictive nature of barbiturates 
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that led to abuse and high rates of overdose.  Since the discovery of anesthetics, 
much work has focused on creating a safe anesthetic state.   
 
Today, general anesthesia is used in about 60,000 patients daily in the US alone, 
mainly for surgical procedures and in pre-and post-operative care (Brown et al., 
2010).  The common features of the anesthetic state induced by all anesthetic 
drugs are immobility, analgesia (pain relief), and hypnosis (sedation/loss of 
consciousness).  Anesthetic drugs can be categorized into 3 groups (Table 1-3 
modified from Solt and Forman) based on how well they induce each of these 
anesthetic properties (Eger et al., 1997, Solt and Forman, 2007, Brown et al., 
2011).  
 
Table I-3.  Classification of General Anesthetic Drugs 
 Group 1 Group 2 Group 3 
General anesthetic 
drugs 
Etomidate 
Propofol 
Pentobarbital 
Nitrous Oxide 
Ketamine 
Xenon 
Halogenated ethers 
(e.g. isoflurane and 
sevoflurane) 
Alkanes (e.g. 
halothane and 
chloroform) 
 
Clinical Features Strong hypnotics 
Weak immobilizers 
Weak analgesics 
 
Weak hypnotics 
Weak immobilizers 
Potent analgesics 
 
Strong hypnotics 
Strong immobilizers 
Weak analgesics 
Molecular Targets GABAA receptors  NMDA receptors 
AMPA receptors 
Neuronal nAChRs 
2-pore K+ channels 
GABAA receptors 
NMDA receptors 
AMPA receptors 
Neuronal nAChRs 
2-pore K+ channels 
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Differences in potency for anesthetization and undesirable, potentially harmful 
side effects, such as respiratory and pulmonary effects, are also distinctive to 
each drug (Urban et al., 2006, Solt and Forman, 2007).  Since drugs are not ideal 
in all anesthetic properties, cocktails of drugs are used to create an anesthetic 
state best fitting for the type of medical procedure, with the patient’s medical 
history and current condition in mind.   
 
Using more than one anesthetic drug can also reduce the concentration of each 
anesthetic required to induce the desired effect, which reduces the side effects of 
each drug (Urban et al., 2006).  Although side effects may be reduced, they are 
not completely mitigated.  Currently the mechanism of action of anesthetic drugs 
is unclear (see below), however it is clear that the anesthetic state is very 
complex and no one drug is likely to ever provide ideal anesthesia (Hemmings et 
al., 2005).  With better understanding of the mechanism of these drugs, we may 
be able improve and enhance our current use of anesthetics. 
 
MECHANISM OF GENERAL ANESTHETICS 
 
Lipid membrane disruption was the original hypothesized mechanism of 
anesthetic action (Perry et al., 1999, Tassonyi et al., 2002, Franks, 2008).  Since 
then, it has been discovered that anesthetics mainly target voltage- and ligand-
gated ion channels, mainly GABA and glutamate receptors (see Table 1-3) 
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(Perry et al., 1999, Solt and Forman, 2007, Franks, 2008).   Although individual 
anesthetics have specific molecular targets, they all induce hypnosis, analgesia, 
and immobility, albeit at varying degrees (Solt and Forman, 2007).  Because of 
their similarities, it has been suggested that the anesthetic state uses the same 
pathways, despite differences in specific molecular targets of individual 
anesthetic drugs (Rudolph and Antkowiak, 2004).     
 
It appears that anesthetics act through the sleep/wake circuits (Alkire et al., 2008, 
Allada, 2008, Franks and Zecharia, 2011). Distinct spontaneous 
encephalographic (EEG) activity under anesthesia, characterized by spindles 
(brief 7-14 Hz bursts of activity) and delta waves (1-4 Hz), is reminiscent of non- 
rapid eye movement (NREM) sleep (Alkire et al., 2008, Allada, 2008, Franks and 
Zecharia, 2011).  Functional magnetic imaging (fMRI) and positron-emission 
tomography (PET) imaging during anesthesia largely reveal a reduction in whole 
brain activity, which also occurs during sleep (Alkire, 2008).   During natural and 
anesthesia-induced sleep, greater depressions in brain activity are measured in 
the spinal cord, brainstem, cerebellum, midbrain, basal ganglia, superior frontal 
gyrus, posterior cingulate, basal forebrain, the insular cortex, prefrontal cortex, 
parietal and temporal association areas, occipitoparietal association cortices, and 
occipital cortex (Urban et al., 2006, Franks and Zecharia, 2011).   Unfortunately, 
anesthetic drugs are not selective for specific brain regions, so it is unclear which 
regions are most important for mediating the anesthetic state.    
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The thalamus may be an important region involved in the effects of anesthetics 
because it is a key player in arousal.  Reductions in blood flow and metabolism in 
the thalamus are measured during anesthesia-induced sleep (Alkire et al., 2008).  
Arousal was depressed when pentobarbital, a GABAA receptor agonist, was 
infused directly into the thalamus (Miller and Ferrendelli, 1990).  On the other 
hand, arousal was induced by direct infusion of nicotine, a nAChR agonist, during 
severoflurane-induced anesthesia in rats (Alkire et al., 2007).  These studies 
suggest the thalamus is important in modulating the duration of anesthesia-
induced sleep through different molecular targets.   
 
GENERAL ANESTHETICS AND nAChRS 
 
Brain regions associated with anesthetic effects also received cholinergic 
signaling, suggesting that ACh and nAChRs modulate the anesthetic state (Fig. I-
5) (Perry et al., 1999).   
 
Halothane, enflurane, and ketamine decrease ACh turnover rates differentially 
throughout the brain, suggesting that modulation of the anesthetic response by 
ACh is diverse (Ngai et al., 1978).  Additionally, the indirect cholinergic agonists, 
physostigmine and tacrine, are commonly used to advance emergence from 
anesthetics (Perry et al., 1999, Brown et al., 2010).  Smoking can affect 
anesthesia, such that smokers are more resistant to the hypnotic effects of 
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propofol (Lysakowski et al., 2006).  This is problematic because higher doses of 
propofol need to be administered to induce an anesthetic state in smokers, 
potentially leading to greater adverse side effects.  
 
 
Figure I-5 Brain regions altered by anesthetics also receive cholinergic 
signaling.   
A schematic of a human brain which highlights regions that are significantly 
changed by anesthetic drugs (Rudolph and Antkowiak, 2004, Alkire et al., 2008, 
Brown et al., 2010).  Areas marked with an * are regions have been implicated in 
effects of an anesthetizing dose of ketamine in humans and rodents (Crosby et 
al., 1982, Davis et al., 1988, Hwang et al., 2012, Kim et al., 2012, Lee et al., 
2013).  The central cholingeric system in the brain has two main pathways 
originating in either the basal forebrain (purple) or the peduncular pontine 
tegmental nucleus (PPTg)-lateral dorsal tegmentum (LDTg) neurons (pink) (Perry 
et al., 1999, Scarr et al., 2013).  Other main providers of acetylcholine in the 
brain are striatal cholinergic neurons  (orange) and neurons in the vestibular 
nuclei that provide cholinergic signaling to the cerebellum (green).       
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Although not the primary target of anesthetics, in vitro studies show that nAChRs 
are inhibited by isolurane, halothane, sevoflurane, nitrous oxide, xenon, 
ketamine, thiopental, propofol, etomidate, and atacurium (Yamakura et al., 2000, 
Coates and Flood, 2001, Flood and Coates, 2002, Tassonyi et al., 2002). These 
in vitro systems have the advantage of identifying specific receptor subtypes that 
respond to anesthetics.  For example, isoflurane and halothane inhibit α2β4, 
α4β2, and α7 nAChRs while ketamine blocks α2β2, α2β4, α3β2, α3β4, α4β2, 
α4β4, and α7 (Yamakura et al., 2000, Coates and Flood, 2001, Flood and 
Coates, 2002, Tassonyi et al., 2002). In many of these studies, clinically relevant 
doses of anesthetic could block nAChRs, however it is still uncertain if these 
subtypes influence the anesthetic state.   Expression of nAChRs in Xenopus 
oocytes revealed that neuronal nAChRs are more sensitive to inhalational 
anesthetics than muscle nAChRs, suggesting that neuronal nAChRs mediated 
effects of general anesthetics (Violet et al., 1997).   
 
Experiments in rodents have shown that nicotine treatment decreases enflurane, 
isoflurane, and sevoflurane analgesic effects and hypnosis duration (Flood et al., 
2002b, Yan et al., 2009).  Blocking nAChRs with mecamylamine or 
chlorisondamine had no effect on isoflurane-induced analgesia or hypnosis, even 
though nicotine modulated both these behaviors (Flood et al., 2002a, b).  
Mecamylamine also enhanced the analgesic effects of ketamine, but which 
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nAChR subunits are involved in this response is still unidentified (Udesky et al., 
2005).  Unfortunately, this is the extent of in vivo studies identifying the influence 
of nAChRs on anesthesia.   
 
KETAMINE 
 
Ketamine, an analog of phencyclidine (PCP), was developed to possess PCP’s 
anesthetic properties without the negative hallucinogenic side effects (White and 
Ryan, 1996).  Strong analgesic effects and lack of respiratory depression 
(negative side effects in most anesthetics) make ketamine the primary anesthetic 
for surgical procedures in the ill, elderly, and pediatric patients, pre- and post-
operative care, and pain management (Alletag et al., 2012, Morgan and Curran, 
2012, Prommer, 2012).  It is also widely used in veterinary medicine (Morgan and 
Curran, 2012).   
 
Ketamine is a unique anesthetic in that all other anesthetic drugs decrease brain 
activity, while ketamine has the opposite effect (Franks, 2008). Increased brain 
function may be the reason ketamine does not decrease respiration effects 
(which can be dangerous in the elderly, ill, or pediatric patients) giving ketamine 
an advantage over other anesthetic drugs (Brown et al., 2010).  Instead of 
decreasing brain activity, ketamine acts by disrupting signaling (Alkire et al., 
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2008, Lee et al., 2013).  This aberrant activity may also be the cause of 
hallucinations and the mechanism for unconsciousness (Brown et al., 2010).  
 
NMDA receptors are the primary molecular targets of ketamine, but in vitro 
studies have identified nAChRs as secondary targets.  In PC12 cells, which 
express endogenous nAChRs, nicotine-evoked whole cell currents were inhibited 
by ketamine (Furuya et al., 1999, Sasaki et al., 2000).  Expression of human 
nAChR subunits in Xenopus oocytes demonstrated ketamine inhibits α2β4, 
α3β4, α4β2, α4β4, α7 nAChRs (Yamakura et al., 2000, Coates and Flood, 2001, 
Tassonyi et al., 2002).  These studies further revealed that β4* nAChRs are more 
sensitive to ketamine than β2* nAChRs (Yamakura et al., 2000).  There are 
discrepancies in vitro about the dose of ketamine required to block nAChRs; in 
some cases nAChRs were not inhibited by doses of ketamine that are 
considered clinically relevant to induce anesthesia (Furuya et al., 1999, Sasaki et 
al., 2000, Yamakura et al., 2000, Coates and Flood, 2001, Tassonyi et al., 2002).  
Therefore it is unclear if nAChRs contribute to the anesthetic effect of ketamine. 
In mice, analgesia effects of ketamine were enhanced by mecamylamine, 
however mecamylamine or DHβE did not influence the dose necessary to 
induced ketamine-induced hypnosis (Udesky et al., 2005).  It still remains unclear 
if nAChRs play a role in the duration of hypnosis and immobility.   With more 
knowledge about the contribution of nAChR subtypes to the anesthetic properties 
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of ketamine, nAChR drugs may be used to supplement ketamine to enhance its 
effectiveness and reduce negative side effects.  
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ABSTRACT 
 
Nicotinic acetylcholine receptors (nAChRs) containing either the α4 and/or α6 
subunit are robustly expressed in dopaminergic nerve terminals in dorsal striatum 
where they are hypothesized to modulate dopamine (DA) release via 
acetylcholine (ACh) stimulation from cholinergic interneurons.   However, 
pharmacological blockade of nAChRs or genetic deletion of individual nAChR 
subunits, including α4 and α6, in mice, yields little effect on motor behavior.  
Based on the putative role of nAChRs containing the α4 subunit in modulation of 
DA in dorsal striatum, we hypothesized that mice expressing a single point 
mutation in the α4 nAChR subunit, Leu9′Ala, that renders nAChRs 
hypersensitive to agonist, would exhibit exaggerated differences in motor 
behavior compared to WT mice. To gain insight into these differences, we 
challenged WT and Leu9′Ala mice with the α4β2 nAChR antagonist dihydro-β-
erythroidine (DHβE). Interestingly, in Leu9′Ala mice, DHβE elicited a robust, 
reversible motor impairment characterized by hypolocomotion, akinesia, 
catalepsy, clasping, and tremor; whereas the antagonist had little effect in WT 
mice at all doses tested.  Pre-injection of nicotine (0.1 mg/kg) blocked DHβE-
induced motor impairment in Leu9′Ala mice confirming that the phenotype was 
mediated by antagonism of nAChRs.  In addition, SKF 82958 (1 mg/kg) and 
amphetamine (5 mg/kg) prevented the motor phenotype. DHβE significantly 
activated more neurons within striatum and substantia nigra pars reticulata in 
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Leu9′Ala mice compared to WT animals, suggesting activation of the indirect 
motor pathway as the circuit underlying motor dysfunction.  ACh evoked DA 
release from Leu9′Ala striatal synaptosomes revealed agonist hypersensitivity 
only at α4(non-α6)* nAChRs.  Similarly, α6 nAChR subunit deletion in an α4 
hypersensitive nAChR (Leu9′Ala/α6KO) background had little effect on the 
DHβE-induced phenotype, suggesting an α4(non-α6)* nAChR-dependent 
mechanism.  Together, these data indicate that α4(non-α6)* nAChR have an 
impact on motor output and may be potential molecular targets for treatment of 
disorders associated with motor impairment.  
 
52
II.A. Introduction 
 
Balanced dopamine (DA) concentrations in striatum (ST) are essential for proper 
functioning of the basal ganglia circuitry and voluntary movement (Rice et al., 
2011).  Pathologically low DA concentrations, as caused by progressive 
neurodegeneration of substantia nigra pars compacta DAergic neurons in 
Parkinson’s disease, leads to motor dysfunction, including akinesia, 
bradykinesia, resting tremor and catalepsy (Martin et al., 2011b).   DA release in 
striatum (as well as other brain regions such as prefrontal cortex and 
hippocampus) is, in part, modulated by nicotinic acetylcholine receptors 
(nAChRs), ligand gated cation channels expressed on DAergic cell bodies and 
terminals, which are activated by the endogenous neurotransmitter, acetylcholine 
(ACh), as well as by the addictive component of tobacco smoke, nicotine (Grady 
et al., 2007, Albuquerque et al., 2009, Tang and Dani, 2009).   Indeed, within 
striatum, high basal levels of ACh are achieved via tonic activity of striatal large 
aspiny cholinergic interneurons, suggesting activation of DAergic terminal 
nAChRs as key regulators of DA release (Zhou et al., 2001, Quik and McIntosh, 
2006, Threlfell et al., 2012). 
 
There are at least three major high affinity populations of nAChRs expressed in 
DAergic neurons in substantia nigra pars compacta: Those that contain the α4 
subunit (α4* nAChR, “*” indicates other subunits coassemble with α4 within a 
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pentameric nAChR complex), those that contain the α6 subunit (α6* nAChR), 
and those that contain both subunits (α4α6* nAChR) (Salminen et al., 2004, 
Grady et al., 2007, Salminen et al., 2007, Gotti et al., 2010). While the majority of 
data indicating an involvement of nAChRs in modulating DA release from 
DAergic nerve terminals stems from studies of rodent synaptosomes and striatal 
slices (Zhou et al., 2001, Salminen et al., 2004, Zhang et al., 2009, Exley et al., 
2012, Threlfell et al., 2012), pharmacological blockade of these receptors in mice 
have little impact on motor behavior (Dwoskin et al., 2008, Jackson et al., 
2009b).  In addition, mouse models that do not express the genes encoding 
either α4 or α6 nAChR subunits reveal few motor deficits, perhaps due to 
compensatory mechanisms (Ross et al., 2000, Champtiaux et al., 2002, Marubio 
et al., 2003).  Thus, the precise impact of α4*, α6*, and α4α6* nAChRs on motor 
behavior is unclear. 
 
While knock-out mice provide insight into the necessity of a targeted nAChR 
subunit, an alternative strategy is to study mouse models harboring “gain-of-
function” mutations in a nAChR subunit (Lester et al., 2003, Drenan and Lester, 
2012).  To date, mice with a gain-of-function mutation in both α4 and α6 subunits 
have been generated (Tapper et al., 2004, Drenan et al., 2008a).   BAC-
transgenic mice expressing α6* nAChR with a point mutation that causes agonist 
hypersensitivity are hyperactive in both a novel environment and in the home 
cage (Drenan et al., 2008a).  However, hyperactivity is abolished by crossing 
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these animals with α4 KO mice, indicating that increased motor activity is a result 
of α4α6* nAChRs that are hypersensitive to ACh (Drenan et al., 2010).  To date, 
motor activity of α4 gain-of-function mice has not been studied in detail.  
Therefore, we were interested in elucidating a role for α4* nAChRs in basal 
ganglia related-movement behavior by analyzing motor behavior in knock-in mice 
that express α4 nAChR subunits with a point mutation (a leucine mutated to an 
alanine, the Leu9′Ala line) in the second transmembrane pore-forming region 
rendering functional receptors 50-fold more sensitive to agonists including ACh 
(Tapper et al., 2004, Fonck et al., 2005).  We hypothesized that, if endogenous 
ACh stimulation of α4* nAChRs were important for DA-dependent motor 
behavior, then blockade of these receptors in Leu9′Ala mice would have 
exaggerated effects helping to uncover the role of these receptors on motor 
output. 
 
II.B. Materials and Methods 
 
Animals Male and female (8- to 14- week-old) Leu9′Ala knock-in mice, α6 KO 
mice and their wild-type (WT) littermates were used for all experiments.  The 
genetic engineering of Leu9′Ala and α6 KO mice have been described previously 
(Champtiaux et al., 2002, Tapper et al., 2004).  These mice have been 
backcrossed to the C57BL/6J background for at least 9 generations.   Mice, bred 
at University of Massachusetts Medical School or the Institute for Behavioral 
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Genetics, University of Colorado, were housed four mice/ cage, received food 
and water ad libitum and kept on a standard 12-h light:12 hr dark cycle.  All 
experiments were conducted in accordance with the guidelines for care and use 
of laboratory animals provided by the National Research Council (National 
Research Council, 1996) or the guidelines for care and use of mice provided by 
National Institutes of Health, as well as with an approved animal protocol from 
the Institutional Animal Care and Use Committee of the University of 
Massachusetts Medical School or the Animal Care and Utilization Committee of 
the University of Colorado. 
 
Drugs Nicotine hydrogen bitartrate, methyllycaconitine citrate salt hydrate, 
hexamethonium, D-amphetamine hemisulfate salt, Chloro-APB hydrobromide 
(SKF 82958), S-(-)-eticlopride hydrocloride, nomifensine, pargyline, atropine 
sulfate, bovine serum albumin (BSA) and diisopropyl fluorophosphate (DFP) 
were purchased from Sigma-Aldrich, St. Louis, MO, USA. Dihydro-β-erythrodine 
hydrobromide (DHβE) was purchased from Tocris Bioscience Bristol, UK. N-2-
(hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES) and sodium salt 
were products of BDH Chemicals distributed by VWR (Denver, CO). [3H]-
dopamine ([3H]-DA) (25-40 Ci/mmol) and Optiphase Supermix scintillation 
cocktail were purchased from Perkin Elmer Life and Analytical Sciences (Boston, 
MA). α-Conotoxin MII (α-CtxMII) was obtained from Dr. J. Michael McIntosh 
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(University of Utah). All drugs administered to mice were dissolved in 0.9% saline 
and administered via intraperitoneal (i.p.) injection at the indicated doses. 
 
Motor Characterizations Drug naïve mice were placed into novel cages and 
allowed about 30 minutes to habituate to the cage.  At time point 0 min, mice 
were tested for akinesia, catalepsy, clasping and tremor (described below).  
Immediately after baseline testing, mice were injected with saline or DHβE and 
characterizations were conducted for each mouse at the indicated time points 
over a 180 min period. In preliminary experiments, the effects of DHβE on motor 
phenotypes including locomotor activity, catalepsy, tremor and akinesia was 
analyzed, comparing genders in Leu9′Ala mice.  Because the resulting analysis 
revealed no significant effect of gender (data not shown), data from male and 
female mice were combined. 
 
Akinesia  Every 30 min, mice were placed into an empty cage and held by the tail 
so hind limbs were hovering above the floor with forelimbs in contact with the 
floor of the cage.  The number of forelimb steps forward was counted for 30 s.  
This was repeated and the two trials were averaged together. 
 
Catalepsy The forelimbs of mice were placed on a raised bar 5 cm from the floor.  
Latency to remove both forelimbs off the bar was measured for up to 2 minutes.  
Catalepsy was measured every 60 min. 
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Clasping and Tremor Mice were tested for clasping and tremor by raising a 
mouse by the tail for 30 seconds and giving a score to depict the degree to which 
the hind limbs were spread apart or for severity of a body tremor.  The scoring for 
clasping was as follows: 0= hind limbs spread wide apart (normal position), 1= 
hind limbs 25% closed, 2= hind limbs 50% closed, 3= hind limbs 75% closed with 
periods of hind limbs clasped, 4= hind limbs fully clasped for 10 seconds.  The 
severity of a body tremor was scored: 0= no tremor, 1= isolated twitches, 2= non-
continuous tremors, 3= consistent tremor. 
 
Locomotor Activity For all experiments measuring locomotor activity, mice were 
given saline injections once a day for 3 days prior to the experiment to reduce 
differences in locomotor activity due to stress from the injection and handling.  
Additionally, on the day of the experiment, mice were habituated to the room for 
1 hr to reduce differences in locomotor activity due to changes in environment 
unrelated to the novel cage.  To measure locomotor activity, mice were placed 
into an individual cage within an infrared photobeam frame (San Diego 
Instruments) and allowed to roam freely for 30 min.  Locomotor activity was 
measured by quantifying the number of beam breaks.  Mice were challenged with 
saline or DHβE and placed into the locomotor chamber at the times indicated.  
Locomotor experiments were counterbalanced such that mice were exposed to 
either saline or drug and then one week later, drug treatments were switched.   
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Thus, each mouse served as its own control.  Additional drug treatments (MLA 
and nicotine) and blocking experiments were tested in separate groups of mice. 
On the day of the experiment, mice were pre-treated with saline, nicotine, 
SKF82958, eticlopride, or amphetamine followed by saline or DHβE 5 min later 
as indicated. For the amphetamine rescue experiment, mice were injected with 
DHβE followed by an injection of saline or amphetamine 15 min after the first 
injection. Mice were placed into locomotor chambers at the times indicated post 
injection and locomotor activity was measured for 30 minutes. 
 
Immunofluorescence To avoid neuronal activation due to stress induced 
handling, all mice were injected with saline once a day for 3 days before the 
experiment.  Separate groups of drug naïve Leu9′Ala and WT mice received 
either saline or DHβE and perfused 150 minutes later.  Prior to perfusion, mice 
were deeply anesthetized with sodium pentobarbital (200 mg/kg i.p.) and then 
perfused transcardially with ice-cold 0.1 M phosphate buffer (PBS, pH 7.4) 
followed by 10 mls ice-cold 4% (W/V) paraformaldehyde (PFA) dissolved in 0.1 
M PBS (pH 7.5).  The brains were harvested and post-fixed in PFA solution for 4 
hr and then cryoprotected in PBS containing 30% sucrose.  Coronal sections (20 
µm thick) containing the striatum (ST) (between 1.18 mm and 0.38 mm from 
bregma) and the substantia nigra (SN) (between -2.92 mm and -3.8 mm from 
bregma) were sliced on a microtome (Leica SM 2000 R, Leica Microsystems Inc., 
Bannockburn IL, USA) and collected into a 24-well plate containing 1x PBS.   
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Sections were washed for 5 minutes in 1x PBS, placed into 0.4% Triton X-100 in 
PBS (PBST) for 5 minutes, washed again with 1x PBS for 5 minutes, and then 
incubated in a blocking solution containing 2% BSA in PBS for 30 min.  Sections 
were incubated with primary antibody for c-Fos (polyclonal, 1:400, Santa Cruz) 
and ChAT (monoclonal 1:100, Santa Cruz) or Tyrosine Hydroxylase (TH, 
monoclonal, 1:1000, Santa Cruz) in the blocking solution overnight at 4°C.  
Sections were washed three times for 5 minutes and incubated in blocking 
solution for 30 min followed by another incubation in the blocking solution 
containing secondary fluorescently-labeled antibodies, goat anti-rabbit Alexa 
Fluor® 488 and goat anti-mouse Alexa Fluor® 594 (1:800, Molecular Probes Inc., 
Eugene USA) at room temperature for 30 min.  Sections were washed five times 
for 5 min/wash and then mounted on slides and covered using VECTASHIELD® 
Mounting medium (Vector laboratories, Inc., Burlingame, CA, USA).   A 
fluorescence microscope (Zeiss, Carl Zeiss MicroImaging Inc, NY, USA) was 
used to identify c-Fos immunopositive neurons, by quantifying intensities that 
were at least two times higher than that of the average value of background 
(sections stained without primary antibody) using a computer-associated image 
analyzer (Axiovision Rel. 4.6).  The TH stain was used to identify the location of 
the SNpc (DAergic) and the SNpr, which is non-DAergic and located below the 
SNpc.    
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[3H]-Dopamine release The methods of Salminen et al, 2007 were followed. 
Briefly, freshly dissected striata were homogenized by hand in 0.5 ml ice-cold 
isotonic sucrose buffered with HEPES (5 mM, pH 7.4). After dilution to 2 ml, 0.5 
ml aliquots were centrifuged at 12,000 x g for 20 min at 4oC.  Aliquots were 
stored on ice as pellets (maximum time 3 hours) until re-suspension in uptake 
buffer [128 mM NaCl, 2.4 mM KCl, 3.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 25 mM HEPES (pH 7.5), 10 mM glucose, 10 µM pargyline, 1 mM 
ascorbic acid)] and incubated at 37oC for 10 min. [3H]-DA (0.1 µM) and DFP (10 
µM) were added and incubation continued for 5 min longer. At this point 8 
aliquots of the crude synaptosome suspension (80 µl each) were placed on filters 
on superfusion platforms and superfused with buffer (uptake buffer with 0.1% 
BSA, 1 µM atropine and 1 µM nomifensine added) at 22oC for 10 min before 
stimulation with various concentrations of agonist or agonist + DHβE in buffer for 
20s followed by buffer. Alternate aliquots were superfused with buffer alone for 7 
min, followed by buffer containing α-CtxMII (50 nM) for 3 min to block activity of 
α6β2*-nAChRs and, subsequently, the same stimulation protocol.  Fractions were 
collected (10s each) into 96-well plates for ~1 min before stimulation, during 
stimulation and ~ 3 min following stimulation using a Gilson FC204 fraction 
collector (Middletown, WI). After addition of Optiphase Supermix scintillation 
cocktail (0.15 ml/well) radioactivity was determined using a 1450 MicroBeta Trilux 
counter (Perkin Elmer Life Sciences-Wallac Oy, Turku, Finland). Data were 
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expressed as units of DA release [summed (cpm – baseline cpm)/(baseline 
cpm)] for fractions 10% or more above baseline. 
 
Data analysis Behavioral immunohistochemical and DA release data were 
analyzed with t-test, one or two-way ANOVA with repeated measures as 
indicated. Post-hoc analysis was done using Bonferroni post-hoc tests. Data 
were analyzed using Graphpad Prism 5 software (Graphpad Software, La Jolla, 
CA, USA).  DA release data were analyzed by curve-fitting using SigmaPlot 8.0 
(Jandel Scientific, San Raphael, CA). 
 
II.C. Results 
 
Previous studies indicate that BAC transgenic mice expressing agonist 
hypersensitive α6* nAChRs are hyperactive and that hyperactivity is abolished 
with genetic deletion of α4 subunit expression (Drenan et al., 2010).  To test the 
hypothesis that Leu9′Ala mice, which harbor a similar mutation in the α4 subunit 
rendering α4* nAChR hypersensitive to ACh and nicotine, are hyperactive, we 
measured baseline locomotor activity of WT and homozygous Leu9′Ala mice.  
Locomotor activity did not significantly differ between genotype (data not shown).  
To test the hypothesis that motor output in Leu9′Ala mice was more sensitive to 
endogenous ACh compared to WT, we challenged Leu9′Ala mice and their WT 
littermates with the competitive β2* nAChR antagonist, DHβE and motor 
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behaviors such as akinesia, catalepsy, clasping, tremor (Figure II-1) and 
locomotor activity (Figure II-2) were measured.   Much like the DA 2 receptor 
(D2R) agonist, quinpirole (Zhao-Shea et al., 2010), DHβE elicited a profound 
abnormal motor phenotype in Leu9′Ala mice compared to WT.  Figure II-1, 
depicts WT and homozygous Leu9′Ala mice 90 min after an i.p. injection of saline 
or DHβE (3 mg/kg in WT and 1 mg/kg in Leu9′Ala, respectively).  DHβE had little 
effect in WT mice (Fig. II-1a), but induced postural abnormalities, such as 
curvature of the back and tail and clasping of the limbs in Leu9′Ala mice 
(indicated by arrows, Fig. II-1b).  Two-way repeated measures ANOVA of 
akinesia (Fig. II-1c) after DHβE in WT and Leu9′Ala mice revealed a significant 
effect of time (F6,108 = 9.030, p<0.0001), genotype (F3,18 = 10.54, p<0.001) and a 
significant interaction between genotype and time (F6,108= 9.966, p<0.0001).  
Post-hoc analysis indicated DHβE significantly reduced number of forelimb steps 
forward in Leu9′Ala compared with WT mice at 30 min (p<0.05) and 60 min 
(p<0.05) post-injection.   Comparison of the cataleptic effect of DHβE in WT and 
Leu9′Ala mice (Fig. II-1d), analyzed by a two-way repeated measures ANOVA, 
did not indicated a significant effect of genotype, time, nor an interaction.  
Analysis of clasping (Fig. II-1e), by two-way repeated measures ANOVA, 
indicated a significant effect of genotype (F3,11 = 20.23, p<0.0001), time (F6,66 = 
3.31, p<0.01), and interaction between genotype and time (F18,66 = 3.67, 
p<0.001).  Further post-hoc analysis revealed that DHβE induced significant 
increases in clasping in Leu9′Ala compared to WT mice at 60 (p<0.05), 90 
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(p<0.001), 120 (p<0.01), 150 (p<0.05), and 180 (p<0.01) min.   Two-way 
repeated measures ANOVA of DHβE-induced tremors (Fig. II- 1f) in Leu9′Ala and 
WT mice revealed a significant effect of genotype (F3,15 = 4.983, p<0.05) and 
interaction between genotype and time (F18,90 = 2.437, p<0.05).  Post-hoc tests 
indicated a significant increase in tremor at 90 and 120 min post DHβE injection 
in Leu9′Ala mice compared to WT.  There was no difference between WT and 
Leu9′Ala mice after a saline injection in any of the motor behavior assays. 
 
To test the effects of blocking α4* nAChRs on locomotion (Figure II-2), saline 
(i.p.) or DHβE was administered to WT (3 mg/kg, i.p., Fig. II-2a, b) and Leu9′Ala 
mice (0.1, 0.3, 1 mg/kg, and 24 hr later (1 mg/kg), i.p., Fig. II-2c, d) and 
locomotor activity was recorded starting at 60 min after post-injection for 30 
minutes.  DHβE (3 mg/kg) did not significantly alter the time course of locomotor 
activity or total ambulation over 30 min in WT mice (Fig. II-2a, b) compared to 
saline injection.  However, DHβE (1 mg/kg) significantly reduced Leu9′Ala 
locomotor activity compared to saline (Fig. II-2c, d).  Two-way repeated 
measures ANOVA revealed a significant effect of drug treatment (F3,11 = 4.637, 
p<0.05), time (F5,55 = 23.19, p<0.0001) and a significant drug treatment ×  time 
interaction (F15,55 = 3.578, p<0.001). Interestingly, locomotor activity returned to 
baseline levels 24 hr after DHβE challenge indicating the effects of DHβE in 
Leu9′Ala mice were reversible. One-way ANOVA revealed a significant main 
effect of treatment in total ambulation in Leu9′Ala mice (Fig. II-2d) (F3,11 = 3.646, 
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p<0.05). Post-hoc analysis indicated that total locomotor activity after 1 mg/kg 
DHβE injection was significantly lower compared to saline (p<0.01) and 24 hr 
post DHβE challenge (p<0.01).  Additionally, locomotor activity was unaffected by 
systemic administration of hexamethonium (1 mg/kg, i.p.), a nAChR antagonist 
which fails to cross the blood brain barrier, indicating that DHβE-induced motor 
dysfunction in Leu9′Ala is mediated by neuronal nAChRs (data not shown).  MLA 
(10 mg/kg, i.p. Fig. II-2e and 2f), an α7 nAChR antagonist, had little effect on 
locomotor activity in Leu9′Ala mice compared to saline, indicating that the DHβE-
induced hypolocomotion was likely a result of blocking α4β2* nAChRs.    To test 
the hypothesis that DHβE is, in fact, acting as a competitive antagonist at α4β2* 
nAChRs, we injected Leu9′Ala mice with nicotine (0.1 mg/kg, i.p.) 5 min prior to 
challenge with DHβE (1 mg/kg, i.p.) and measured locomotor activity 1 hr post 
injection. Interestingly, nicotine (0.1 mg/kg, i.p.) prevented DHβE-induced 
hypolocomotion in Leu9′Ala mice (Fig. II-2e) indicating that the DHβE phenotype 
is specifically elicited by blockade of nAChRs. 
 
DHβE induced motor deficits in Leu9′Ala mice through blockade of neuronal 
nAChRs via a CNS-specific mechanism, raising the possibility that DHβE is 
blocking α4* nAChRs in the basal ganglia.  Importantly, α4* nAChRs are robustly 
expressed in DAergic neuron soma and terminals of the substantia nigra pars 
compacta where they modulate DA release in dorsal ST (Salminen et al., 2004).  
Thus, antagonizing these receptors could decrease DA release and elicit the 
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observed hypolocomotor phenotype. To test a potential involvement of DA, 
Leu9′Ala mice were pre-injected with SKF82958, a D1R agonist (1 mg/kg, i.p), 
eticlopride, (1 mg/kg, i.p.), a D2R antagonist, or the dopamine transporter 
competitive substrate, amphetamine (5 mg/kg, i.p.), 5 minutes prior to a DHβE 
challenge (1 mg/kg, i.p.) and locomotor activity was measured 90 min later (Fig. 
II-3a, b).  Two-way repeated measures ANOVA revealed a significant effect of 
pre-injection (F3,17 = 31.43, p<0.0001), time (F5, 85 = 5.21, p<0.001) and 
significant interaction (F15, 85 = 2.09, p<0.05).  Post-hoc analysis indicated 
amphetamine and SKF82958 significantly increased locomotor activity compared 
to DHβE alone (Fig. II-3a).  A one-way ANOVA of average total ambulation (Fig. 
II-3b) indicated a significant effect of drug pre-injection (F3,14 = 25.77, p<0.001) 
and post-hoc analysis revealed that amphetamine (p<0.001) and SKF82958 
(p<0.05) significantly increased locomotor activity compared to DHβE alone 
suggesting increasing DA release in striatum or activating D1Rs is sufficient to 
prevent DHβE-induced hypolocomotion in Leu9′Ala mice.  Although statistical 
analysis of eticlopride did not indicate a significant difference, there was a partial 
block of hypolocomotor activity indicated by increased locomotor activity counts 
above zero. In addition, all DA signaling compounds prevented rigidity (data not 
shown).   
 
To test if increasing DAergic signaling could rescue DHβE-induced 
hypolocomotion in Leu9′Ala mice, we challenged Leu9′Ala mice with DHβE and 
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administered saline or amphetamine 15 min after the initial antagonist injection 
(Fig. II-3c, and 3d).   Two-way repeated measure ANOVA revealed a significant 
effect of post-injection (F1,6 = 19.91, p < 0.01) but not time. Post-hoc analysis 
indicated an amphetamine post-injection significantly increased activity 
compared to saline at each time point.  Average total locomotor activity was also 
significantly increased after an amphetamine post-injection compared to saline (t 
= 4.46, p < 0.01).   We also tested the action of SKF82958, eticlopride, or 
amphetamine alone in WT (Fig. II-4a and b) and Leu9′Ala (Fig. II-4e and f) mice 
in the absence of DHβE.  A two-way repeated measures ANOVA of drug 
treatment over time in WT mice (Fig. II-4a) revealed a significant main effect of 
drug treatment (F3,20 = 26.18, p<0.0001), time (F5,100 = 16.25, p<0.001) and a 
significant interaction between drug treatment and time (F15,100 = 3.42, p<0.001).  
Post-hoc analysis indicated a significant effect of amphetamine at various time 
points as indicated in FigII-4a.  One-way ANOVA indicated that there was a 
significant effect of drug treatment (F3,23 = 26.18, p<0.0001) on total locomotor 
activity summed over 30 min. Further post-hoc analysis revealed a significant 
increase in locomotor activity after amphetamine (p<0.001), a significant 
decrease after eticlopride (p<0.05), but no difference after SKF82958 compared 
to a saline injection.  These drugs had similar effects in Leu9′Ala mice (Fig. 4c 
and d, a significant main effect of drug treatment, F3,20 = 9.98, p<0.001 and time, 
F5,100 = 6.94, p<0.001).  There was also a significant effect of drug treatment 
when analyzing total locomotor activity over 30 min (Fig. II-4d) (F3, 23 = 9.781, 
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p<0.001, One-Way ANOVA) and post-hoc analysis revealed amphetamine 
significantly increased locomotor activity (p<0.01), while eticlopride decreased 
locomotor activity (p < 0.05).  Effects of DA signaling did not differ between 
genotypes (two-way ANOVA indicated a significant effect of drug treatment (F3,40 
= 22.66, p<0.0001) but not genotype nor a significant interaction).  Taken 
together these data indicate that prevention of DHβE-induced hypolocomotion in 
Leu9′Ala mice was not an artifact of baseline hypersensitivity to DA signaling 
compounds in these animals. 
 
Targeting DA receptor signaling through pharmacology was able to fully or 
partially alleviate DHβE-induced hypolocomotion in Leu9′Ala mice, suggesting a 
role for the direct and indirect basal ganglia pathways.  To test this hypothesis, 
we used immunohistochemistry to examine c-Fos expression as a marker for 
neuronal activation in the dorsal ST (Fig. II-5a) and substantia nigra pars 
reticulata (SNr) (Fig. II-5b) of WT and Leu9′Ala mice in response to DHβE.   For 
this experiment, WT and Leu9′Ala mice were challenged with saline (i.p.) or 
DHβE (1 mg/kg, i.p.) and the dorsal ST was immunolabled for c-Fos (a 
transcription factor and marker of neuronal activation (Cole et al., 1989) (red), 
ChAT (cholinergic acetyltransferase to identify cholinergic neurons, green) and 
the nucleic acid stain, 4',6-diamidino-2-phenylindole (DAPI) (blue).  The SNr was 
stained for c-Fos (green), tyrosine hydroxylase (TH, a marker of 
catecholaminergic neurons, specifically of DAergic neurons in the SN pars 
68
compacta, red), and DAPI (blue).  Figures II-5a and b depict micrographs 
illustrating c-Fos expression after DHβE injection in Leu9′Ala mice.  The total 
number of c-Fos immuno-positive neurons was counted in each brain region and 
analyzed by a two-way ANOVA.  In the dorsal ST (Fig. II-5a), there was a 
significant effect of drug treatment (F1,108 = 20.68, p<0.001), genotype (F1,108 = 
19.46, p<0.001), and a significant interaction between drug treatment and 
genotype (F1,108 = 20.78, p<0.001).  Post-hoc analysis indicated that there was a 
significant increase of c-Fos immuno-positive neurons in the dorsal ST in 
Leu9′Ala mice after DHβE (p<0.001) compared to WT.  In the SNr there was a 
significant effect of drug treatment (F1,52 = 31.44, p<0.001), genotype (F1,52 = 
30.88, p<0.001), and a significant interaction between drug treatment and 
genotype (F1,52 = 31.44, p<0.001).  Post-hoc analysis indicated that there was a 
significant increase of c-Fos immuno-positive neurons in the dorsal ST in 
Leu9′Ala mice after DHβE (p<0.001) compared to WT.  c-Fos expression did not 
colocalize with ChAT immuno-positive (i.e. cholinergic) neurons in ST or TH 
immune-positive neurons in SNpc indicating that neurons activated by DHβE 
were likely GABAergic.  DHβE did not significantly increase c-Fos expression in 
WT mice compared to saline in either brain region.  Together these data indicate 
that there is activation of neurons within the motor pathway, specifically of the 
indirect pathway which controls/reduces movement in Leu9′Ala mice challenged 
with DHβE, indicated by activation of both dorsal ST and SNr (Gerfen and 
Surmeier, 2011). 
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To test the hypothesis that DA release in ST from Leu9′Ala mice is more 
sensitive to nicotinic agonists compared to WT, we compared ACh-evoked and 
nicotine-evoked DA release from ST synaptosomes of Leu9′Ala homozygous, 
heterozygous, and WT mice.  Both ACh- and nicotine-stimulated DA release from 
striatal synaptosomes was concentration-dependent in all three genotypes (Fig. 
II-6).  The total concentration-response relationship for ACh-mediated DA release 
in Leu9′Ala heterozygous and homozygous was only slightly changed compared 
to WT synaptosomes with a small shift to lower EC50 values (Fig. II-6a, Tables II-
1 and II-2). A somewhat larger leftward shift was seen in Leu9′Ala heterozygous 
and homozygous synaptosomes compared to WT using nicotine as agonist (Fig. 
II-6d, Tables II-1 and II-2). To determine the relative contribution of α4* versus 
α6* nAChRs on agonist-evoked DA release, we measured release in the 
presence of α-conotoxin MII (α-CtxMII), an α6* nAChR selective antagonist (Fig. 
II-6b and 6e).  The α-CtxMII-resistant fraction of DA release (mediated by α4β2*-
nAChR) was more sensitive to both ACh and nicotine in heterozygous and 
homozygous Leu9′Ala synaptosomes compared to those from WT mice (Fig. II-
6b, 6e and Table II-1) and maximum release was significantly decreased (Figure 
II-6b, 6e and Table II-2).  In contrast, the α-CtxMII-sensitive component of DA 
release (mediated by α6β2*-nAChR) in Leu9′Ala homozygous synaptosomes 
was not significantly more sensitive to either agonist compared to heterozygous 
or WT synaptosomes (Fig. II-6c, 6f and Table II-1).  However, Rmax was 
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significantly increased for the α-CtxMII-sensitive component of nicotine 
stimulated DA release (Fig. II-6c, 6f and Table II-2).  Together, these data 
indicate that α4(non-α6)* nAChRs in striatal synaptosomes are hypersensitive to 
agonist in Leu9′Ala heterozygous and homozygous mice. 
 
As blockade of α4β2* nAChRs using DHβE elicited a hypolocomotor phenotype 
in Leu9′Ala mice, we next measured the inhibitory-response relationship for 
DHβE on agonist evoked DA release in Leu9′Ala and WT synaptosomes (Fig. II-
7) as well as determined Ki values for each genotype for DHβE inhibition of ACh-
evoked release (Table II-3).  At α4(non-α6)*-nAChRs as well as at α6*-nAChRs, 
DHβE dose-dependently inhibited DA release evoked by either ACh (Fig. II-7) or 
nicotine (data not shown).  Interestingly, evoked DA release at α4(non-α6)* 
nAChR in Leu9′Ala homozygous synaptosomes was significantly more resistant 
to DHβE than the WT or heterozygous Leu9’Ala under equivalent agonist 
activation (Fig. II-7 and Table II-3). This effect is largely caused by a decrease in 
EC50 value (~9-fold) at α4*-nAChR with some increase (~2-fold) in Ki value for 
DHβE (Table II-3). EC50 values for ACh at α6*-nAChR (Table II-1) as well as Ki 
values for DHβE at α6*-nAChR (Table II-3) were unchanged by the α4Leu9′Ala 
mutation despite the known existence of the α4α6β3β2-nAChR subtype in 
DAergic neurons of WT mice (Salminen et al., 2004, Salminen et al., 2007). 
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To determine the contribution of α6*-nAChRs to the DHβE-induced phenotype in 
Leu9′Ala mice, we crossed Leu9′Ala mice to α6 KO animals and measured 
locomotor responses after antagonist treatment (Fig. II-8).   In α6 KO mice on an 
α4 WT background, DHβE did not significantly modulate activity compared to 
saline (Fig. II-8a, b).  Interestingly, DHβE significantly reduced locomotor activity 
in Leu9′Ala homozygous mice on an α6 KO background compared to saline and 
resulted in a motor phenotype indistinguishable from Leu9′Ala mice on a WT 
background (Fig. II-8b, c). 
 
II.D. Discussion 
 
Hypersensitive α4* nAChRs do not affect basal levels of locomotor activity 
 
Previously, hyperactivity was reported in a BAC transgenic mouse line 
expressing hypersensitive α6* nAChRs, suggesting a functional role for this 
receptor subtype in baseline motor behavior (Drenan et al., 2008b).  
Hyperactivity in this mouse line was also dependent on expression of the α4 
subunit as crossing the α6 hypersensitive line to an α4 KO mouse line abolished 
locomotor hyperactivity (Drenan et al., 2010).  Interestingly, we observed no 
significant differences in baseline locomotor activity between Leu9′Ala and WT 
mice.  Recently, Cohen et. al. reported hyperactivity in BAC α6* nAChRs was a 
consequence of α6* L9′S nAChR subunit copy number (Cohen et al., 2012).  
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Mice with lower copy numbers were not hyperactive compared to those with 
higher copy numbers.  Since Leu9′Ala α4 mice were generated via homologous 
recombination and only express two copies of the Leu9′Ala α4 nAChR gene 
(Tapper et al., 2004), it is possible that hyperactivity would be observed in mice 
expressing additional copies of the mutant nAChR subunit gene.   Alternatively, 
compensation may account for the lack of hyperactivity. Leu9′Ala mice developed 
with α4* nAChRs hypersensitive to ACh, therefore there may be compensatory 
nAChR receptor expression, replacement of nAChR subunits, or altered DA 
receptor expression.  Indeed, α4* nAChR activity is down-regulated in 
homozygous Leu9′Ala thalamus and cortical synaptosomes compared to WT 
(Fonck et al., 2005).  In addition, expression of α6* nAChRs is limited to DAergic 
nerve terminals (Drenan et al., 2008a); whereas α4* nAChRs are widely 
expressed in DAergic, GABAergic, and glutamatergic neurons within the 
nigrostriatal pathway (Champtiaux et al., 2003, Marubio et al., 2003, Wooltorton 
et al., 2003, Xiao et al., 2009).  Lack of hyperactivity may be a consequence of 
α4* nAChR activity in non-DAergic neurons. 
 
Antagonism of hypersensitive α4* nAChRs leads to motor deficits 
 
Antagonism of α4* nAChRs in Leu9′Ala mice evoked robust, reversible 
parkinsonian-like symptoms characterized by hypoactivity, akinesia, catalepsy, 
and tremor.  These symptoms have been previously shown to be associated with 
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DA depletion.  Therefore we hypothesize that the abnormal motor symptoms 
observed after blocking hypersensitive α4* nAChRs are an effect of low levels of 
DA in dorsal ST.  Although absolute confirmation of our hypothesis requires 
measuring DA release in striatum in vivo, DHβE induced c-Fos expression in 
Leu9′Ala dorsal ST and SNpr suggests inactivation of the direct motor pathway 
and activation of the indirect motor pathway.  Indeed, the motor phenotype was 
alleviated by 1) increasing DA release using amphetamine, 2) by increasing 
direct motor pathway activation directly through D1R agonism, or 3) by 
antagonizing D2Rs, thereby redirecting available DA to activate the direct 
pathway.  DHβE had no measureable behavioral effect in WT mice potentially 
because blockade of WT α4* nAChRs may not reduce striatal DA concentrations 
sufficiently low enough to induce a measurable motor phenotype. 
 
Effect of DHβE is independent of α6 subunit incorporation 
 
Although α4* and α6* nAChRs are expressed in DAergic nerve terminals in 
striatum, their functional roles are not equal in this region.  DA release in the 
ventral striatum, associated with reward based behaviors, is preferentially 
modulated by α6* and α4α6* nAChRs versus α4(non-α6)* nAChRs while the 
latter preferentially modulate DA release in the dorsal ST, associated with 
movement (Salminen et al., 2007, Drenan et al., 2008b, Exley et al., 2008, Exley 
et al., 2011, Exley et al., 2012).  Approximately 25 to 30% of agonist evoked 
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[3H]dopamine release from dorsal ST synaptosomes is mediated by α6* nAChRs 
resulting in a potentially more robust role for α4* nAChRs in modulating dorsal 
ST DA release  (Salminen et al., 2004).  In addition, approximately 50 to 60% of 
terminally expressed α6* nAChRs also contain an α4 subunit, which increases 
the receptors’ sensitivity to ACh (Champtiaux et al., 2003, Marubio et al., 2003, 
Salminen et al., 2004, Salminen et al., 2007).  Interestingly, the dose response 
relationship for agonist induced DA release in striatal synaptosomes was shifted 
to the left in Leu9′Ala mice compared to WT only for the α-CtxMII insensitive 
nAChR fraction indicating that α4(non-α6)* nAChRs were hypersensitive to 
agonist; whereas Rmax was increased in the α-CtxMII sensitive fraction indicating 
a compensatory increase in α6* nAChRs in Leu9′Ala synaptosomes.  Knocking 
out the α6 subunit in hypersensitive α4* nAChR Leu9′Ala mice had no effect on 
the motor phenotype induced by DHβE suggesting that observed behaviors are 
caused solely by antagonism of α4(non-α6)* nAChRs.    It was recently reported 
that regulation of DA release probability in the dorsal ST is dominated by α4α5* 
nAChRs and that incorporation of α5 is critical for functioning of DA release from 
terminal expressed α4* nAChRs (Exley et al., 2012).   Incorporation of the α5 
subunit into α4* nAChRs increases agonist sensitivity and also increases 
permeability to Ca++ (Ramirez-Latorre et al., 1996, Tapia et al., 2007).  In striatal 
synaptosome preparations, α4α5* nAChRs are responsible for ~70% DA release 
(Salminen et al., 2004).  Additionally, these receptors are more resistant to 
desensitization (Grady et al., 2012).  Thus it is likely that the DHβE-sensitive 
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nAChRs responsible for the abnormal motor phenotype in Leu9′Ala mice also 
contain the α5 subunit.   These receptors may regulate basal DA concentrations 
in dorsal ST. 
 
Implications of nAChRs mediated DA release 
The relationship between cholinergic and DAergic signaling in the striatum is 
complex.  Cholinergic neurons are tonically active and pauses in their activity 
coincide with changes from a phasic to bursting activity in DA neurons which 
increase DA release for neuronal signaling encoding messages for reward, 
learning, and motor behaviors (Rice et al., 2011).  Depleting endogenous ACh 
decreases electrically evoked DA release by 90%, highlighting the balance of 
ACh and DA (Zhou et al., 2001).  Additionally, synchronous cholinergic activation 
can increase DA release via terminal nAChRs; a process independent of 
neuronal activity (Threlfell et al., 2012).  In WT mice, DHβE blocked this increase 
in DA release revealing that α4β2* nAChRs mediate this response.  Our model 
suggests that α4(non-α6)* nAChRs play a significant role in maintaining DA 
levels for normal movement behavior which may be, in part, regulated by this 
uncoupled terminal DA release. While the DHβE-induced phenotype in Leu9′Ala 
mice observed in our study is likely exaggerated due to the agonist 
hypersensitivity of α4* nAChRs in this mouse line, it nevertheless indicates the 
importance of these receptors on motor function.  Motor output in normal 
functioning basal ganglia may not be affected by antagonism of these receptors 
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most likely due to redundancy of DA modulatory mechanisms.  However, under 
pathological conditions when a substantial number of DA neurons have 
degenerated, such as in Parkinson’s disease, targeting these receptors may 
have a larger impact on motor deficits and may be ideal candidates for 
therapeutic drugs. 
 
Much like the phenotype described here, we previously reported that Leu9′Ala 
mice treated with a DA D2 receptor agonist, quinpirole, also develop reversible 
akinesia, rigidity, catalepsy, and tremor (Zhao-Shea et al., 2010).  Here we show 
that directly blocking α4* nAChRs in Leu9′Ala leads to a more severe phenotype.  
More precisely, quinpirole-treated Leu9′Ala homozygous mice most closely 
resemble DHβE-treated Leu9′Ala heterozygous mice (data not shown); whereas 
hypolocomotion is more severe in DHβE-treated Leu9’Ala homozygous mice. 
Thus, it is possible that a functional interaction between D2Rs and α4* nAChRs 
on DA terminals occurs such that activation of D2Rs inhibits α4* nAChRs, 
potentially working in concert as a mechanism to regulate striatal DA levels 
(Quarta et al., 2006). 
 
It is also possible these Leu9’Ala mice have altered connectivity of GABA 
interneurons that control activity of the direct and indirect pathways similar to that 
shown under low DA conditions, where 6-OHDA treatment and subsequent DA 
depletion led to an increase in connections between fast-spiking interneurons 
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and indirect pathway neurons (Gittis et al., 2011, Gittis and Kreitzer, 2012).  Such 
a change could alter the importance of ACh levels controlled by DA D2 receptors 
on cholinergic interneurons as well as activation of nAChRs on GABA 
interneurons. The result could be activation of indirect pathway neurons relative 
to the direct pathway upon decrease of ACh release or block of α4β2 nAChR. 
 
We have shown that antagonism of hypersensitive Leu9′Ala α4* nAChRs in mice 
induces a robust, reversible motor phenotype, which can be prevented by 
targeting the DAergic system.  α4(non-α6)* nAChRs play a major role in this 
response suggesting that these receptors may be critical for maintaining DA 
levels necessary for normal motor behavior.  Together these data indicate 
α4(non-α6)* nAChRs in dorsal ST may represent therapeutic candidates for 
alleviating motor dysfunction, such as in Parkinson’s Disease.  
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Figure II-1  
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Figure II-1.  DHβE induces motor abnormalities in Leu9'Ala mice.  a-b) 
Representative pictures of the phenotypic effect induced by DHβE 90 minutes 
after injection in a) WT (3 mg/kg DHβE, i.p.) and b) Leu9'Ala homozygous  (1 
mg/kg DHβE, i.p.) mice.  Arrows highlight hind limb rigidity, arched back, and 
curled tail in Leu9'Ala mice.  c-f)  Motor symptoms were characterized every 30 
min for 180 min in WT and Leu9'Ala mice immediately following an i.p. challenge 
of 3 or 1 mg/kg DHβE, respectively. c) Akinesia: Number of forelimb steps 
forward were counted for 30 seconds (WT SAL: n=4, WT DHβE: n=4, Leu9'Ala 
SAL: n=4, Leu9'Ala DHβE: n=7). d) Catalepsy: Latency for forelimbs to fall off a 
raised bar was recorded (WT SAL: n=4, WT DHβE: n=5, Leu9'Ala SAL: n=4, 
Leu9'Ala DHβE: n=6).  e) Clasping of hind limbs during a 10 second period was 
measured: 0 = hind limbs spread wide apart, 1 = hind limbs are 25% closed, 2 = 
hind limbs are 50% closed, 3 = hind limbs are 75% closed with some clasping, 4 
= constant clasping. (WT SAL: n=4, WT DHβ E:  n=5, Leu9'Ala SAL: n=4, 
Leu9'Ala DHβE: n=3).  f) Tremor score:  0 = no tremor, 1 = isolated twitches, 2 = 
tremor with periods of calm, 3 = constant tremor (WT SAL: n=4, WT DHβE:  n=4, 
Leu9'Ala SAL: n=4, Leu9'Ala DHβE: n=7). *p<0.05, **p<0.01, and ***p<0.001 
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Figure II-2 
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Figure II-2.  DHβE induces hypolocomotion in Leu9'Ala mice.  a) WT mice 
were placed into novel cages 60 minutes after saline (i.p., n=4) or DHβE 
challenge (3 mg/kg, i.p, n=4) and locomotor activity was measured for 30 
minutes. Each data point represents the 5 min sum of ambulatory activity.  b) Bar 
graphs represent total ambulation during 30 min of locomotor activity in WT mice 
measured in panel a.  c) Locomotor activity in homozygous Leu9'Ala mice 60 min 
after saline (i.p., n=4), 60 min after DHβE (0.1-1 mg/kg, i.p., n=4), and 24 hrs 
after DHβE (1 mg/kg, i.p, n=4). d) Total ambulation was quantified for each 
condition as in panel b.  e)  Saline (i.p., n=4), MLA (10 mg/kg, i.p., n=4), DHβE (1 
mg/kg, i.p., n=4), and NIC (0.1 mg/kg, i.p.) 5 minutes before DHβE (1 mg/kg, i.p., 
n=4) was administered to Leu9'Ala mice and locomotor activity was measure 60 
min later.  f) Total ambulation over 30 minutes in Leu9'Ala mice was quantified 
for each condition in panel e and compared to saline control. *p<0.05 and **p < 
0.01 
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Figure II-3. Pharmacologically targeting DAergic signaling prevents DHβE-
induced hypolocomotion in Leu9'Ala mice. a) Homozygous Leu9'Ala mice 
were placed into novel cages 90 min after administration of DHβE (1 mg/kg, i.p.) 
after preinjection of saline (SAL, 1 mg/kg; i.p.; n=4), SKF-38393 (SKF, 1 mg/kg, 
i.p., n=4), eticlopride (ETIC, 1 mg/kg, i.p., n=4), or amphetamine (AMPH, 5 
mg/kg, i.p., n=4) and activity was measured for 30 min. Each data point 
represents the 5 min sum of ambulation at a given time point. b) Averaged 30 
min sum of activity was quantified. c) Homozygous Leu9'Ala mice were 
challenged with DHβE (1 mg/kg, i.p.) followed by a saline (n = 4) or amphetamine 
(5 mg/kg, i.p., n = 4) injection 15 min later.  Mice were placed into activity cages 
90 min after the DHβE injection when motor deficits were at their peak.  d) 
Averaged 30 min sum of activity was quantified.  *p<0.05,  **p < 0.01, ***p < 
0.001. 
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Figure II-4.  DAergic signaling is not altered in Leu9'Ala mice compared to 
WT mice.  Locomotor activity was measure 90 minutes after administration of 
saline (i.p., n=6), SKF (1 mg/kg, i.p., n=6), ETIC (1 mg/kg, i.p., n=6), and AMPH 
(5 mg/kg, i.p., n=6) in a) WT and c) Leu9'Ala.  Total ambulation over 30 minutes 
for b) WT and d) Leu9'Ala mice after challenge of drugs from panel a and c, 
respectively as in Figure 3.  *p<0.05 and ***p<0.001 
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Figure II-5.  Neuronal activation by DHβE in the dorsal ST and SNr. WT and 
homozygous Leu9′Ala were perfused 150 minutes after a challenge of saline 
(i.p.) or DHβE (1 mg/kg, i.p.) and coronal sections (20 µm thick) from the dorsal 
ST or SNr were isolated and immunolabeled to detect c-Fos and ChAT 
expression (ST) or TH expression (SNr).  a) Top, representative brain atlas 
picture of illustrating ST region analyzed.  An immuno-labeled coronal section 
from Leu9’Ala mice after injection with DHβE depicting c-Fos (red) and ChAT 
(green) expression is shown. DAPI stained nuclei are labeled blue.  Bottom, 
number of c-Fos immuno-positive neurons/slice in WT and Leu9′Ala mice after 
saline or DHβE injection (3 mice/ treatment, 10 slices/mouse).  b) Top, 
representative brain atlas picture of illustrating SNr region analyzed. An immuno-
labeled coronal section from Leu9’Ala mice after injection with DHβE depicting c-
Fos (green) and TH (red) expression is shown. DAPI stained nuclei are labeled 
blue.   c and d) quantification of c-Fos immuno-positive neurons in WT and 
Leu9'Ala after saline or DHβE (3 mice/ treatment, 10 slices/mouse).  ***p<0.001 
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Figure II-6. Concentration response curves for ACh- and nicotine-
stimulated [3H]-DA release from striatal synaptosomes.  a) Total ACh-
stimulated [3H]-DA release, b) α4β2*-nAChR mediated [3H]-DA release 
measured in the presence of α-CtxMII (50 nM) and c) α6β2*-nAChR-mediated 
[3H]-DA release determined by difference (a – b). Data represent means ± sem 
for n=9 +/+, n=8 +/Leu9′Ala and n=10 Leu9′Ala/Leu9′Ala mice.  d-f) Analogous 
curves for nicotine-stimulated response.  Data represent means ± SEM for n=8 
mice of each genotype. 
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Figure II-7. Effect of DHβE on ACh-stimulated [3H]-DA release.  The α-
CtxMII- resistant (α4β2*-nAChR-mediated) response in the homozygous 
Leu9′Ala is significantly less inhibited by DHβE (* different from WT) under the 
three conditions tested. The heterozygous Leu9′Ala were different only for 
condition b. No differences with genotype were seen for the effect of DHβE on 
the α-CtxMII-sensitive (α6β2*-nAChR mediated) portion of the response. All data 
expressed as % response in the absence of DHβE. Data represent means ± 
SEM for n=5 +/+, n=4 +/Leu9′Ala and n=3 Leu9′Ala/Leu9′Ala mice. 
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Figure II-8. α4(non-α6)β2* nAChRs mediate effect of DHβE in Leu9′Ala 
mice.  a) α6KO/WT (n=8) mice were placed into novel cages 60 min after saline 
or DHβE challenge (1 mg/kg, i.p) and locomotor activity was measured for 30 
minutes. Each data point represents the 5 min sum of ambulatory activity. b) 
Average summed ambulation over 30 min from panel a.  c) α6KO/Leu9′Ala mice 
(n=2) were placed into novel cages 60 min after saline or DHβE challenge (1 
mg/kg, i.p) and locomotor activity was measured for 30 minutes. Each data point 
represents the 5 min sum of ambulatory activity.  b) Bar graphs represent 
averaged total ambulation during 30 min of locomotor activity in WT mice 
measured in panel a.  *p<0.05, **p<0.01, and ***p<0.001. 
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Table II-1. Comparison of EC50 values for DA release  
Genotype  EC50 (µM) for 
Total DA 
release  
EC50 (µM) for 
α4β2-
mediated 
α-CtxMII-
resistant 
EC50 (µM) 
for 
α6β2-
mediated 
α-CtxMII-
sensitive 
+/+       ACh 0.41 ± 0.06 0.72 ± 0.11 0.14 ± 0.04 
+/Leu9′Ala    ACh 0.22 ± 0.07 * 0.30 ± 0.06 * 0.13 ± 0.11 
Leu9′Ala/Leu9′Ala   ACh 0.14 ± 0.05 * 0.08 ± 0.05 *+ 0.24 ± 0.15  
+/+        Nic 2.59 ± 0.13 4.16 ± 0.33 0.91 ± 0.12 
 
+/Leu9′Ala    Nic 1.66 ± 0.15 * 1.74 ± 0.36 * 0.71 ± 0.16 
Leu9′Ala/Leu9′Ala   Nic 0.57 ± 0.10 *+ 0.52 ± 0.12 *+ 0.73 ± 0.24 
*Significantly different from +/+ 
+Significantly different from +/Leu9′Ala 
Table II-2. Comparison of Rmax values for ACh and nicotine  
Genotype  Rmax (units) 
Total DA 
release 
Rmax (units) 
α4β2-
mediated 
α-CtxMII-
resistant 
Rmax (units) 
α6β2-mediated 
α-CtxMII-
sensitive 
+/+       ACh 12.76 ± 0.56 10.76 ± 0.56 3.53 ± 0.30 
+/Leu9′Ala    ACh 11.94 ± 1.02 8.06 ± 0.52 * 4.55 ± 0.97 
Leu9′Ala/Leu9′Ala    ACh 12.51 ± 1.07 4.16 ± 0.06 *+ 9.22 ± 1.68 *+ 
+/+       Nic 10.40 ± 0.13 8.16 ± 0.19 2.65 ± 0.08 
+/Leu9′Ala    Nic 11.90 ± 0.33 * 9.19 ± 0.57  3.04 ± 0.13 
Leu9′Ala/Leu9′Ala    Nic 10.50 ± 0.50 + 5.66 ± 0.41 *+ 5.72 ± 0.68 *+ 
Units are (cpm released- baseline cpm)/(baseline cpm). 
*Significantly different from +/+ 
+Significantly different from +/Leu9′Ala 
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Table II-3. Comparison of IC50 and Ki values (nM) for DHβE  
Genotype IC50 (nM) 
α4β2-
mediated 
α-CtxMII-
resistant 
using 3 µM 
ACh 
IC50 (nM) 
α4β2-
mediated 
α-CtxMII-
resistant 
using 0.3 µM 
ACh 
IC50 (nM) 
α6β2-
mediated 
α-CtxMII-
sensitive 
using 3 µM 
ACh 
IC50 (nM) 
α6β2-
mediated 
α-CtxMII-
sensitive 
using 0.3 µM 
ACh 
+/+  60 ± 4 11 ± 1  1848 ± 848 238 ± 169 
+/Leu9′Ala  95 ± 23  12 ± 4 1175 ± 358 180 ± 49  
Leu9′Ala/Leu9′Ala  1175 ± 412 
*+ 
 68 ± 12 *+ 714 ± 140 118 ± 35  
     
 Ki (nM) 
α4β2-
mediated 
α-CtxMII-
resistant 
using 3 µM 
ACh 
Ki (nM) 
α4β2-
mediated 
α-CtxMII-
resistant 
using 0.3 µM 
ACh 
Ki (nM) 
α6β2-
mediated 
α-CtxMII-
sensitive 
using 3 µM 
ACh 
Ki (nM) 
α6β2-
mediated 
α-CtxMII-
sensitive 
using 0.3 µM 
ACh 
+/+ 12 ± 1 8 ± 1 83 ± 38 77 ± 55 
+/Leu9′Ala 9 ± 2 6 ± 2 42 ± 13 49 ± 13 
Leu9′Ala/Leu9′Ala 31 ± 11 *+ 14 ± 3 *+ 53 ± 10 39 ± 12 
 
* significantly different from +/+.  + significantly different from +/Leu9′Ala. 
Notes: Data collected at 3 µM ACh from 5 WT (+/+), 4 heterozygous 
(+/Leu9′Ala), 2 homozygous (Leu9′Ala/Leu9′Ala) mice and at 0.3 uM ACh from 5 
WT, 4 heterozygous, 3 homozygous mice.  For each, 4-5 concentrations of 
DHβE were assayed, 0, 0.01, 0.1, 1, 10 µM with and without 50 nM αCtxMII.  
Data was curve fit from all individual points for each ACh concentration using the 
single exponential decay equation: f=a*exp(-b*x), where a=uninhibited release,  
b=decay constant and 0.693/b=IC50 value.   The Ki values were calculated from 
the equation: Ki=IC50/(1+[ACh]/EC50) where EC50 values are taken from Table II-
1.  By ANOVA, using all determinations of Ki, the resistant Ki for heterozygous 
and homozygous is significantly different than WT.  
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CHAPTER III. 
DHβE INDUCES A MOTOR PHENOTYPE AND AN AVERSIVE 
STATE IN MICE CONTAINING HYPERSENSITVE α4* NICOTINIC 
ACETYLCHOLINE RECEPTORS 
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ABSTRACT 
Dopamine (DA) is the primary neurotransmitter involved in the motor and reward 
pathway.   Depletion of DA concentrations in the dorsal striatum can lead to 
movement disorders while depletions in the ventral striatum, also known as the 
nucleus accumbens (NAc), are associated with withdrawal.  Nicotinic 
acetylcholine receptors (nAChRs) can modulate DA release, thus may play a 
large role in motor and withdrawal-associated behaviors.  We previously reported 
that mice containing hypersensitive α4* nAChRs (Leu9′Ala) challenged with 
DHβE, an α4* nAChR antagonist, exhibit robust motor deficits characterized by 
hypolocomotion, akinesia, catalepsy, tremors, and hindpaw clasping.  Here we 
investigate the effects of DHβE in Leu9′Ala heterozygous mice which induces a 
less robust phenotype (characterized by hypolocomotion, akinesia, myoclonic 
jerk, and hindpaw clasping).  In addition to motor symptoms, these mice also 
condition a place aversion to DHβE and exhibit decreased locomotor activity in 
response to DHβE (before other motor deficits are apparent).  These behaviors 
are normally associated with nicotine withdrawal.  We hypothesize that DHβE 
decreases DA levels in the NAc, through α4* nAChRs, to induce a withdrawal like 
syndrome, in the absence of chronic nicotine exposure.  This suggests that α4* 
nAChRs may be potential therapeutic targets to treat movement deficits and 
nicotine withdrawal.  
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III.A. Introduction 
Dopamine (DA) levels in the striatum regulate motor output in the basal ganglia 
motor circuit (Rice et al., 2011).  Nicotinic acetylcholine receptors (nAChRs), 
located on cell bodies and terminals of DAergic neurons that project from the 
substantia nigra pars compacta (SNpc) to the striatum, mediate DA release by 
responding to acetylcholine (ACh) provided by cholinergic signaling to the SNpc 
and cholinergic interneurons in the striatum (Grady et al., 2007, Albuquerque et 
al., 2009). In striatal slices, electrically-evoked DA release decreased by 90% 
after acetylcholine (ACh) depletion or nAChR antagonism (Zhou et al., 2001).  
Experiments in striatal synaptosomes reveal that the majority of nicotine-
mediated DA release in the striatum is mediated through presynaptic α4* 
nAChRs and the minority (about 30%) is mediated by α6* nAChRs (Salminen et 
al., 2004, Threlfell et al., 2012).  These experiments suggest that nAChRs play a 
major role in regulating striatal DA release; therefore, these receptors likely 
modulate motor output.  However, pharmacological blockade of nAChRs or 
genetically deleting these receptors has little significant effect on motor output 
(Ross et al., 2000, Champtiaux et al., 2002).  As a result, elucidating the 
functions of nAChRs on motor output has been difficult.  Fortunately, mice 
expressing hypersensitive α4* or α6* nAChRs may be used to elucidate the roles 
of these receptors in motor activity.  Transgenic mice expressing gain-of-function 
α6* nAChRs are spontaneously hyperactive (Drenan et al., 2010).  Knock-down 
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of the α4 subunit in these mice reduced locomotor activity back to levels 
measured in WT mice, suggesting that the α4α6β2* nAChR is important for 
movement (Drenan et al., 2010).  I have previously reported that α4(non-α6)* 
nAChRs mediate a robust, transient motor deficit, characterized by 
hypolocomotion, akinesia, catalepsy, and rigidity, and tremors, induced by 
antagonizing α4* nAChRs with DHβE, a selective α4β2* nAChR antagonist, in 
knock-in mice with enhanced sensitivity to ACh due to a mutation in the α4 
subunit (Leu9′Ala) (Chapter II).  I hypothesized that antagonism of these 
receptors caused a major depression of DA levels, which generated significant 
motor deficits.  Challenging Leu9′Ala homozygous mice with amphetamine or a 
DA D1 receptor agonist prior to DHβE treatment prevented the DHβE-induced 
motor phenotype, supporting the hypothesis that the phenotype is DA-
dependent. 
 
NAChRs regulate other DA signaling pathways, most notable is their role in the 
reward pathway involved in nicotine reward, addiction, and withdrawal (De Biasi 
and Salas, 2008, Albuquerque et al., 2009).  Using Leu9′Ala homozygous mice, 
α4* nAChRs were shown to be sufficient for nicotine reward, which is associated 
with increased DA concentrations in the nucleus accumbens (NAc) (Tapper et 
al., 2004, Markou, 2008).  Local infusion of DHβE into the VTA blocks nicotine-
self administration, which is important for nicotine dependence (Watkins et al., 
1999).  Nicotine withdrawal, associated with decreased accumbal DA 
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concentrations, can be elicited with DHβE in nicotine dependent mice 
(Hildebrand et al., 1999, Watkins et al., 2000).   The aversive nicotine withdrawal 
state is measured by conditioned place aversion, fear conditioning, anxiety, and 
reduced reward (Epping-Jordan et al., 1998, Watkins et al., 2000, Bruijnzeel and 
Markou, 2004, Kenny and Markou, 2005, Jackson et al., 2008, Portugal et al., 
2008, Stoker et al., 2008).  Together, these results suggest that α4* nAChRs 
modulate nicotine reward and withdrawal behaviors through DA signaling.  
 
Given that α4* nAChRs modulate DA release throughout the brain, I hypothesize 
that antagonism of hypersensitive α4* nAChRs in Leu9′Ala mice will result in a 
decreased DA release.  To test this hypothesis, I tested motor and withdrawal-
related behaviors in DHβE-challenged Leu9′Ala and WT mice.  Here, I show that 
blocking α4* nAChRs in Leu9′Ala heterozygous mice produces a motor 
phenotype characterized by hypolocomotion, myoclonic (involuntary) jerks, 
akinesia, and hindlimb clasping, and also a withdrawal-like state measured by 
decreased locomotor activity and conditioned place aversion.  Both 
hypolocomotion and aversion are often associated with lowered DA levels, 
suggesting that blockade of Leu9′Ala α4* nAChRs can be used as a model to 
study α4* nAChRs in DA signaling-related behaviors. 
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III.B. Materials and Methods 
 
Animals In all experiments, female Leu9′Ala knock-in and wild-type littermate 
(WT) mice were used. These mice have been backcrossed to C57BL/6 mice for 
at least 9 generations.  The genetic engineering of the Leu9′Ala line has been 
previously described (Tapper et al., 2004).  Within the animal facilities at the 
University of Massachusetts Medical School under a 12h light: 12 h dark lighting 
cycle, mice bred, housed with no more than 5 mice per cage, and receive food 
and water ad libitum.  All experiments were conducted in accordance with the 
guidelines for care and use of laboratory animals provided by the National 
Research Council (National Research Council, 1996) as well as with an 
approved animal protocol from the Institutional Animal Care and Use Committee 
of the University of Massachusetts Medical School. 
 
Drugs Dihydro-β-erythroidine hydrobromide (DHβE) was purchased from Tocris 
Bioscience Bristol, UK. DHβE was dissolved in a 0.9% saline and administered 
via an intraperitoneal (i.p.) injection at a dose of 3 mg/kg. 
 
Locomotor Activity For all experiments measuring locomotor activity, mice were 
given saline injections once a day for 3 days prior to the experiment to reduce 
differences in locomotor activity due to stress from the injection and handling.   
On the day of the experiment, mice were habituated to the room for about 40 
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minutes.  Locomotor chambers equipped with infrared photobeams (San Diego 
Instruments) were used to measure locomotor activity by quantifying the number 
of beam breaks.  Mice were given saline (i.p.) or DHβE (3 mg/kg, i.p.) and placed 
into novel cages within locomotor chambers at the time points indicated and 
measured for 30 minutes with beam breaks summed every 5 minutes.  Mice 
served as their own control such that the first experiment half of the mice 
received saline and the other half received DHβE in the first round of locomotor 
activity.  Then locomotor activity was measured again the following week in the 
same group of mice.  Mice that received saline the first week were administered 
DHβE and mice that already received DHβE were administered saline.  
 
Motor Characterizations Motor characterizations were previously described in 
Soll et al. 2013.  First, mice were habituated to a novel cage before a battery of 
motor characterizations was conducted.  Over a time course of 180 minutes, 
myclonic jerk, akinesia, catalepsy, clasping, and tremor were measured at the 
indicated time points.  Prior to administration of saline (i.p.) or DHβE (3 mg/kg, 
i.p.), the motor characterizations were measured (“0” time point). 
 
Myoclonic Jerk Before mice were handled for the characterization tests 
(described below), mice were observed for 30 seconds in the habituated cage.  
During the 30-second time period, the number of myclonic jerks was counted.  
This test was conducted every 30 minutes. 
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Akinesia In an empty cage, mice were lifted by the tail so that forelimbs remained 
on the floor.  Two trials were conducted, each lasting 30 seconds, counting the 
number of forepaw steps.  This test was conducted every 30 minutes and the two 
trials were averaged for each time point. 
 
Catalepsy Following the akinesia test, a raised bar 5 centimeters from the floor 
was placed within the same empty cage.  The forelimbs of the mouse were 
placed on the bar and latency to remove them was measured for up to 2 minutes.  
This was measured every 2 hours. 
 
Clasping and Tremor Mice were raised by their tail and tremor and clasping were 
evaluated over 10 seconds.  A score was given to depict the degree of clasping 
or body tremor occurred.  The scoring for clasping was as follows: 0 = hind limbs 
spread wide apart (normal position), 1 = hind limbs 25% closed, 2 = hind limbs 
50% closed, 3 = hind limbs 75% closed with periods of hind limbs clasped, 4 = 
hind limbs fully clasped for 10 seconds.  The severity of a body tremor was 
scored: 0 = no tremor, 1 = isolated twitches, 2 = intermittent tremors, 3 = 
continuous tremor. 
 
Conditioned Place Aversion Conditioned place aversion (CPA) is used to test for 
a drug’s ability to induce a negative state.  Located within a sound attenuation 
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chamber to avoid outside disturbances, the CPA apparatus (model ENV-3013, 
Med Associates, Inc.) contains 2 chambers separated by a neutral compartment 
with guillotine doors for access to either chamber.  All 3 compartments contain 
infrared photobeams to record activity, which is recorded by MED-PC software.  
The smaller, central, neutral compartment is grey with smooth PVC flooring and 
guillotine doors to access the neighboring chambers.  These neighboring 
chambers are larger and differ from each other in color (white or black) and metal 
flooring (mesh or rod).  The neutral compartment is grey with smooth PVC 
flooring.  Before CPA experiments, all mice were exposed to an i.p. injection of 
saline and placed in the room with the CPA chamber for about 30 minutes with 
the sound attenuation fan on for habituation purposes.  During pre-conditioning, 
conditioning, and test days, mice were also habituated to the room with the 
sound attenuation fan on for at least 30 minutes.  On the pre-conditioning day, 
drug-naïve mice were placed into and confined to the central grey chamber 
(neutral) for 5 minutes.  After this time, the guillotine doors were manually lifted 
and mice were allowed to roam freely between a white and dark chamber for a 
30-minute period to assess baseline preference and time spent in each chamber.  
For the following 2 conditioning days, mice were trained to associate each 
chamber with a drug.  In the morning of each conditioning day, each mouse was 
administered saline (i.p.) and immediately confined to the non-preferred chamber 
(determined on pretest day) for 30 minutes.  In the afternoon, mice were 
administered DHβE (i.p., 3 mg/kg) and immediately confined to the preferred 
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chamber for 30 minutes.  On test day, mice were initially placed into and 
restricted to the grey chamber for 5 minutes.  After the 5-minute restriction 
period, the doors were lifted and mice were free to roam all chambers for 30 
minutes and time spent in each chamber was measured.  A difference score was 
calculated as the time spent in the saline- or DHβE-paired chamber on test day 
minus habituation day.  Decreased time spent in the DHβE-paired chamber on 
the test day compared to pre-test day indicated aversion. 
 
Data Analysis Behavioral data were analyzed with t-test, one or two-way ANOVA 
with repeated measures, as indicated. Post-hoc analysis was done using 
Bonferroni post-hoc tests.  Data were analyzed using GraphPad Prism 5 
software (GraphPad Software, La Jolla, CA, USA).  
 
III.C. Results 
 
Our previous study revealed that hypolocomotion along with akinesia, catalepsy, 
and tremor in Leu9′Ala mice occurred after blocking α4* nAChRs (Soll et al., 
2013).  To test if a similar motor phenotype could be induced by DHβE in 
Leu9′Ala heterozygous mice, we compared locomotor activity and motor 
behaviors including myoclonic jerk, akinesia, catalepsy, clasping, and tremor  
(Fig. III-1) in Leu9′Ala heterozygous and wild-type littermate (WT) mice 
challenged with saline or DHβE.  Indeed, DHβE induced an intermediate motor 
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phenotype in Leu9′Ala heterozygous mice compared to their homozygous 
counterparts.  Upon a 5 minute observation staring at 90 minutes after DHβE 
challenge, WT mice revealed no effect of drug, but Leu9′Ala mice had temporary 
bouts of being “frozen” in place and exhibited an abnormal posture, straub tail 
(rigid and erect), rigidity, and clasped hind paws (data not shown).  To 
characterize deficits in motor behaviors induced by DHβE in Leu9′Ala 
heterozygous mice, measurements for myoclonic jerk, akinesia, catalepsy, 
clasping, and tremor were taken at specific times over 3-hours.  Analysis by a 
two-way repeated measures ANOVA of myoclonic jerks (Fig. III-1a) indicated a 
significant effect of time (F6,84 = 4.888, p=0.0002), genotype (F1,84 = 20.46, p= 
<0.0001) and an interaction between time and genotype (F6,84 = 4.888, 
p=0.0002).  Bonferroni’s post-hoc analysis indicated DHβE significantly 
increased the number of myoclonic jerks in Leu9′Ala heterozygous compared to 
WT mice at 90 (p=0.0002) and 120 minutes (p<0.0001).  Two-way repeated 
measures ANOVA analysis of akinesia (Fig. III-1b) revealed a significant effect of 
time (F 6, 133 = 6.727, p<0.0007) and genotype (F 6, 133 = 10.29, p=0.0017).  
Although there was not a significant cataleptic effect of DHβE (Fig. III-1c), there 
was a trend toward increased catalepsy in Leu9′Ala heterozygous mice 
compared with WT at 120 minutes analyzed by Bonferroni’s post hoc analysis.  
Analysis of clasping (Fig. III-1d) by two-way repeated measures ANOVA, 
indicated a significant effect of genotype (F 6,119 = 44.61, p<0.0001), time (F6, 119 = 
8.257, p<0.0001), and interaction between genotype and time (F6, 119= 8.257, 
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p<0.0001).  Further post-hoc analysis by Bonferroni’s test revealed that DHβE 
induced significant increases in clasping of Leu9′Ala heterozygous compared to 
WT mice at 90 (p<0.0001) and 120 minutes (p<0.0001).  DHβE did not induce 
tremors in WT or Leu9′Ala heterozygous mice (Fig. III-1g). 
 
Locomotor activity was measured 60 minutes after administration of saline (i.p.) 
or DHβE (3 mg/kg i.p.) in WT and Leu9′Ala heterozygous mice to test for 
differences in ambulation after α4* nAChR blockade (Fig. III-2).  WT mice 
exhibited no changes in activity level in either the locomotor activity time course 
(Fig. III-2a) or total ambulation over 30 minutes (Fig. III-2b).  There was a 
significant reduction in locomotor activity in Leu9′Ala heterozygous mice in both 
the time course and total ambulation.   Two-way repeated measures ANOVA 
analysis of locomotor time course (Fig. III-2c) revealed a significant effect of drug 
treatment (F1,90 = 52.31, p<0.0001) and time (F5,90 = 8.475, p<0.0001).  
Bonferroni post-hoc analysis indicated that DHβE induces hypolocomotion 60 
minutes post-injection with statistical significance at 65 (p<0.05), 70 (p<0.001), 
75 (p<0.001), 80 (p<0.05), and 85 (p<0.05) minutes.  A paired t-test analyzing 
total ambulation over 30 minutes in Leu9′Ala mice (Fig. III-2d) revealed that 
DHβE induced significant hypolocomotion 90 minutes after administration 
(p<0.05).  No significant differences in basal activity levels were measured 
between Leu9′Ala heterozygous and WT mice (data not shown).  
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CPA and hypolocomotion are common features of a drug withdrawal state in 
rodents and are associated with low DA levels in the NAc, a brain region within 
the reward circuitry (Laviolette and van der Kooy, 2004, De Biasi and Salas, 
2008).  To test the hypothesis that α4* nAChR blockade in Leu9′Ala 
heterozygous mice induces a negative withdrawal like syndrome, we tested for a 
CPA and locomotor activity (prior to emergence of motor symptoms which occur 
90 minutes post challenge) (Fig. III-3).  Drug-free mice were able to freely roam 
in a CPA apparatus before and after conditioning of saline (i.p.) or DHβE (3 
mg/kg, i.p.) to specific chambers.  Decreased time spent in the chamber after 
conditioning compared to pre-conditioning is associated with aversion.  WT mice 
(Fig. III-3a) did not condition a place aversion to DHβE, however Leu9′Ala 
heterozygous (Fig. III-3b) displayed a significant aversion to the drug as indicated 
by a paired t-test (p<0.05). 
 
Locomotor activity was measured 15 minutes after administration of saline (i.p.) 
or DHβE (3 mg/kg, i.p.).  Motor deficits, such as akinesia and catalepsy, were not 
apparent at this time point.  Locomotor activity was unchanged by DHβE 
compared with a saline injection in WT mice (Fig. III-3c and e).  However 
Leu9′Ala heterozygous mice displayed depressed locomotor activity (Fig. III-3d 
and f).  Two-way repeated measures ANOVA analysis of the locomotor activity 
time course (Fig. III-3e) revealed a significant effect of drug treatment (F1, 65 = 
36,86, p<0.0001) and genotype (F4,65 = 16.93, p<0.001).  There was a significant 
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decrease of locomotor activity at 25 (p<0.05), 30 (p<0.05), and 35 (p<0.05) 
minutes.  Total ambulation (Fig. III-3f) was also significantly decreased (p<0.05). 
 
III. D. Discussion 
 
DHβE induces a motor deficit in Leu9′Ala heterozygouserozygous mice 
 
We previously described that antagonism of hypersensitive α4* nAChRs in knock 
in (Leu9′Ala) mice induced a reversible, robust motor phenotype characterized by 
hypolocomotion, akinesia, catalepsy, tremor, and hind limb clasping (Soll et al., 
2013).  However, these mice had a very robust, saturating phenotype and may 
consequently limit its potential as a model to investigate α4* nAChRs role in 
spontaneous motor behavior.  I hypothesize that blocking α4* nAChRs in the 
Leu9′Ala heterozygous mice will result in an intermediate phenotype associated 
with decreases in DA levels.  Since mice are only heterozygous for 
hypersensitive receptors, reductions in DA levels should not be as steep as 
hypothesized to occur in Leu9′Ala homozygous mice, thus resulting in a 
phenotype in heterozygous mice that is less robust.  This potentially would allow 
us to study finer modifications to motor behaviors after further pharmacological 
perturbation, rendering these mice a better alternative model than using Leu9′Ala 
homozygous mice to study the role of α4* nAChRs in motor output. 
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Indeed, an intermediate phenotype was induced by DHβE in Leu9′Ala 
heterozygous mice but no deficits were revealed in WT mice after challenge with 
DHβE.  Abnormal freezing movements, straub tail, and abnormal posture were 
observed in DHβE challenged Leu9′Ala heterozygous mice.  Additionally I 
measured increased akinesia and myoclonic jerks as well as a robust clasping 
phenotype.  In a time-course, I found that these motor characterizations were 
strongest at approximately 90 minutes and were alleviated about 3 hours later, 
demonstrating that the phenotype is reversible. Leu9′Ala heterozygous mice 
have a stronger clasping phenotype compared with homozygous mice, probably 
as a result of decreased catalepsy which could limit range of motion needed for 
clasping in homozygous mice (Soll et al., 2013).  Myoclonic jerks were only 
present in heterozygous mice.  In addition, a tremor response to DHβE is not 
apparent in Leu9′Ala heterozygous mice, but was previously recorded in 
Leu9′Ala homozygous mice (Soll et al., 2013).  
 
The DHβE-induced motor deficits were debilitating in Leu9′Ala homozygous 
mice, which was most apparent in DHβE’s abolition of locomotion measured at 
60 minutes (Soll et al., 2013).  However, in Leu9′Ala heterozygous mice 
locomotor activity is significantly decreased but still some levels of locomotor 
activity are retained.  Once again, this resembles a less robust phenotype than 
exhibited by DHβE-challenged Leu9′Ala homozygous mice.  It is interesting to 
note that both Leu9′Ala homozygous and heterozygous mice do not have 
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differences in basal levels of activity when compared to WT mice.  This suggests 
that there is some type of compensation occurring, most likely a downregulation 
of Leu9′Ala α4* nAChRs, so that the hyperactivity of the α4* nAChRs do not 
affect overall locomotor activity in a drug naïve Leu9′Ala mice.   
 
One interesting aspect of this phenotype is the time frame in which it occurs.  
Measured by decreased locomotor activity, the onset of the phenotype emerges 
around 60 minutes with the most robust effects transpiring at 90 minutes and 
lasting until 120 minutes until they begin to dissipate around 3 to 4 hours.  Our 
model mimics the onset and reversal of akinesia after blockade of the medial 
forebrain bundle by tetrodotoxin in mice (Galati et al., 2009).  Microdialysis 
measured decreases in striatal DA levels as low as approximately 25% of 
baseline.  Therefore, akinesia in tetrodotoxin-challenged mice results from low 
striatal DA levels.  Since motor symptoms are occurring within the same time 
frame, it supports our hypothesis that DA levels are decreased in Leu9′Ala mice 
challenged with DHβE. 
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A withdrawal like state is induced in drug-naïve Leu9′Ala heterozygous mice by 
blocking α4* nAChRs 
 
A primary component of the reward circuitry is the DAergic projection from the 
ventral tegmental area (VTA) to the NAc.  Rewarding drugs increase DA levels in 
the NAc, while decreases in DA are measured after spontaneous or precipitated 
withdrawal in rodents (Fung et al., 1996, Hildebrand et al., 1998, Rada et al., 
2001, Gaddnas et al., 2002, Rahman et al., 2004).  Furthermore, α4 KO mice do 
not self-administer nicotine, but re-expression of α4* nAChRs in the VTA, but not 
the SNpc, rescues this behavior, implying a role for VTA α4* nAChR in nicotine-
evoked DA release in the NAc (Pons et al., 2008).   Low DA levels in the NAc are 
thought to bring about withdrawal behaviors in nicotine dependent rodents 
(Hildebrand et al., 1999, Watkins et al., 2000).  DHβE can induce an affective 
withdrawal syndrome, classified by anxiety, CPA, and hypolocomotion, in 
nicotine-dependent mice (Damaj et al., 2003, Jackson et al., 2009a).  To test our 
hypothesis that DHβE induces a widespread lowered DA state in Leu9′Ala mice, 
we tested behaviors associated with affective withdrawal.  If observed, these 
results would imply that changes in DA levels occur in DA signaling pathways 
outside the motor circuit.  Despite the fact the drug-naïve WT mice were unable 
to condition a place aversion to DHβE, drug-naïve Leu9′Ala heterozygous mice 
exhibited a CPA response.  Additionally, locomotor activity was decreased by 
DHβE in Leu9′Ala heterozygous mice but not WT.  This was tested at a time 
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period prior to onset of motor symptoms such as clasping, rigidity, straub tail, and 
myoclonic jerks, suggesting that hypolocomotion is associated with an affective 
state and not a motor deficit.  Direct infusion of mecamylamine into the VTA of 
nicotine-dependent rats will condition a place aversion and decrease locomotor 
activity (Hildebrand et al., 1999).  This confirms that both CPA and 
hypolocomotion measured at 30 minutes are reflective of an aversive state 
modulated by the primary circuitry involved in reward and withdrawal and not a 
direct effect of the primary motor circuit. 
 
Further investigation is needed to truly assess changes in reward as a result of a 
withdrawal state in Leu9′Ala mice challenged with DHβE.  The most direct 
measurement of reward is intracranial self-stimulation (ICSS).  Reward deficits 
were measured through elevated ICSS levels after either spontaneous 
withdrawal or mecamylamine-precipitated withdrawal from nicotine in mice 
(Johnson et al., 2008).  It is suggested that the ICSS test not only assesses 
decreased reward, but may reflect the negative reinforcement of nicotine that 
drives drug seeking behaviors and impedes smoking cessation (Koob et al., 
2004, Johnson et al., 2008). 
 
One advantage of studying the effects of DHβE in Leu9′Ala mice is that chronic 
nicotine treatment necessary to induce dependence in WT mice is time 
consuming, lasting from a few weeks to even as long as 2 or more months 
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depending on the method of nicotine administration (Pietila et al., 1998, Isola et 
al., 1999, Damaj et al., 2003).  Our model utilizes an inherent heightened 
dependency on basal ACh levels to evaluate behaviors after blocking these 
receptors in drug-naïve mice, thereby bypassing the need to chronically treat 
mice to induce changes required for dependency and withdrawal.  Although this 
is not an ideal model for nicotine withdrawal, it may be used to identify the 
affective behaviors modulated by α4* nAChRs and to further elucidate the 
mechanism of this modulation. 
 
A model for α4* nAChR mediation of a lowered DA state 
 
I propose that there is a significance to the progression of DA-related behaviors 
over time in our model.  I hypothesize that the motor and aversive behaviors in 
Leu9′Ala mice after DHβE challenge are associated with reductions in the DA 
levels in the striatum and NAc occurring at different times.  As in our model, an 
affective state measured by CPA and hypolocomotor activity occurs before the 
onset of the motor symptoms.  This progression of symptoms is mimicked in 
Parkinsons’s Disease (PD) where an affective state consisting of anxiety and 
depression is thought to precede motor symptoms (PD) (Shiba et al., 2000, 
Ishihara and Brayne, 2006, Jacob et al., 2010, Poletti et al., 2012).  NAChR 
upregulation in the substantia nigra pars compacta has been measured in mild to 
moderately lesioned mice that do not exhibit hypolocomotor behavior, suggesting 
110
that nAChR upregulation leads to increased DA release in order to delay onset of 
motor symptoms (Kryukova et al., 2013).  A similar upregulation, especially of 
α4* nAChRs, occurs in response to chronic nicotine exposure and may be a 
mechanism by which smoking has a neuroprotective effect against PD (Flores et 
al., 1992, Thacker et al., 2007, Quik et al., 2009, Chen et al., 2010).  Furthermore 
α4β2* nAChRs are protected during nigrostriatal damage, suggesting these 
receptors may be good therapeutic targets for increasing DA levels (Bordia et al., 
2007, Quik et al., 2009). 
 
The Leu9′Ala mouse model could be a unique system to study α4* nAChRs in 
several DA- related behaviors.  In order to establish this model, we need to test 
our hypothesis that Leu9′Ala mice challenged with DHβE have decreased DA 
levels.  The most direct and definitive method would be to use in vivo 
microdialysis to measure DA levels in the dorsal striatum and NAc over a time 
course and correlate the changes in DA levels with the onset and extinction of 
behaviors.  Once we have established DA level change in Leu9′Ala mice 
challenged with DHβE, it will confirm that this model can be used to test for α4* 
nAChR modulation of DA-related behaviors.  Further experiments, such as local 
infusion of DHβE or shRNA knockdown of α4* nAChRs, can be pursued to tease 
apart the mechanism of this modulation by distinct brain regions and even 
specific cell subtypes. 
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Figure III-1 
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Figure III-1. DHβE induces motor abnormalities in Leu9′Ala heterozygous 
mice.  a-d)  Characterization of motor symptoms in WT and Leu9′Ala 
heterozygous mice measured every 30 minutes over a 180-minute time period 
immediately following DHβE (3 mg/kg, i.p.).  a) Myoclonic jerk:  Number of 
myoclonic jerks were counted in 30 seconds (WT: n=5, Leu9′Ala heterozygous: 
14).  b) Akinesia:  Number of forelimb steps forward were counted for 30 seconds 
(WT: n=4, Leu9′Ala heterozygous: n=14).  c) Catalepsy:  Latency for forelimbs to 
fall off a raised bar for 2 minutes was recorded (WT: n=5, Leu9′Ala: heterozygous 
n=14).  d) Clasping of hind limbs during a 10-second period was measured (WT: 
n=3, Leu9′Ala heterozygous: n=14). e) tremor (WT: n=5, Leu9′Ala: heterozygous 
n=14)***p < 0.001, ****p<0.0001 analyzed by Bonferroni post-hoc test. 
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Figure III-2. DHβE decreases locomotor activity of Leu9′Ala heterozygous 
mice.  a) WT mice were placed into novel cages 60 minutes after saline (i.p., 
n=4) or DHβE challenge (3 mg/kg, i.p, n=4) and locomotor activity was measured 
for 30 minutes. Each data point represents the 5-minute sum of ambulatory 
activity.  b) Bar graphs represent total ambulation during 30 min of locomotor 
activity in WT mice measured in panel a.  c) Locomotor activity in Leu9′Ala 
heterozygous mice starting 60 min after saline (i.p., n=7) or DHβE (3 mg/kg, i.p., 
n=7).  d) Total ambulation was quantified for each condition as in panel b *p<0.05 
and **p < 0.01 analyzed by Bonferroni’s post-hoc test. 
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Figure III-3. A negative state is induced in DHβE-challenged Leu9′Ala 
heterozygous mice Time spent in the DHβE (3 mg/kg, i.p.) paired chamber 
before and after conditioning in a) WT (n=3) and b) Leu9′Ala heterozygous (n=4) 
mice in the conditioned place aversion assay.  A time course of 30 minute 
locomotor activity was measured starting 15 minutes after challenge with saline 
(i.p.) or DHβE (3 mg/kg, i.p.) in c) WT (n=4) and d) Leu9′Ala heterozygous mice 
(n=7).  Each data point represents the 5-minute sum of ambulatory activity.  e 
and f) Total ambulation was quantified for WT and Leu9′Ala heterozygous mice, 
respectively.  *p<0.05 and **p < 0.01 analyzed by Bonferroni’s post-hoc test. 
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CHAPTER IV. 
NICOTINIC ACETYLCHOLINE RECEPTORS CONTAINING AN α4 
OR α6 SUBUNIT INFLUENCE KETAMINE-INDUCED HYPNOSIS 
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ABSTRACT 
 
Compounds that produce sedation, immobilization, and analgesia are considered 
general anesthetics.  Ketamine is classified as an NMDA antagonist, but also 
blocks nicotinic acetylcholine receptors (nAChRs). It is still debated whether 
concentrations of ketamine necessary to block nAChRs are clinically relevant to 
the anesthetic actions of ketamine, or only contribute to the drug’s side effects.  
Here we show evidence that nAChRs indeed do modulate the hypnotic effects of 
ketamine in vivo.  Using the loss of righting reflex (LORR) assay, we first showed 
that nicotine, an nAChR agonist, as well as mecamylamine, hexamethonium, and 
methyllycaconitine (MLA), nAChR antagonists, alter duration but not latency of 
ketamine-induced LORR.  We then compared the ketamine-induced hypnosis of 
α4 nAChR subunit knock out mice (α4 KO) to wild-type littermates (WT) and 
found α4 KO had reduced LORR durations, but tolerance to ketamine was 
unaffected.  Additionally, mecamylamine had no effect on ketamine-induced 
LORR in α4 KO mice.  We also found longer LORR durations in α6 KO mice 
compared with WT.  Together, these data suggest that nAChRs play a 
modulatory role in the hypnotic actions of ketamine.  
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IV.A. Introduction 
 
Elderly and pediatric surgical patients are the most common recipients of 
ketamine anesthesia.  General anesthetics act as cardiovascular and pulmonary 
depressants, which can cause life-threatening effects in these patients.  
Ketamine is unique because it increases blood pressure, heart rate, and cardiac 
output (White and Ryan, 1996, Alletag et al., 2012).  Ketamine’s fast induction 
rate and amnesic and analgesic properties also make this drug a valuable 
anesthetic for surgical procedures, pre-operative care, pre-administration of other 
general anesthesia, and pain control (White and Ryan, 1996, Prommer, 2012).   
Despite ketamine’s attributes, widespread use of ketamine has been limited as a 
result of its negative side effects, such as vomiting and hallucinations (White and 
Ryan, 1996, Tassonyi et al., 2002, Alletag et al., 2012).  
 
Despite the wide administration of ketamine in the medical field, the mechanism 
of its actions is still largely unknown.  While most research has focused on its 
main target, N-methyl D-aspartate (NMDA) receptors, in vitro systems have 
established neuronal nicotinic acetylcholine receptors (nAChRs) as additional 
targets of ketamine (Scheller et al., 1996, White and Ryan, 1996, Furuya et al., 
1999, Sasaki et al., 2000).  Nicotine-induced currents in PC12 cells, which have 
endogenous expression of nAChRs, were blocked by ketamine with an IC50 of 
2.8 µM, which is lower than the clinically relevant concentration range of 
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ketamine (2-7 µM) (Furuya et al., 1999, Coates and Flood, 2001).  Expression of 
human α2β2, α2β4, α3β2, α3β4, α4β2, and α4β4 in Xenopus oocytes found IC50 
values of ketamine to inhibit ACh-induced currents in nAChRs ranged from 9.5 
µM to 92 µM, outside the range of clinical relevance and, based on these values, 
found that sensitivity to ketamine was greater in β4* than in β2* nAChRs and 
greater in α4* followed by α3* and then α2* (Yamakura et al., 2000).  Coates and 
Flood found that ketamine was more effective at human α7 nAChRs (IC50 20 µM) 
than human α4β2 nAChRs (IC50 50 µM) in Xenopus oocytes, but once again IC50 
values were outside the range of clinical relevance (Coates and Flood, 2001).  
Ketamine blocked ACh-induced currents in Xenopus oocytes expressing chick 
α4β4 with an IC50 value of 0.24 µM, which is much lower than what has been 
found with expression of human α4β4 (Flood and Krasowski, 2000).  Based on 
these studies, it is unclear if nAChRs are blocked at clinically relevant doses of 
ketamine to induce anesthetic effects.   
 
Very little work has examine whether nAChR modulate anesthetic effects of 
ketamine in vivo. Udesky et al. demonstrated that mecamylamine, a non-
selective nAChR antagonist, enhanced analgesic effects of ketamine, implicating 
nAChRs in non-hypnotic properties of ketamine (Udesky et al., 2005).  However, 
it still remains unclear whether concentrations of ketamine necessary to block 
nAChRs are clinically relevant to the hypnotic actions of ketamine or only 
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contribute to the drug’s analgesic properties and other effects (Furuya et al., 
1999, Sasaki et al., 2000, Tassonyi et al., 2002). 
 
To bridge this gap in knowledge, I tested the hypothesis that nAChRs modulate 
the hypnotic response to ketamine. I discovered that the duration of ketamine-
induced loss of righting reflex was altered by nAChR-targeted pharmacological 
agents and in nAChR subunit knock out (KO) mice, implicating a role for nAChRs 
in ketamine-induced hypnosis.  
 
IV.B. Materials and Methods 
 
Animals Drug-naïve female C57BL/6 (WT, Jackson laboratories), α4 KO, and α6 
KO and their wild-type littermates (WTLM) between the ages of 8 and 14 weeks, 
were used for loss of righting reflex experiments.  The genetic engineering and 
genotyping protocol for α4 KO and α6 KO mice was previously described (Ross 
et al., 2000, Champtiaux et al., 2002).  Genetically modified mice have been 
backcrossed to the C57BL/6J background for at least 9 generations.   All mice 
were bred and housed, up to five mice per cage, at the University of 
Massachusetts Medical School.  Mice were kept on a standard 12h light: 12h 
dark lighting cycle and food and water were accessible ad libitum.  All 
experiments were conducted in accordance with the guidelines for care and use 
of laboratory animals provided by the National Research Council (National 
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Research Council, 1996), as well as with an approved animal protocol from the 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School. 
 
Drugs Nicotine hydrogen bitartrate (NIC), mecamylamine hydrocloride (MEC), 
methyllycaconitine citrate salt hydrate (MLA), and hexamethonium (HEX) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Dihydrobeta-erythrodine 
hydrobromide (DHβE) was purchased from Tocris Bioscience (Bristol, UK).  
Ketamine hydrocloride was purchased from Vedco, Inc. (St. Joseph, MO).  All 
drugs were dissolved in 0.9% saline and administered via interperitoneal (i.p.) 
injection at the indicated doses.  
 
Loss of Righting Reflex The hypnotic effects of ketamine were measured using 
the loss of righting reflex (LORR) assay.  To avoid variation in LORR 
experiments from stress of injection and handling, mice were given a saline (i.p.) 
injection once a day for 3 days prior to each experiment.  Additionally, on the day 
of the experiment, mice were habituated to the room for approximately 40 
minutes and all experiments were conducted at the same time of day to avoid 
differential effects of ketamine based on the time of day known as 
chronopharmacology (Sato et al., 2004).  Mice were administered ketamine (100 
mg/kg or 200 mg/kg as stated, i.p.) and then the latency to the LORR was 
measured.  The LORR was determined when mice were unable to right 
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themselves after 5 seconds following supine placement into a V-shaped trough.  
Mice remained in this position until recovery from the LORR.  Mice were 
considered “recovered” when they could right themselves 3 times in the span of 1 
minute.   The duration of LORR was calculated by subtracting the time of the 
initial LORR from the time of recovery.  
 
Loss of righting reflex with nicotine: Mice were pre-administered saline (i.p.) or 
nicotine (1 mg/kg, i.p., made fresh and titrated to pH 7.2) 5 minutes before 
ketamine administration.  Latency to the LORR and time of recovery were 
measured and duration of the LORR was calculated as above. 
 
Loss of righting reflex with nAChR antagonists: Mice were pre-administered 
saline (i.p.) or an nAChR antagonist (3 mg/kg MEC, i.p., 10 mg/kg MLA, 3 mg/kg 
DHβE, or 1 mg/kg HEX) 15 minutes before ketamine administration.  Latency to 
the LORR and time of recovery were measured and duration of the LORR was 
calculated as above. 
 
Tolerance to LORR   Ketamine (100 mg/kg, i.p.) was administered to α4 KO and 
WTLM mice and LORR latency and duration were measured.  This was repeated 
for the next 3 consecutive days, thus totaling 4 days.  To calculate the percent of 
baseline, the LORR measurement from each day was divided by the baseline 
LORR measurement from day 1.  
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Data Analysis Behavioral data were analyzed with unpaired t-test or one-way 
ANOVA as indicated using Graphpad Prism 5 software (Graphpad Software, La 
Jolla, CA, USA).  Multiple comparison tests were used to identify differences 
between groups.  Statistical significance was set at p<0.05.  
 
IV.C. Results 
 
Mecamylamine (MEC), a non-specific nicotinic acetylcholine receptor (nAChR) 
antagonist, enhances the analgesic properties of ketamine (Udesky et al., 2005).  
Therefore, I hypothesized that nAChRs may also modulate the hypnotic effects of 
ketamine. To test my hypothesis, I pre-administered a nAChR agonist or 
antagonist before a hypnosis-inducing dose of ketamine (100 mg/kg, i.p.) and 
then measured latency to LORR and the duration of the LORR (Fig. IV-1).  
Similar to the findings from Udesky et al, 2005, the latency to the LORR was not 
significantly altered in the presence of a nAChRs agonist or antagonist (data not 
shown).  Nicotine (NIC) significantly increased duration of LORR in WT mice 
(Fig. IV-1a) measured by an unpaired t-test (t=3.575, p<0.01).  Complementing 
these results, MEC (Fig. IV-1b) decreased LORR duration in WT mice (t=2.666, 
p<0.05).  Selective pharmacological blockade of α4β2* (* denotes that other 
subunits may also co-assemble with α4 and β2 subunits in the receptor) nAChRs 
with DHβE or blocking α7 nAChRs with MLA had no significant effect on 
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ketamine-induced LORR duration (Fig. IV-1c and d, respectively).  Interestingly, 
peripheral blockade of nAChRs with HEX has the opposite effect of MEC and 
increases sleep duration (t=2.116, p<0.05).  Taken together, this suggests that 
nAChRs can modulate ketamine-induced LORR duration. 
 
Although ketamine antagonizes α4* nAChR function in vitro, the role, if any, in 
vivo is unknown. I hypothesized that α4* nAChRs are likely targets of the 
hypnotic response to ketamine (Fig. IV-2) (Coates and Flood, 2001).  Genetic 
deletion of the α4 nAChR subunit in mice (α4 KO) altered ketamine-induced 
LORR duration (Fig. IV-2a) but not latency (data not shown) in a dose-dependent 
manner.  Analysis by two-way ANOVA indicated that there was a significant 
effect of genotype (F1,29 = 482.6, p<0.0001) and drug treatment (F1,29 = 18.98, 
p=0.0002) and significant interaction between genotype and drug treatment (F1,29 
= 4.487, p<0.05).  Further analysis by Tukey’s multiple comparisons test 
indicated that there was a significant difference between drug doses in WTLM  
(p<0.0001) and α4 KO (p<0.0001) and between WTLM and α4 KO after 200 
mg/kg ketamine (p<0.01).  Comparing WTLM and α4 KO after 100 mg/kg 
ketamine revealed significant difference (Tukey, P<0.05) in this experiment, but a 
significant effect of genotype was observed at this ketamine dose in other 
experiments (Fig. IV-2b, IV-2d).  To test if α4* nAChRs are also involved in 
tolerance to ketamine, I measured latency and duration of LORR after 
consecutive treatments of ketamine for 4 days (Fig. IV-2b).  Once again there 
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was no difference in the latency to LORR between α4 KO and WTLM mice on 
days 1-4 (data not shown).  A two-way ANOVA analysis revealed a significant 
effect of genotype (F1,51= 9.598, p<0.001) and day (F3,51= 20.65, p<0.0001) 
between α4 KO and WTLM in duration of LORR across days 1-4.  Differences 
between the two genotypes in LORR duration were apparent only on day 1 as 
indicated by a Sidak’s multiple comparison test (p<0.01).  Figure IV-2c depicts 
measurements of tolerance to ketamine over 4 days of ketamine administration 
by analyzing the % difference from baseline LORR (day 1 LORR duration) on 
each day.  There is a significant effect of genotype (F3,51= 63.49, p<0.0001) and 
day (F1,51=10.73, p<0.01).   Further, a Bonferroni’s multiple comparisons test 
reveals a difference between WTLM and α4 KO on day 4 (p<0.05).  Pre-
challenging with MEC in α4 KO and WTLM reveal an overall significant effect on 
drug by two-way ANOVA (F1,21 = 5.096, p<0.05).  Only a significant difference in 
drug treatment was apparent in WTLM (Fig. IV-2d).  Tukey’s multiple comparison 
test reveal a significant difference between saline- and MEC-treated WTLM 
(p<0.01), and saline-treated WTLM and saline-treated α4 KO (p<0.01) and MEC-
treated WTLM (p<0.01).  
 
To date, a role for α6* nAChRs in the response to anesthetics has not been 
examined.  To test the hypothesis that α6* nAChRs are modulators of ketamine-
induced hypnosis I challenged WTLM and α6 knock out (α6 KO) mice with 
ketamine (100 mg/kg, i.p.) and measured latency and duration of ketamine-
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induced hypnosis (Fig. IV-3).  An unpaired t-test found a significant difference 
between WTLM and α6 KO latency to LORR (t=2.798, p<0.05) and LORR 
duration (t=2.576, p<0.05).  
 
IV.D. Discussion 
 
Nicotinic acetylcholine receptors modulate duration of ketamine-induced 
hypnosis 
 
Previous in vitro studies demonstrated nAChRs are inhibited by ketamine (Flood 
and Krasowski, 2000, Yamakura et al., 2000).  In vivo work shows that 
mecamylamine modulate ketamine’s analgesia properties (Udesky et al., 2005).  
Taken together, I hypothesize that these receptors may also modulate the 
hypnotic effects of ketamine.  Udesky et al. first looked at how pharmacological 
blockade of nAChRs could change the dose of ketamine required to induce 
hypnosis, yet failed to see any effect (Udesky et al., 2005).  Using a standardized 
dose of ketamine, I measured both latency to LORR and duration of LORR in 
response to ketamine plus pharmacological blockade of nAChRs, both 
measurements that were disregarded in the Udesky et al. study.  Latency to the 
ketamine-induced LORR was unchanged by pharmacological targeting of 
nAChRs in mice challenged with either a nAChR agonist or antagonist.  This 
suggests that initiation of hypnosis is unaffected by nAChRs.  However, nicotine, 
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mecamylamine, and hexamethonium significantly changed the duration of the 
LORR, indicating that nAChRs modulate maintenance of the hypnotic state 
and/or emergence from the hypnotic state.  
 
Most strikingly, my results reveal opposing effects of mecamylamine and 
hexamethonium on the modulation of ketamine-induced sleep duration (Fig. IV-
1b and e, respectively).  Both drugs are nAChRs antagonists, but 
hexamethonium cannot cross the blood brain barrier.  Thus, i.p. administration of 
hexamethonium antagonizes only peripheral nAChRs.  My results imply that 
there are separate roles for nAChRs in the central nervous system (CNS) and 
the peripheral nervous system (PNS) in modulating the hypnotic actions of 
ketamine.  This may be a reflection of nAChR subtype expression in the PNS 
versus the CNS.  Together this might suggest that modulation of ketamine-
induced hypnosis occurs through different nAChR subtypes expressed in multiple 
pathways mediating ketamine hypnosis. 
 
One caveat to the LORR assay as a measurement of hypnosis is that mice must 
be capable of righting themselves.  It is possible that increased LORR duration 
by HEX may not be a reflection of peripheral nAChRs involvement in hypnosis 
but rather a secondary affect.  Hypnosis and immobility are controlled by the 
CNS, whereas muscle relaxation is an effect of the PNS (Tassonyi et al., 2002, 
Rudolph and Antkowiak, 2004).   Two subtypes of nAChRs, heteromeric α3β4* 
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receptors and homomeric α7 nAChRs, have already been established in 
ketamine’s actions in the PNS (Tassonyi et al., 2002).  Therefore it is likely that 
ketamine blocks peripheral α3β2* and α7 nAChRs, leading to an increase in 
muscle relaxation and other effects that impedes righting ability, resulting in 
increased LORR duration after ketamine plus HEX.   
 
Homomeric α7 nAChRs do not modulate ketamine-induced hypnosis.  
 
Sub-anesthetic concentrations of ketamine and its metabolites inhibit α7 nAChRs 
in vitro (Coates and Flood, 2001, Tassonyi et al., 2002, Moaddel et al., 2013).  As 
a result, I wanted to test the hypothesis that these receptors were also involved 
in the hypnotic response to ketamine.  I found that MLA, an agonist selective for 
α7 nAChRs, had no affect on ketamine-induced hypnosis (Fig. IV-1d). One 
caveat is that I only used one dose of MLA and ketamine.  It is possible that MLA 
may have an effect with a higher dose of ketamine or a larger dose of MLA may 
be used.  The dose of MLA used in this study (10 mg/kg) is higher than the dose 
required to induce a nicotine withdrawal syndrome in mice (7.5 mg/kg), therefore 
10 mg/kg MLA should be sufficient to induce behavioral differences with 
ketamine if α7 nAChR are involved (Damaj et al., 2003). From experiments 
performed, I conclude that α7 nAChRs modulate non-hypnotic effects of 
ketamine. 
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Opposing modulation of ketamine-induced hypnosis by α4* and α6* nAChRs 
  
Ketamine can inhibit α4* nAChRs in oocytes (Flood and Krasowski, 2000, 
Yamakura et al., 2000, Coates and Flood, 2001). For that reason, I hypothesized 
that α4* nAChRs modulate the hypnotic effects of ketamine.  Consistent with my 
pharmacological experiments, latency to LORR was not changed by genetic 
deletion of α4 nAChRs, however the duration of LORR was decreased at each of 
the two doses tested in α4 KO mice (Fig. IV-2a).  It is surprising that LORR 
experiments indicated that hypnotic duration was altered in α4 KO animals, yet 
pharmacological blockade of α4β2* nAChRs using DHβE had no effect (Fig. IV-
1c).  One possibility is that α4 KO mice may metabolize ketamine at a different 
rate than WTLM and this possibility should be examine in future studies.  It is 
also possible that differences in LORR duration in α4 KO mice and not by DHβE 
may suggest α4(non-β2)* nAChRs modulate ketamine-induced hypnosis 
because DHβE is more selective for α4β2* nAChR.  A likely subtype is the α4β4* 
nAChR, which has a higher sensitivity to ketamine than α4β2* nAChRs and is 
expressed in brain regions associated with anesthetic responses, such as the 
habenula and interpeduncular nucleus (IPN), and cerebellum (Flood and 
Krasowski, 2000, Yamakura et al., 2000, Tassonyi et al., 2002).  
 
The rapid tolerance to the hypnotic effects of ketamine has been reported to be 
mediated by the CNS rather than an increase in rate of drug metabolism (White 
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and Ryan, 1996).   Using mice expressing hypersensitive α4* nAChRs, Tapper et 
al. found that α4* nAChRs were sufficient for tolerance to nicotine-induced 
hypothermia (Tapper et al., 2004).  Furthermore, α4 KO mice failed to show 
tolerance to nicotine-induced hyperactivity (Cahir et al., 2011).  Together, this 
shows a necessity and sufficiency of α4* nAChRs to mediate tolerance to 
nicotine.  I tested the role of α4* nAchRs in tolerance to ketamine by measuring 
ketamine-induced LORR over 4 consecutive days (Fig. IV-2b and c).  Decreased 
duration to ketamine hypnosis in α4 KO mice was only significant the first day of 
administration and completely vanished by day 3.  To measure differences in 
tolerance, I compared the percent of day 2-4 duration of LORR to that of day 1 
(baseline).  In WTLM and α4 KO, there is a rapid tolerance to ketamine indicated 
by the decreased LORR duration between day 1 and 2 and by the decreased 
percent of baseline on day 2 (Figure IV-2b and c).  The drop in percent of 
baseline on day 2 did not decrease further in either α4 KO or WTLM, suggesting 
there was no further tolerance after day 2 in these two populations.  Additionally, 
there was no difference between the percent of baseline between α4 KO and 
WTLM, except on day 4.  Overall, I conclude that α4* nAChRs do not significantly 
modulate tolerance to ketamine-induced hypnosis.  Since tolerance to ketamine 
is not affected by α4* nAChRs, this also further supports the idea that ketamine 
metabolism is not responsible in acute LORR differences between genotypes.   
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The α6 nAChR has only recently become of interest and a role for these 
receptors has yet to be evaluated in general anesthesia (Flood and Role, 1998, 
Tassonyi et al., 2002, Changeux, 2006, Yang et al., 2009).  It is a potential 
candidate involved in the anesthetic response because of its expression in brain 
regions implicated in anesthetic actions, such as the thalamus, IPN, and 
habenula (Herkenham, 1981, Champtiaux et al., 2002, Franks, 2008).  I found a 
significant decrease in latency to LORR in α6 KO mice.  Surprisingly, this was 
the only receptor I identified to influence latency to LORR, modulating induction 
of hypnosis.  Additionally I measured a significant increase in duration of 
hypnosis indicating modulation of either maintenance or emergence from 
hypnosis.  
 
The opposing modulation of duration of LORR by α4* and α6* nAChRs is 
intriguing and may be a reflection of the differential expression pattern of these 
two receptor subtypes.  α4* nAChRs are widely expressed in a variety of different 
neuronal subtypes (e.g., dopaminergic and GABAergic neurons) throughout the 
CNS and PNS.  On the other hand, α6* nAChRs are mainly restricted to 
catecholaminergic neurons in the CNS, specifically in the midbrain, ventral 
tegmental area, and substantia nigra, and also expressed in the thalamus and 
IPN (most likely on neuron terminals) (Le Novere et al., 1996, Klink et al., 2001, 
Azam et al., 2002, Yang et al., 2009).  The opposing results obtained by blocking 
α4* or α6* nAChRs may imply a mechanism, based on their expression patterns, 
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in which these two nAChR subtypes regulate different processes within the same 
pathway or modulate two different pathways.  
 
Some theorize that there is a shared circuitry mediating hypnosis amongst all 
anesthetics (Rudolph and Antkowiak, 2004, Alkire, 2008).  Under that 
assumption, it is no surprise that nAChRs play a role in modulating the effects of 
ketamine since they have been implicated in modulating hypnotic actions of other 
general anesthetics such as inhalation anesthetics (Alkire et al., 2007, Yan et al., 
2009).  One study reported shorter sleep durations after intracerebroventricular 
infusion of nicotine in mice anaesthetized with emulsified enflurane, isoflurane, or 
sevoflurane (Yan et al., 2009).  Additionally, mecamylamine had no effect on 
induction of hypnosis by sevoflurane, however intrathalamic infusion of nicotine 
awakened mice out of the sevoflurane-induced sleep (Alkire et al., 2007). Both 
studies complement my data and together suggest nAChRs modulate 
maintenance and/or emergence from drug-induced hypnosis.  Moreover, the 
study by Alkire et al, implicates thalamic nAChRs in mediating arousal (Rudolph 
and Antkowiak, 2004, Alkire et al., 2007).  The thalamic network has already 
been linked to arousal from anesthesia, including ketamine (Rudolph and 
Antkowiak, 2004, Alkire, 2008, Franks, 2008, Hwang et al., 2012). α4* nAChRs 
are likely targets.  Although widely expressed, these receptors are densely 
populated in the thalamus.  Additionally, my data showing α4 KO mice have 
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decreased ketamine-induced sleep duration support a role for α4* nAChRs in the 
maintenance and/or emergence from a ketamine-induced hypnotic state.  
 
This work provides the first evidence of nAChR-mediated modulation of 
ketamine-induced hypnosis.  Further experiments need to be carried out to 
elucidate how α4* and other nAChRs (e.g., α6* nAChRs) modulate different 
functions of hypnosis.  Such knowledge will direct the development of drugs to 
supplement ketamine improving safety and efficacy of anesthesia.  
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Figure IV-1. Pharmacological modulation of nAChRs alters duration of 
ketamine anesthesia in WT mice  
Duration of ketamine-induced LORR in WT mice.  a) Administration of saline (i.p. 
n=8) or nicotine (1 mg/kg nic, i.p, n=8) 5 minutes prior to ketamine (100 mg/kg, 
i.p.) b-e) Saline or drug was administered 15 minutes before ketamine 
(100mg/kg, i.p.) b) Saline (i.p. n=7) and mecamylamine (3 mg/kg, i.p. n=14), c) 
Saline (i.p., n=8) and DHβE (3 mg/kg, i.p., n=8), d) Saline (i.p., n=14) and MLA 
(10 mg/kg, i.p., n=14)  e) Saline (i.p., n=15) and hexamethonium (1 mg/kg, i.p., 
n=14)   *p <0.05 and **p<0.01 in unpaired t-test. 
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Figure IV-2. α4 KO have decreased ketamine-induced sleep 
Duration of ketamine induced sleep (a-d). a) α4 KO and WTLM response to 100 
mg/kg (WTLM = 9, α4 KO= 10) and 200 mg/kg (WTLM, n= 5, α4 KO, n=9) 
ketamine (i.p.)  b) Ketamine (100 mg/kg, i.p.) was administered for 4 consecutive 
days and duration of LORR was measured in WT (n=7) and α4 KO (n=8).  c)  
The percent of baseline duration of LORR.  d) Saline (i.p.) (WTLM, n=7, α4 KO, n 
=7) or mecamylamine (3 mg/kg, i.p.)(WTLM, n=5, α4KO, n=6) administration 15 
minutes before ketamine (100 mg/kg, i.p.)  *p<0.05, **p<0.01, ****p<0.0001 in a 
two-way ANOVA with either a Tukey’s (a and d) or Sidak’s (b) or Bonferroni’s (c) 
multiple comparison’s test. 
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Figure IV-3. Ketamine induces longer LORR in α6 KO mice  
WTLM (n=7) and α6 KO (n=8) mice were administered ketamine (100 mg/kg, 
i.p.) and a) latency to LORR and b) duration of ketamine-induced LORR *p<0.05 
in a unpaired t-test. 
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CHAPTER V. 
DISCUSSION 
138
 
V.A. α4(non-α6)* nAChRs are necessary for modulating motor output 
 
Chapters II and III present evidence for involvement of the α4* nAChR in 
movement.  The foundation of this research is based on evidence which 
indicates that striatal dopamine release is modulated by α4* nAChRs, however 
manipulation of these receptors through pharmacological antagonism or knock-
out nAChR subunit mouse models had yet to establish a significant role for these 
receptors in motor output (Ross et al., 2000, Salminen et al., 2004, Jackson et 
al., 2009a, Threlfell et al., 2012).   
 
In order to demonstrate that α 4* nAChRs play a role in spontaneous motor 
behavior, we utilized our knock-in mouse model which expresses a point 
mutation in the α4 subunit rendering receptors 50-fold more sensitive to agonists 
than a wild-type receptor (Tapper et al., 2004).  We hypothesized that these mice 
are more sensitive to basal levels of ACh; in these mice, blocking hypersensitive 
receptors would result in observable changes in motor function that are not 
apparent in WT mice.  Blocking hypersensitive receptors with the α4β2* nAChR 
selective antagonist DHβE in both homozygous (Chapter II) and heterozygous 
(Chapter III) Leu9’Ala mice induced a motor phenotype characterized by 
hypolocomotion, akinesia, catalepsy, tremor, hind-paw clasping, and abnormal 
posture.  These symptoms (except hindlimb clasping) are characteristic of those 
139
in Parkinson’s disease, which arise from low striatal DA levels as a result of the 
degeneration of SNpc DAergic neurons (Martin et al., 2011a).  We therefore 
hypothesized that striatal DA levels in the Leu9′Ala mice challenged with DHβE 
would also be reduced.   Pharmacological targeting of the DAergic system 
through amphetamine, D1R agonism or D2R antagonism, could rescue the 
DHβE-induced hypolocomotor activity in Leu9′Ala homozygous mice.  These 
data indicated a role for DA in the phenotype.   
 
C-Fos gene expression data in Chapter II indicated activation of neurons in the 
striatum and substantia nigra pars reticulata was present in Leu9’Ala 
homozygous but not WT mice challenged with DHβE, which is consistent with 
activation of the indirect DA pathway, a circuit that regulates suppression of 
movement and becomes overly active in PD patients (Gerfen and Surmeier, 
2011).  I hypothesize that c-Fos expression in the striatum is present in D2R 
expressing MSNs.  This assumption is based on evidence that expression of c-
Fos in the striatum was in non-cholinergic neurons and over-activation of the 
indirect pathway can lead to motor deficits similar to symptoms observed in this 
model.  Identification of the type of c-Fos expressing neuron would be useful to 
test this hypothesis.  To distinguish between D1R and D2R expressing neurons, 
neuropeptides that are associated with their respective DA receptors, such as 
dynorphin (for D1R MSNs) and enkephalin (for D2R MSNs), can be used as 
markers (Steiner and Gerfen, 1998, Reiner et al., 1999).  If c-Fos is not 
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expressed in these neurons, then it is possible that GABAergic interneurons may 
be involved.  To identify different subtypes of GABAergic interneurons, markers 
for somatostatin, parvalbumin/calretinin, or neuropeptide Y/nitric oxide synthase 
may be used (Tepper et al., 2010).   
 
Although c-Fos was apparent in the striatum of DHβE-challenged Leu9’Ala mice, 
c-Fos expression was not as extensive as I predicted since DA antagonism by 
haloperidol induces c-Fos expression in 100-200 per slice in the striatum in mice 
(Patel et al., 1998).  I looked for c-Fos activation 180 minutes after the initial 
DHβE injection to capture c-Fos activation when the DHβE-induced phenotype 
was most robust.  It is possible that the phenotype may occur as a consequence 
of neuronal activation at a much earlier time point, therefore we are not 
measuring at the optimal time point necessary to detect the peak of c-Fos 
activation.  A time-course of c-Fos activation would be needed to identify the 
peak of c-Fos activation, which may occur earlier or later than the time point 
captured in the c-Fos experiment in Chapter II.  Furthermore, c-Fos is a marker 
for neuronal activation. We are likely measuring neuronal disinhibition, however, 
since DHβE is an antagonist.  This is important because we cannot detect all the 
regions that are directly affected by DHβE since inhibition cannot be detected by 
c-Fos.  Therefore, it is likely that other brain regions may also play a role in the 
motor phenotype induced by DHβE.  
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We were interested in further investigating whether α4α6β2* nAChRs modulated 
the phenotype induced by DHβE in Leu9′Ala mice in Chapter II. The α4α6β2* 
nAChR subtype is expressed on DAergic terminals and has the highest affinity 
for nicotine (Salminen et al., 2004, Grady et al., 2007, Salminen et al., 2007).  
This subtype also modulated hyperactivity exhibited in a gain-of-function α6* 
nAChR mouse model (Drenan et al., 2010).  ACh-evoked DA release in 
synaptosomes from Leu9′Ala mice revealed that hypersensitivity to ACh and 
nicotine was independent of the α6 subunit.  Genetic deletion of the α6 nAChR 
subunit in Leu9′Ala mice had no effect on DHβE-induced hypolocomotion, which 
reveals that α4(non-α6)* nAChRs modulate a motor deficit induced by DHβE in 
Leu9′Ala mice. Together these models present evidence that α4(non-α6)* and 
α4α6* nAChRs play separate roles in mediating DA release and motor output. 
 
The synaptosome data presented in Chapter II also reveal other interesting 
information about the Leu9’Ala mice.  The higher sensitivity of the Leu9’Ala mice 
to nicotine and ACh was not detected in the synapotosomes.  This may be 
accounted for by the fact that we were measuring total DA released from 
synpatosomes.  Other nAChRs expressed in the terminal and in post-synaptic 
fractions included in the synpatosome affect total DA release.  Additionally, 
downregulation of Leu9’Ala α4* nAChRs in Leu9’Ala mice may compensate for 
hypersensitivity to ACh and nicotine, which may be reflected in a lack of 
sensitivity to ACh and nicotine measured by total DA release in synaptosomes.  
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This is supported by our synaptosome data that revealed a downregulation of α4* 
nAChRs in Leu9’Ala mice indicated by a decreased Rmax value in the α-CtxMII-
resistant component for nicotine and ACh in Leu9’Ala mice compared to WT 
(Table II-2).  Additionally, Rmax value in the α-CtxMII-sensitive component was 
increased in Leu9’Ala mice suggesting that the α6* nAChRs were upregulated 
(Table II-2).  Together, this suggests that there is compensation by the number of 
expressed receptor subtypes in Leu9’Ala mice.   
 
There are still many questions surrounding the mechanism of the gain-of-function 
mutation in the Leu9′Ala mouse. This mutation increases sensitivity of α4* 
nAChRs to agonists by 50-fold via changing the gating properties of the receptor, 
not by altering the binding sites for agonists or antagonists (Tapper et al., 2004).  
I predict that basal levels of ACh have a larger effect on hypersensitive α4* 
nAChRs than other nAChR subtypes in the striatum.  If this were true, then 
higher striatal DA levels would be expected to result in Leu9′Ala mice exhibiting 
basal hyperactivity.  Since hyperactivity was not apparent in these mice, it 
suggests that compensation occurs to counteract the heightened response to 
ACh.  Basal levels of DA in the striatum do not differ between Leu9′Ala and WT 
mice and neither do their responses to AMPH and to D1R agonism and D2R 
antagonism (Zhao-Shea et al., 2010, Soll et al., 2013).  This suggests that 
compensation does not occur in the amount of DA release or mechanisms 
downstream in DA signaling.  After reviewing these data, I hypothesize that 
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compensation occurs in cholinergic signaling or the number of Leu9′Ala receptors 
available for activation.  There are two possible ways that receptors could be 
affected:  decreasing number of Leu9′Ala receptors expressed or larger numbers 
of Leu9′Ala receptors exists in a desensitized state, meaning they are already 
bound by agonist and in an inactive state.  In both scenarios a smaller number of 
receptors would be available to modulate DA release, therefore DA release 
would be comparable to WT levels.  Then, with a smaller subset of active 
Leu9′Ala receptors, antagonism would have a greater effect.  Synaptosome data 
(discussed earlier) suggests that there is a downregulation of α4* nAChRs in the 
Leu9′Ala mice which may account for normal DA striatal levels and heightened 
response to blocking these receptors with DHβE.  In the latter case, if fewer 
Leu9′Ala α4* nAChRs are expressed, blocking these receptors would potentially 
lead to a greater response as a result of a greater dependency on the expressed 
receptors to provide normal DA release.   
 
Although the Leu9′Ala mutation in the α4 subunit does not occur naturally, the 
Leu9′Ala model is a tool that can be used to study the role of endogenous α4* 
nAChRs in motor output.  In a normally functioning DA system in the basal 
ganglia, α4* nAChRs may not have a large effect on motor function since DA 
levels required for motor function are relatively stable: only major decreases lead 
to motor deficits.  It is likely that other receptors may compensate for small, 
temporary DA losses.  In a condition where there are consistently low DA levels, 
144
such as in PD, these α4* nAChRs may have a larger impact.   In a recent study, 
an agonist for β2* nAChRs, TC-8831, improved motor coordination after 6-
hydroxydopamine lesioning in mice, supporting nAChRs as a promising class of 
targets for the therapeutic treatment of PD (Kucinski et al., 2013).  Currently the 
most effective treatment for PD is dopamine replacement using L-DOPA, 
however tolerance to the treatment reduces its effectiveness over time (Quik et 
al., 2011b).  My data highlights the importance of α4* nAChR in motor function 
and therefore suggests that targeting α4* nAChRs using nAChR allosteric 
modulators or agonists in order to promote DA release may be effective 
treatments for PD or may also be used in combination with lower doses of L-
dopa to help improve the duration of L-DOPA effectiveness in PD treatment 
(Quik et al., 2012).   
 
Future Directions 
 
1. Are striatal DA levels decreased in Leu9’Ala mice challenged with DHβE? 
 
Hypolocomotion, rigidity, postural abnormalties, and tremors are symptoms are 
Parkinson’s disease resulting from low dopamine levels in the St caused from the 
progressive degeneration of DAergic neurons in the SNpc (Martin et al., 2011a).  
Leu9′Ala mice challenged with DHβE exhibit a similar motor phenotype.  
Therefore, I propose that DHβE-induced motor symptoms in Leu9′Ala mice are 
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caused by a depletion of striatal DA as a consequence of blocking α4* nAChRs 
on SNpc DAergic neurons.  Pharmacologically targeting of the DAergic system to 
block the phenotype provides supportive data for this hypothesis, however it is 
necessary to measure DA concentrations after DHβE challenge in Leu9′Ala and 
WT mice to confirm my hypothesis.  Striatal DA concentrations should be 
measured every half an hour over the span of 4 hours (the average time that the 
phenotype lasts) after DHβE administration.  Since we are interested in 
measuring the amount of DA released into the striatum, the best ways to 
measure this would be to use either microdialysis or fast-scan cyclic voltammetry 
(FSCV).  Both techniques can be performed in vivo and will provide the temporal 
resolution necessary to measure DA levels in the striatum at multiple time points 
after DHβE administration.  Microdialysis is better suited for our interests 
because were are interested in time resolution in minutes to hours and FSCV is 
better used for sub-second time resolution (Robinson et al., 2003).  This may 
provide interesting information correlating behavioral symptoms onset with 
specific decreases in DA concentrations.    
 
2. Is nicotine neuroprotective or is upregulation of α4* nAChRs masking motor 
symptoms after DAergic lesion? 
 
Smokers have a lower incidence of PD, suggesting that nicotine has 
neuroprotective effects (Thacker et al., 2007, Chen et al., 2010).  The 
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mechanisms for nicotine’s neuroprotective effects remain to be completely 
elucidated.  It is possible that upregulation of nAChRs as a result of smoking may 
contribute to masking symptoms of neurodegeneration.   Upregulation of 
nAChRs occurs in the striatum after a mild MPTP-induced lesion in a pre-
symptomatic PD mouse model (Kryukova et al., 2013).  It is theorized that the 
upregulation of nAChRs increases DA neuron firing as a compensatory 
mechanisms to mask mild to moderate loss of DAergic neurons.  Potential 
nAChR candidates are α4β2* nAChRs because they are preferentially 
upregulated after chronic nicotine (Gotti et al., 2009, Quik and Wonnacott, 2011). 
Additionally, α4α6β2* nAChRs expressed on DA terminals in the striatum are 
vulnerable to drug-induced lesion, suggesting they are highly affected by 
lesioning (Bordia et al., 2007).  Neuroprotective effects of nicotine are also 
inhibited in α4 KO mice and DHβE inhibits nicotine protection against rotenone-
induced DAergic degeneration (Ryan et al., 2001, Takeuchi et al., 2009).  
Collectively this provides evidence for the necessity of α4β2* nAChRs in 
nicotine’s neuroprotective effects against lesioning.  I hypothesize that α4* 
nAChRs are also sufficient for neuroprotective effects of nicotine in response to 
drug-induced neurodegeneration.  To test this hypothesis, Leu9′Ala mice could 
be chronically treated with low concentrations of nicotine, therefore selectively 
activating only hypersensitive receptors, before a 6-hydroxydopamine-induced 
lesion.  If α4* nAChRs are indeed sufficient for neuroprotection, then nicotine-
treated Leu9′Ala mice would exhibit a reduction in 6-hydroxydopamine lesioning 
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compared to nicotine-treated WT mice.  The power of this model is that nicotine 
levels used to chronically treat Leu9′Ala mice would only affect the hypersensitive 
receptors.  It is also possible that the hypersensitive mutation would be enough 
for neuroprotective effects so lesions in control animals (drug-naïve Leu9′Ala and 
WT mice) are necessary to identify if any differences in the absence of nicotine 
treatment.  This experiment would rule out modulation by other nAChR subtypes 
and provide further evidence that α4* nAChRs are therapeutic targets for PD.  
 
3.  Where is DHβE (specifically) acting to induced motor symptoms? 
 
The robust nature of the DHβE-induced motor phenotype in Leu9′Ala mice could 
be a consequence of global Leu9′Ala α4* nAChR antagonism.  Expression of α4* 
nAChRs is not limited to the basal ganglia, but expressed in other motor-related 
areas, particularly the spinal cord (Wada et al., 1989).  It is possible that localized 
antagonism of α4* nAChRs in the striatum of Leu9′Ala mice or localized 
expression of Leu9′Ala α4* nAChRs in a WT animal would not necessarily 
replicate the phenotype, but rather mimic certain aspects such as hypolocomotor 
activity.  One experiment to assess which phenotypes are associated with the 
striatum is to locally knock-down the α4 subunit in Leu9′Ala mice in the SNpc and 
then challenge mice with DHβE and test for motor deficitsIt is possible that since 
α4* nAChRs are expressed in the spinal cord, postural abnormalities may occur 
as well as related motor deficits.  The reverse of this experiment can also be 
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accomplished where Leu9’Ala α4* nAChRs can be expressed in SNpc DAergic 
neurons using a viral mediated re-expression system in DAT-Cre mice.  
Challeneging mice containing hypersensitive α4* nAChRs soley in the SNpc with 
DHβE would test the sufficiency of α4* nAChRs in the SNpc to induce specific 
motor deficits.  
 
V.B.  A model for α4* nAChRs in DA-related behaviors 
 
In Chapter III, I expanded my investigation of the effects of DHβE in Leu9′Ala to 
test the hypothesis that blockade of Leu9′Ala α4* nAChRs affects other DA 
pathways.  Decreased DA levels in the nucleus accumbens (NAc), a brain region 
within the reward circuitry, accompany nicotine withdrawal symptoms (Hildebrand 
et al., 1998, Liu and Jin, 2004).  I measured DHβE-induced hypolocomotion and 
conditioned place aversion in Leu9′Ala mice, both common assays to test for a 
withdrawal state.  Hypolocomotor activity and a CPA response in Leu9’Ala 
heterozygous mice challenged with DHβE suggests that blocking hypersensitive 
α4* nAChRs lowered DA levels in the NAc.  I hypothesize that Leu9′Ala mice 
may have an intrinsic dependency on ACh due to their hypersensitivity, enabling 
the manifestation of a withdrawal state in nicotine-naïve Leu9′Ala heterozygous 
mice.  Normally withdrawal would require chronic nicotine treatment followed by 
its discontinuation to elicit a response in WT mice, however in the Leu9′Ala 
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model simply blocking hypersensitive α4* nAChRs is sufficient to induce the 
withdrawal-like state without chronic nicotine treatment. 
 
Future Directions 
 
1.  Are accumbal DA concentrations decreased by DHβE treatment in Leu9′Ala 
mice?  
 
Demonstrating lowered accumbal DA concentrations after DHβE challenge in 
Leu9′Ala mice would verify my hypothesis that DA decreases in the reward 
circuit.  It would additionally be likely that DA decreases would be measured in 
other DA signaling pathways that are modulated by α4* nAChRs.  Along with 
microdialysis data from the striatum, DA measurements in the NAc would 
characterize the reduction in DA over time, which could then be correlated to 
onset of hypolocomotion and CPA.  This could provide a unique perspective on 
DA and behavioral onset. 
 
2.  Do Leu9’Ala challenged with DHβE exhibit other affective symptoms?  
 
Leu9’Ala mice condition a place aversion to DHβE and exhibit hypolocomotor 
activity, which are associated with an affective nicotine withdrawal state.  
However, the affective withdrawal state is characterized by a variety of behaviors 
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including anxiety and reduced reward.  Therefore other affective nicotine 
withdrawal associated behaviors (see Tables I-1 and I-2) need to be tested to 
assess if a true nicotine withdrawal-like syndrome is being produced (as 
expected if blocking α4* nAChRs in Leu9′Ala mice leads to low DA 
concentrations in the NAc).   
 
Interestingly, PD patients also suffer from non-motor symptoms including anxiety 
and depression (Shiba et al., 2000, Ishihara and Brayne, 2006, Poletti et al., 
2012).  These non-motor symptoms are thought to pre-date the onset of motor 
symptoms (Ishihara and Brayne, 2006, Jacob et al., 2010).  The onset of the 
withdrawal-like state and motor symptoms induced by DHβE in Leu9′Ala mice 
mimics the onset of non-motor and motor PD symptoms.  Varenicline, an FDA-
approved α4* nAChR partial agonist, is used for smoking cessation and relieves 
affective withdrawal symptoms (Gonzales et al., 2006, Jorenby et al., 2006, West 
et al., 2008).  Since PD patients also suffer from a similar affective state, 
varenicline or other α4* nAChR-targeted drugs may not just treat motor 
symptoms but additionally may alleviate affective symptoms and possibly 
function as a neuroprotective agent. 
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2. Are α4* nAChRs sufficient to induce affective symptoms in the VTA? 
 
I show that α4* nAChRs are important to anti-reward associated behaviors such 
as condition place aversion and hypolocomotor activity.  In mice chronically 
treated with nicotine, a localized infusion of MEC into the VTA not only 
decreased locomotor activity and conditioned a place aversion, but it also 
reduced NAc DA levels by 25% (Hildebrand et al., 1999).  A direct infusion of 
DHβE into the VTA of Leu9’Ala mice can be used to test the hypothesis that α4* 
nAChRs specifically in the VTA are sufficient to conditioned place aversion and 
hypolocomotor activity response.  If this is not sufficient, other regions that 
express α4* nAChR and have been associated with affective symptoms, such as 
the IPN and habenula may also be tested.  This approach could provide 
evidence that α4* nAChRs in the VTA are important in withdrawal.   
 
V.C.  nAChR modulation of the hypnotic state induced by anesthetic drugs 
 
Chapter IV and Appendix I investigate the role of nAChRs in the hypnotic effects 
of two drugs, ketamine and ethanol.  Anesthetic drugs are hypothesized to use 
the same pathways involved in the sleep/wake cycle in order to induce 
unconciousness (Rudolph and Antkowiak, 2004).  Interestingly, many brain 
regions associated with consciousness receive cholinergic signaling, providing a 
link to nAChR involvement in sleep and wakefulness and anesthesia (Perry et al., 
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1999).  Lesion of the pedunculopontine tegmental (PPTg) nucleus, a key source 
of ACh for the basal ganglia, disrupts sleep/wake transitions and affects cortical 
activation during periods of wake, NREM, and REM states, however, it is 
undetermined if these lesions affect anesthesia (Petrovic et al., 2013).  
Functional differences in brain activity by anesthetic drugs occur in brain regions 
associated with sleep and wakefulness. For example, in anesthetized rats ACh 
turnover is decreased throughout the brain by halothane and in the caudate 
nucleus and hippocampus with ketamine (Ngai et al., 1978).  Ketamine-induced 
increases in regional cerebral blood flow in the anterior cingulate cortex and 
increases in the orbital frontal region in healthy human subjects were reduced 
with nicotine exposure (Rowland et al., 2010).   These data provide further 
evidence that ACh influences the sleep/wake cycle and anesthesia.  
 
Nicotine also modulates the hypnotic effects of volatile anesthetics, establishing 
a role for nAChRs in the hypnotic properties of anesthetics (Yan et al., 2009).  
Based on this evidence and previous studies that show nAChR are inhibited by 
ketamine (Flood and Krasowski, 2000, Yamakura et al., 2000, Coates and Flood, 
2001), I investigated a role for nAChR modulation of the hypnotic effects of 
ketamine. Nicotine, mecamylamine, and hexamethonium did not affect initiation 
of ketamine-induced hypnosis, but all these drugs modulated duration of 
ketamine-induced hypnosis.  I also investigated different subunits that modulate 
this response.  MLA had no effect, suggesting α7 nAChRs do not modulate 
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hypnotic responses.  Although DHβE also did not have an effect on duration of 
hypnosis, α4 KO mice displayed reduced ketamine-induced LORR durations, 
suggesting that hypnosis was modulated by α4(non-β2)* nAChRs.  In addition, 
α6 KO mice exhibited a shorter latency and a longer duration of ketamine-
induced hypnosis.  Taken together, my data demonstrate that α4* and α6* 
nAChRs play a role in ketamine-induced hypnosis. 
 
Future Directions 
 
1.  Where do α4* and α6* nAChRs modulate the hypnotic response to ketamine? 
  
By comparing ketamine-induced neuronal activation, using c-Fos as a marker, in 
WT and α4 KO and α6 KO mice, I would be able to identify brain regions that are 
activated by anesthetic doses of ketamine and ethanol.  Differences in c-Fos 
expression between mouse strains will most likely be moderate since all mouse 
strains exhibit drug-induced hypnosis.  It is important to note that c-Fos 
expression is not immediate and therefore c-Fos activity will not provide 
information about brain regions are involved in the different states of hypnosis: 
induction versus maintenance, and emergence.  Recording EEG activity or 
functional magnetic resonance imaging would offer better time resolution.  
Further LORR studies using a viral re-expression of nAChR subtypes into 
specific brain regions or direct infusion of ketamine and ethanol or nAChR 
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targeting drugs (in combination with an i.p. injection of ketamine or ethanol) into 
specific brain region would further specify which regions are important in the 
hypnotic effects of these drugs.  A thalamic infusion of nicotine awakened rats 
out of a sevoflurane-induced sleep (Alkire et al., 2007).  This study highlights the 
thalamus as a potential region in which nAChRs may modulate hypnotic effects 
of anesthetics.   
 
2.  Are nAChRs involved in the hypnotic effects of other anesthetic drugs? 
 
Since nAChRs are inhibited by other anesthetic drugs in vitro, it is likely nAChRs 
also modulate the hypnotic effects of these drugs in vivo.  In order to test this, α4 
and α6 nAChR KO models would be utilized to test the hypnotic effects, using 
the LORR assay, of other anesthetic drugs such as pentobarbital.  Comparing c-
Fos in KO models and WT mice may also provide further information about brain 
regions that are involved.  This may then be combined with ketamine c-Fos data 
to identify brain region in which nAChRs modulate hypnotic effects of these 
drugs.  
 
V.D. Conclusion 
 
My thesis explores how DHβE treatment of Leu9′Ala mice provides a model to 
study the role of α4* nAChRs in motor behaviors and an aversive state 
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associated with DA loss. I also provide evidence that α4* and α6* nAChRs 
influence the hypnotic responses to ketamine. Taken together, these data 
demonstrate the diverse roles of nAChRs in anesthesia-induced hypnosis and 
DA-related behaviors and point to the potential of nAChRs as attractive targets in 
neurodegeneration and treatment of PD symptoms. 
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ABSTRACT 
 
According to the World Health Organization, alcohol contributes to approximately 
2.5 million deaths annually.  The molecular mechanisms of alcohol’s actions are 
widespread, but it is becoming more evident that neuronal nicotinic acetylcholine 
receptors (nAChRs) play a large role in alcohol’s rewarding properties and other 
behaviors associated with alcohol addition.  Many nAChR subunits, including α3, 
α5, α6, α7, and β2 have been implicated in alcohol’s hypnotic effects, however, a 
role for α4 has yet to be established.  Here, I explored the hypnotic effects of 
high doses of alcohol by testing the loss of righting reflex (LORR) in α4 KO mice.  
I found that α4 KO mice do not differ in latency or duration of the LORR to an 
acute dose of ethanol, but α4 KO are more resistant to tolerance to the duration 
of ethanol-induced hypnosis after repeated exposures to ethanol.  These data 
suggest that α4* nAChRs play a role in tolerance to high doses of ethanol.   
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AI.A. Introduction 
 
Excessive drinking contributes to 79,000 deaths and accounts for $223.5 billion 
dollars in medical costs a year in the US alone (Naimi, 2011).  It is estimated that 
about 70-75% of alcohol-dependent people also smoke, even though smoking 
rates over the past decade have dropped in the US (Bobo and Husten, 2000).  
Given that there is a strong association between smoking and drinking, it has 
been suggested that nicotinic acetylcholine receptors (nAChRs), which modulate 
nicotine dependence, may also play a role in ethanol-related behaviors and could 
be promising therapeutic targets for alcoholism (Davis and de Fiebre, 2006, 
Hendrickson et al., 2013).  
 
Ethanol elevates dopamine (DA) release into the nucleus accumbens (NAc) from 
DAergic neurons originating in the ventral tegmental area (VTA), which is 
characteristic of all rewarding drugs (Hendrickson et al., 2013).  Increases in DA 
concentrations by ethanol can be inhibited by mecamylamine, a non-selective 
nAChR antagonist, administered systemically or by a direct infusion into the VTA 
in rodents (Blomqvist et al., 1997, Larsson et al., 2002).  Mecamylamine also 
reduces ethanol self-administration, which suggests nAChRs modulate ethanol’s 
rewarding effects (Ericson et al., 1998, Hendrickson et al., 2009).  More recent 
studies have identified that α4* nAChRs modulate ethanol reward and drinking 
(Kuzmin et al., 2009, Hendrickson et al., 2010, Hendrickson et al., 2011, Liu et 
160
al., 2013).  For example, rewarding doses of ethanol fail to induce a conditioned 
place preference in mice lacking the α4 subunit of nAChRs (α4 KO) and low 
doses of ethanol that cannot conditioned a place preference in WT mice are 
rewarding in mice expressing hypersensitive α4* nAChRs (Liu et al., 2013). 
Additionally, varenicline, a FDA approved α4β2* nAChR partial agonist, can 
reduce ethanol consumption in rodent models and in heavy-drinking smokers, 
which implicates α4β2* nAChRs as therapeutic targets for ethanol behaviors 
(Steensland et al., 2007, McKee et al., 2009, Hendrickson et al., 2010).  
Varenicline was designed to target α4β2* nAChRs, but it is also a partial agonist 
of α3β2* and α6* nAChRs and a full agonist of α3β4 and α7 subtypes, but with a 
much lower affinity (Coe et al., 2005, Jorenby et al., 2006, Mihalak et al., 2006).  
In self-administration studies, knocking out α7 or β2* nAChR is not sufficient to 
block reductions in ethanol consumption by varenicline, providing evidence of 
varenicline’s promiscuity (Kamens et al., 2010a). 
 
Anesthetic properties of ethanol are also modulated by nAChRs.  Nicotine 
attenuates ataxia induced by ethanol through α4β2* and α7 nAChRs in the 
cerebellum (Dar et al., 1994, Taslim et al., 2008, Taslim and Saeed Dar, 2011).  
Mice selectively bred for differences in hypnotic responses to ethanol 
differentiate in their sensitivity to nicotine’s effect on heart rate, locomotor activity, 
body temperature, and seizures (Heston et al., 1974, De Fiebre et al., 1987).  
Binding differences to nicotine and α-bungarotoxin in these mouse lines were 
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measured in the cerebellum, thus implicating both high affinity and α7* nAChRs 
(De Fiebre et al., 1987).  Further studies in these mouse strains found difference 
in polymorphisms in non-coding and coding gene sequences of the α4 nAChR 
subunit (Stitzel et al., 2000, Stitzel et al., 2001).  Additionally, cerebral inhibition 
of α4* nAChRs attenuates ataxia induced by anesthetic doses of ethanol (Taslim 
et al., 2008).  Conversely, varenicline increases ataxic and hypnotic effects of 
ethanol, however it is unclear if this effect is through α4* nAChRs (Kamens et al., 
2010b).   
 
To confirm that α4* nAChRs modulate the hypnotic effects of ethanol I measured 
the latency to the loss of righting reflex (LORR) and duration of the LORR in α4 
KO and WT mice.  I also tested tolerance to the hypnotic effects of ethanol in 
these mice by administering hypnotic doses of ethanol for 5 consecutive days.  
My results show acute effects of ethanol in WT and α4 KO mice were not 
significantly different.  However, after 5 days of ethanol exposure, α4 KO mice 
were more resistance to the ethanol-induced tolerance measured by the LORR, 
suggesting that α4* nAChR play a role in ethanol tolerance.  
 
AI.B. Materials and Methods 
 
Animals Drug naïve female α4 nAChR subunit knock-out (α4 KO) mice and wild-
type littermates (WT) were used to test the hypnotic effects of ethanol.   α4 KO 
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mice were backcrossed onto the C57BL/6J background for at least 9 generations 
and genetic engineering of these mice were described by Ross et al. (Ross et al, 
2000).  In the University of Massachusetts Medical School animal facilities, mice 
were bred and housed with no more than 5 mice per cage and given food and 
water ad libitum while on 12hr light: 12 hr dark lighting cycle.   All experiments 
were conducted under an approved animal protocol from the Institutional Animal 
Care and Use Committee of the University of Massachusetts Medical School and 
followed the guideless of the National Research Council (National Research 
Council, 1996).   
 
Drugs 190 proof absolute anhydrous ethanol (Pharmco-Aaper) was dissolved in 
0.9% saline and was administered at a concentration of 4 g/kg via an 
interperitoneal (i.p.) injection.  
 
Loss of Righting Reflex The loss of righting reflex (LORR) assay is used to study 
the hypnotic effects of drugs.  To avoid variation in LORR experiments from 
stress of injection and handling, mice were given a saline (i.p.) injection once a 
day for 3 days prior to each experiment.  Additionally, on the day of the 
experiment, mice were habituated to the room for approximately 40 minutes.  
The latency to the LORR and duration of the LORR was measured after 4 g/kg 
ethanol (i.p.).  Immediately after ethanol administration mice were continuously 
placed in the supine position, in a v-shaped trough, until mice were unable to 
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right themselves within 5 seconds.  The time point between the ethanol injection 
and the LORR was recorded and indicates the latency to the LORR.   Time was 
continuously measured until mice they able to right themselves 3 times within 1 
minute, which was deemed the time of recovery.  The duration of the LORR was 
calculated as the recovery time minus the latency to the LORR.     
 
Tolerance to the Ethanol-Induced LORR Ethanol (4 g/kg, i.p.) was administered 
once a day for 5 consecutive days.  LORR latency and duration were measured 
on days 1, 2 and 5 to assess acute tolerance between days 1 and 2 and chronic 
tolerance (between days 1 and 5).  A difference score measured the change in 
LORR by subtracting LORR on the day measured from day 1.   
 
Data Analysis Behavioral data were analyzed with an unpaired t-test or two-way 
multiple comparisons ANOVA as indicated using GraphPad Prism 5 software 
(GraphPad Software, La Jolla, CA, USA).  
 
AI.C. Results 
 
To identify a role for α4* nAChRs in the hypnotic response to ethanol, we 
assessed the loss of righting reflex in α4 KO and WT mice over 5 consecutive 
ethanol treatments.  There was no significant difference in the latency to LORR 
measured between WT and α4 KO on any of the days tested, suggesting that 
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initiation of ethanol-induced hypnosis is not modulated by α4* nAChRs (data not 
shown).  After the first exposure to ethanol (Fig. AI-1a) there was a trend, 
although not statistically significant, for α4 KO mice to have a longer duration of 
the ethanol-induced LORR.  The trend developed into a significant change by 
day 2 of ethanol administration measured by an unpaired t test (t=6.620, p<0.05) 
(Fig. AI-1b).  The difference between α4 KO and WT mice was further enhanced 
by day 5 (t=3.455, p<0.01) (Fig. AI-1c).   
 
AI.D. Discussion 
 
Varenicline increases duration of ethanol-induced ataxia at high doses, however 
varenicline is not selective for only α4β2* nAChRs, so the mechanism of its 
actions is unclear (Kamens et al., 2010b).  Despite varenicline’s lack of 
selectivity, I hypothesize that α4* nAChRs modulate the hypnotic effects of 
alcohol.  I evaluated the latency and duration of the ethanol-induced LORR after 
an acute dose of ethanol in α4 KO and WT mice.  Measuring the LORR response 
after exposing mice to the same dose of ethanol for 5 consecutive days also 
tested tolerance to the hypnotic effects of ethanol in α4 KO mice and WT.  My 
results indicated that there were no significant differences in the acute effects of 
ethanol between α4 KO and WT in the LORR duration.  However, α4 KO 
displayed a delayed tolerance to the hypnotic effects after repeated ethanol 
exposures. 
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I observed a trend toward an increase in LORR duration in α4 KO compared with 
WT mice on day 1, but it was not statistically significant, suggesting that α4* 
nAChR do not have a major role in the modulation of acute ethanol-induced 
hypnosis. These data on acute ethanol-induced hypnosis were surprising 
because hypnosis studies in α5, α6, α7, and β2 KO mice reveal these receptor 
subunits influence acute effects of ethanol hypnosis (Bowers et al., 2005, 
Kamens et al., 2012, Dawson et al., 2013, Santos et al., 2013).  No changes 
were measured in latency to ethanol-induced LORR on any day (data not 
shown), which was consistent with these previous studies (Bowers et al., 2005, 
Kamens et al., 2012, Dawson et al., 2013, Santos et al., 2013).  However, 
reductions in ethanol-induced LORR duration were observed in β2 KO mice and 
in WT mice challenged with DHβE, an α4β2* nAChR antagonist (Dawson et al., 
2013).  This response complements increases in ethanol-induced sleep duration 
by varenicline.  Unlike modulation by β2* nAChRs, my study shows that genetic 
deletion of α4 trends toward an increase in sensitivity toward ethanol-induced 
sleep duration.  The opposing effects in β2 KO and α4 KO mice suggest that 
separate receptors subtypes modulate these behaviors.  For example α3β2 
nAChRs have been implicated in ethanol-induced hyperlocomotion and genetic 
deletion of the α3 nAChR subunit resulted in decreased sensitivity to acute 
ethanol (Larsson et al., 2002, Kamens et al., 2009). 
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Ethanol-induced hypnosis studies in α5, α6, and α7 subunit KO mice have 
reported significantly longer LORR durations (Bowers et al., 2005, Kamens et al., 
2012, Santos et al., 2013).  α5 or α6 subunits may co-assemble in α4* nAChRs, 
therefore I expected that α4* nAChRs would also modulate this response.  This 
study suggests that α4* nAChRs do not play a major role in modulating acute 
hypnotic effects of ethanol and that α5* and α6* nAChR that do not contain the 
α4 subunit most likely modulate acute hypnotic effects of ethanol (Bowers et al., 
2005). 
 
Although α4* nAChR did not play a major role in the acute effects of ethanol-
induced hypnosis, there was statistically significant increase in the LORR 
duration in α4 KO compared to WT mice by day 2.  Since the trend on day 1 
developed into a statistically significant difference by day 2 and day 5, it is 
possible that α4* nAChR may play a minor role in the acute effects of ethanol-
induced hypnosis.  The increased sensitivity to ethanol is not an effect of 
sensitization since both α4 KO and WT mice develop tolerance to the hypnotic 
effects of ethanol.   WT mice developed a tolerance to ethanol-induced hypnosis 
by day 2 which decreased further by day 5, however the LORR duration in α4 KO 
mice did not change on day 2, but was decreased by day 5.  This suggests that 
α4 KO have a delayed tolerance response to the hypnotic effects of ethanol.   
Since α4 KO mice developed tolerance without α4* nAChRs, it is possible that 
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there were compensatory changes in the α4 KO mice that may effect this 
behavior.  
 
Differences in ethanol metabolism could account for differences in ethanol-
induced LORR duration.  Liu et al. confirmed there were no acute differences in 
ethanol metabolism between α4 KO and WT mice after 2 g/kg of ethanol (Liu et 
al., 2013).  It is still possible that metabolic changes between α4 KO and WT 
mice may occur at the higher doses of ethanol, which were used in this study, 
and after multiple exposures to ethanol.  Collins et al. verified that tolerance to 
multiple exposures of ethanol is an effect of reduced sensitivity in the CNS after 
chronic ethanol treatments because decreased ethanol-induced sleep time occur 
despite increased blood ethanol levels (Collins et al., 1988).  Although ethanol 
metabolism still needs to be measured in α4 KO and WTLM after multiple 
exposures, it is unlikely that there are significant differences that would account 
for differences in LORR duration between α4 KO and WTLM mice after multiple 
exposures to ethanol. 
 
This study provides evidence for α4* nAChRs modulation of tolerance to the 
hypnotic effects of ethanol after repeated exposures, but not to the acute effects 
of ethanol-induced hypnosis. The mechanisms of alcohol tolerance and hypnosis 
are poorly understood.  This works expands the role of α4* nAChRs in ethanol-
168
behaviors and adds to the subtypes of nAChRs which modulate hypnotic effects 
of ethanol.   
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Figure AI-1. α4 KO are more sensitive to the ethanol-induced LORR 
Duration of the LORR response to ethanol.  LORR duration was measured in WT 
(n=10) and α4 KO (n=11) after 4 g/kg ethanol (i.p.) on a) day 1 b) day 2 and c) 
day 5.  *p<0.05 and **p<0.01 in unpaired t-test 
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